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 ABSTRACT 
Epstein-Barr virus (EBV) encodes at least 40 microRNAs (miRNAs), an important class of 
negative regulators that control gene expression through posttranscriptional mechanisms. 
However the contribution of these EBV-encoded miRNAs to the pathogenesis of virus-
associated lymphomas remains poorly understood. Using newly-developed PCR assays, we 
first quantified the levels of viral BHRF1 and BART miRNAs in a range of EBV-positive cell 
lines. We show for the first time that all three BHRF1 miRNAs are abundantly expressed in 
Wp-restricted Burkitt lymphoma (BL) cells, but not Latency I BL cells lacking detectable Cp- 
or Wp-initiated EBNA transcripts. In contrast to some earlier reports, we also detected robust 
expression of BART miRNAs in B cell lines, although there was wide variation between 
individual miRNAs in a given cell. Analysis of BHRF1 and BART transcription, both in 
latent and lytic infection, suggested that maturation may be a key step in regulating steady-
state miRNA levels. We also successfully generated lentiviral systems to express the BHRF1 
miRNAs and developed reporter constructs to measure BHRF1 miRNA-dependent repression 
in vivo. While attempts to identify BHRF1 miRNA-induced changes on the BL transcriptome 
were inconclusive, our data suggest that the BHRF1 miRNAs are insufficient to affect BL cell 
growth and cell survival.  
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1. Introduction 
1.1 Discovery of microRNAs 
MicroRNAs (miRNAs) are a species of small, 20-22 nucleotide (nt) regulatory RNA capable 
of controlling over a third of human genes (1). They have been implicated in numerous 
pathways including differentiation, apoptosis, cellular proliferation and human diseases such 
as cancer. Here we discuss the identification of the first two miRNAs and how it was 
discovered that these molecules were part of a large group of highly conserved regulatory 
molecules. 
The products of two genes involved in the timing of Caenorhabditis elegans larval 
development, lin-4 and let-7, were the first molecules to be classified as miRNAs (2-6). 
Rather than encoding a protein, both genes transcribe a 22 nt RNA predicted to be derived 
from a longer stem-loop precursor. The lin-4 product was complementary to multiple areas of 
the lin-14 gene product 3′ un-translated region (UTR) previously shown to be important in the 
negative regulation of lin-14 by lin-4 (2, 7, 8). An analogous situation was observed for let-7 
and the lin-41 3′ UTR (9). Thus lin-4 and let-7 were proposed to post-transcriptionally 
regulate lin-14 and lin-41 respectively by binding their 3′ UTR targets and preventing 
translation.  
Considering that a let-7 gene homolog exists in other organisms such as humans and 
Drosophila melanogaster (10), a broad search was conducted for similar RNA species in 
other animals. Initially over 100 candidate genes were found (30 in humans, 20 in fruit fly and 
60 in worms) (4-6), many of which were remarkably conserved among different species. 
These small RNAs formed a unique class of molecule termed miRNAs and were found to be 
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increasingly abundant across mammals, flies, fish, worms and many other species (11-21). 
Currently there are 21,264 published miRNA sequences which are collectively stored in the 
miRNA database miRBase (22, 23).  
 
1.2 Biogenesis of miRNAs 
The mechanisms through which mature miRNAs are generated have been investigated in 
great detail. Briefly, we know that miRNAs are transcribed in the nucleus as part of a large 
precursor transcript called a pri-miRNA. They are then processed to their mature form in two 
stages; once in the nucleus by Drosha and again in the cytoplasm by Dicer. An overview of 
these steps is outlined in Fig. 1.1, taken from Bushati and Cohen (24). In this section we will 
discuss each step of the miRNA biogenesis pathway. 
MiRNA genes are found in all areas of the human genome except the chromosome Y (25-27). 
They commonly form large polycistronic miRNA gene clusters within intergenic regions of 
the genome. They also locate to protein coding regions of the genome, where they are 
primarily embedded within introns. Primary miRNA-containing transcripts (pri-miRNA) are 
transcribed by polymerase II (pol II) (28) and contain structural features associated with 
mRNA, such as 5′ caps and poly A tails (29).  
Pri-miRNAs are processed in the nucleus by a multi-protein micro-processing complex which 
includes Drosha (class 2 ribonuclease III) and DGCR8 (DiGeorge syndrome critical region 
gene 8) (30). Drosha asymmetrically cleaves the pri-miRNA into a 60-100 nt transcript with 2 
unpaired 3′ nucleotides and a 5′ phosphate group (31, 32); this transcript is termed the pre-
miRNA. DCGR8 in turn serves both to guide Drosha to the pri-miRNA and specify the site of 
Fig. 1.1. Simplified schematic of the miRNA biogenesis pathway 
(image taken from Bushati and Cohen) (24). MiRNAs are transcribed 
in the nucleus as part of a long precursor (pri-miRNA). They are 
processed by Drosha in the nucleus to a shorter intermediate (pre-
miRNA) and exported to the cytoplasm. They are then processed in 
the cytoplam by Dicer to a mature miRNA duplex. One strand is 
selected as the guide and loaded into an Argonaute protein as part of 
miRISC. 
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cleavage (31). Some miRNA genes within protein coding regions of the genome can be 
processed in a Drosha-independent manner termed the mirtron pathway (33, 34). In this case 
the lariat released by the mRNA splicing machinery directly folds into a pre-miRNA thus 
bypassing the need for Drosha.  This can only occur when the 5′ and 3′ ends of the lariat 
possess a suitable level of complementarity or “hairpin potential”. Examples of mammalian 
miRNAs processed in this manner include miR-877 and miR-1224 (35).  
Subsequent transport of the pre-miRNAs across the nuclear membrane is mediated by nuclear 
receptor Exportin-5 (36, 37). Exportin-5 recognizes pre-miRNAs via their size, structure, and 
unpaired 3′ end (38, 39). Once Exportin-5 has bound a pre-microRNA target, it associates 
with RAN-GTP and nucleoporin and subsequently crosses the nuclear membrane (40). 
Release of the pre-miRNA in the cytoplasm is triggered by the catalytic conversion of RAN-
GTP to RAN-GDP (41).  
Pre-miRNAs are processed to mature miRNAs by Dicer (class 3 type III ribonuclease) (42, 
43). Dicer has a number of functional domains. The double stranded RNA (dsRNA) binding 
domain and the PAZ domain recognize the pre-miRNA stem and 3′ overhang respectively, 
while the catalytic RNAse domain cleaves the pre-miRNA to a double stranded miRNA 
duplex (44, 45). Finally unwinding of the double stranded duplex might be mediated by the 
Dicer helicase domain (46-48).  
Single stranded mature miRNAs need to be loaded into an Argonaute (Ago) protein-
containing silencing complex termed miRISC before they can regulate gene expression. This 
step occurs in tandem with Dicer maturation and is mediated by the RISC loading complex 
(RLC), which consists of Dicer, TRBP (HIV trans-activating response RNA-binding protein) 
and an Ago protein (48-51). Usually only one strand of a miRNA duplex, termed the guide, is 
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loaded into miRISC (52, 53). Its selection depends on the relative thermodynamic properties 
of the four base pairs at its 5′ terminus. If these base pairs bind less stably on one strand as 
compared to the other then it will be chosen as the guide. Recent evidence has suggested a 
role for the helicase domain of Dicer in thermodynamic sampling of the miRNA duplex (54). 
The precise fate of the unloaded strand, termed the passenger, is a matter of debate (55-57). 
However in the absence of strand bias, both strands may be loaded into miRISC (4, 16), in 
which case the passenger is denoted with a * (22).  
Ago proteins are one of the key catalytic components of miRISC while the guide strand 
miRNA acts in target recognition. In humans miRNAs can be loaded into Ago1 through 
Ago4, although only Ago2 possesses the ability to directly cleave target RNA (57-59). The 
consequences of this will be discussed in section 1.4. 
 
1.3 Regulation of miRNA synthesis 
Because miRNAs regulate over a third of human genes it is important that their biogenesis is 
carefully controlled (1). Thus miRNA production is tightly regulated at the levels of 
transcription, processing and miRISC formation. The current section will discuss some of the 
mechanisms through which the cell regulates miRNA biogenesis. 
The transcription of pri-miRNAs is influenced in part by the nature and location of their 
promoters (60, 61). Intergenic miRNAs, such as miR-210, have their own transcriptional unit 
(61). Intronic miRNAs depend in part on host gene transcription (17, 26, 62), although many, 
such as the miR-17 cluster, are additionally regulated by their own internal promoters (60). 
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MiRNA promoters can be influenced by cellular transcription factors, for instance p53 and c-
myc activate the miR-34 and miR-17 clusters, respectively (63-67).  
Processing of the pri-miRNA is regulated via proteins which interact with the micro-processor 
complex and/or the pri-miRNA to stimulate or repress maturation (68, 69). Four of these 
proteins, SMAD, p53, ADAR and KSRP have been illustrated in Fig. 1.2 (adapted from 
Treiber et al) and will be discussed in more detail (70). The TNF-β responsive SMAD protein 
family binds a subset of miRNAs that contain R-SMAD binding elements (R-SBE) in their 
stems, such as miR-21 and miR-199a, and also interact with RNA helicase p68 (71, 72). 
These interactions both help tether the pri-miRNA to the micro-processing complex and 
enhance Drosha cleavage. P53 can promote processing of a group of growth-suppressive 
miRNAs (i.e. pri-miR-145 and pri-miR-16-1) as part of the DNA damage response (73). 
While the precise mechanism is unclear, it involves an association with RNA helicase p68 and 
is distinct from p53 mediated transcriptional regulation. KSRP (KH-type splicing regulatory 
protein) binds to terminal loop G-rich sequences present in certain pri-miRNAs, such as pri-
miR-let-7a and pri-miR-21, and promotes both Drosha and Dicer mediated maturation (74). 
KSRP activity is enhanced in an ATM-dependent manner thus providing another link between 
the DNA damage response and miRNA biogenesis (75). Finally the editing of certain pri-
miRNAs, i.e. pri-miR-142, by ADAR deaminases, which converts adenosine to inosine, may 
occur. This results in impaired Drosha processing and eventual degradation by the 
ribonuclease Tudor-SN, which specifically recognizes inosine containing dsRNA  (76).  
The mechanisms regulating pre-miRNA nuclear export are not understood. The observation 
that some pre-miRNAs (pre-miR-31, pre-miR-105 and pre-miR-128a) are selectively retained 
in the nucleus suggests the existence of some form of regulation (77). Furthermore mutations 
Fig. 1.2. The processing and function of miRNAs is 
carefully regulated (image adapted from Treiber et al) (70). 
Mechanisms illustrated in green increase miRNA processing 
and function. Similarly mechanisms illustrated in red 
antagonize miRNA processing and function.  
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in exportin-5 are typically observed in cancer and lead to a global block on export and 
consequent decrease in mature miRNA levels (78).  
The processing of pre-miRNAs by Dicer in the cytoplasm is also subject to regulation. The 
auto-regulatory feedback loop established between the human lin-28 and the let-7 miRNA 
family serves as a well characterized example (Fig. 1.2). Lin-28 binds to the conserved 
GGAG loop sequences on pre-miR-let-7 to prevent processing by Dicer, whilst both mature 
let-7 and miR-125 in turn suppress lin-28 (79, 80). Lin-28 mediated inhibition involves 
recruitment of TUT4 (terminal uridyl transferase 4) which adds a poly-U tail to the pre-miR-
let7 3′ end; this serves both to impair Dicer processing and mediate pre-miRNA degradation 
(81-84). In humans lin-28 is highly expressed in undifferentiated human embryonic stem cells 
(ESC) and helps maintain an undifferentiated phenotype (83, 85, 86) while let-7 mediates 
terminal differentiation (3, 10, 87). Thus the balance of lin-28 and let-7 in part control ESC 
fate. Incidentally over expression of human lin-28 promotes tumour growth (88) which is 
likely in part due to over expression of let-7 oncogene targets Ras, HMGA2 and c-myc (89-
92).  
The accumulation of fully processed mature miRNAs is influenced by their relative stability. 
For instance while many miRNAs exhibit half lives well beyond 8 hours, some have 
relatively short half lives i.e. miR-382 (93). Conversely the stability of some miRNAs can be 
increased through binding certain proteins (94). Furthermore miRNA turnover is generally 
accelerated in certain cell types e.g. in neuronal cells (95). Non-miRNA components of 
miRISC can also be targeted, e.g. in stem cells lin-41 impairs miRISC formation by causing 
Ago protein degradation (Fig. 1.2) (96).  
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1.4 Regulation of target genes by miRNAs 
As discussed towards the end of section 1.2, mature miRNAs are loaded into the miRISC 
complex. In this complex the miRNA confers target specificity while Ago mediates target 
suppression  (97). The current section will initially discuss the nature of the miRNA 
interaction with target mRNA. Thereafter we will focus on four proposed mechanisms by 
which miRISC is believed to suppress mRNA: endonucleolytic cleavage, inhibition of 
translation initiation, inhibition of translation elongation and mRNA destabilization. 
Conventionally miRNAs bind sites in the 3′ UTR of mRNA. Some miRNAs bind the open 
reading frame (ORF) or 5′ UTR of their target; just how effective these sites are remains 
unclear (98-100). The degree of complementarity seen in an miRNA-mRNA interaction is 
somewhat species dependent. Plant miRNAs usually bind their target perfectly, whilst in 
mammals the interaction is usually characterized by a number of bulges and mismatches (101-
103). In both cases, miRNA function is highly dependent on perfect binding of the target to 
nucleotides 2 through 7 on the 5′ end of the miRNA; this region is called the miRNA seed and 
is considered to be the most important factor in determining target specificity (102). At times, 
binding of this region alone may be sufficient for miRNA function; similarly bulges or 
mismatches in this region, especially a G:U wobble, greatly impair  miRNA function (104, 
105).  
The 3′ UTR sequences surrounding the miRNA binding site can also impact on miRNA 
function; a proximity of the miRNA binding site to AU rich regions correlates with site 
efficacy whilst being near to other miRNA binding sites allows for a cooperative target 
repression  (98). Binding sites for miRNAs broadly fall into three groups termed canonical, 
marginal and atypical (104, 106). Canonical sites include perfect binding of the miRNA seed 
Chapter 1 
 
 
8 
 
as well as an additional match at position 1 or 8. Marginal sites only include binding of 6 
miRNA nucleotides which includes all or most of the seed. Atypical sights are seed 
mismatched but compensate through additional binding of the miRNA 3′ end.  
Understanding how miRNAs bind has led to the development of miRNA target prediction 
programs including Targetscan (102, 107), TargetscanS (1), PicTar (108), MiRanda (109, 
110), Microcosm targets (22), PITA Top (111), EIMMo (112) and Diana-microT (113, 114). 
The number and types of criteria used by these programs to define targets varies. All look for 
moderate or strong seed binding as well as cross-species conservation. Other variables include 
thermodynamic stability of miRNA-mRNA base-pairing, the proximity of the miRNA 
binding site to AU rich regions in the target 3′ UTR, and the degree to which miRISC can 
access the target. While undoubtedly helpful, target prediction programs have their 
shortcomings. Target predictions generated by a given program show limited overlap with 
those produced by a different program (114). This is in part due to different programs using 
different criteria. Even when the same criteria are used, different programs may have defined 
the constraints of said criteria in a slightly different way. For instance TargetscanS sets cross-
species conservation at a minimum of 5 species while MiRanda only requires conservation 
among rodents and humans. Importantly computer predictions do not necessarily validate 
experimentally (115). Those that do validate are being added to a specialist data base, 
TarBase (115, 116).  
While miRNAs are responsible for tethering the miRISC complex to target mRNA, Ago 
proteins are responsible for target repression. Depleting Ago proteins from cultured 
mammalian and insect cells inhibits the ability of miRNAs to regulate their target genes (117, 
118). Furthermore unloaded Ago protein can repress gene expression when artificially 
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tethered to the 3′ UTR of a reporter mRNA (119). There are four species conserved Ago 
proteins in humans consisting of Ago1 though Ago4 (120-122). They share three domains 
termed PAZ, MID and PIWI; the function of these domains in the context of miRNAs is only 
partially understood (123-125). The PAZ interacts with the 3′ end of mature miRNAs (124) 
while there is some evidence to suggest the MID domain binds both the 5′ phosphate of 
mature miRNAs and the 5′ m7G cap of mRNA (126, 127). The PIWI domain mediates 
endonucleolytic cleavage of mRNA targeted by siRNAs and miRNAs; note that in humans 
this may only occur in the context of Ago2 (58, 59, 128). The ability of Ago proteins to 
mediate target repression appears to depend on binding to the GW182 protein. Preventing the 
interaction between Ago and GW182 has been shown both in vivo and in vitro to impair 
miRNA mediated gene silencing (118, 129-133).  
Even today the precise mechanisms by which miRNAs mediate target repression remain 
somewhat unclear and several models have been suggested (Fig. 1.3)(134). As touched upon 
earlier, miRNAs can direct the cleavage of their target mRNAs in an Ago2 dependent manner 
(Fig. 1.3A); an example of this in animals is cleavage of HOXB8 directed by miR-196 (135). 
This mechanism is dependent both on endonucleolytic activity specific to Ago2, and on the 
miRNA being perfectly complementary to its target (58, 136). However miRNAs are not 
preferentially loaded into Ago2 over Ago1, Ago3 and Ago4 (58) and in contrast to plant 
miRNAs, the vast majority of animal miRNAs form mismatches with their target; this creates 
a bulge in the miRNA-target duplex which interferes with Ago2 mediated cleavage (97). 
Nonetheless an early study in human cells has suggested that some siRNAs can direct 
cleavage of imperfectly bound targets (137). Therefore we can not be entirely sure just how 
important Ago2 endonuclease activity is in mammalian miRNA mediated gene silencing. 
Fig. 1.3. Multiple models have been proposed for the regulation of target 
genes by miRNAs (image taken from Pasquinelli) (134). Eukaryotic initiation 
factors, eIFs, (orange) bind the 5′ m7G cap and associate with the poly-A 
binding protein, PABPC (purple); this results in circularization of a mRNA 
species which is needed to stimulate translation. (A) Perfectly 
complementary interactions between miRNAs and their targets favours Ago2 
mediated endonucleolytic cleavage of target mRNA. (B) Imperfect pairing of 
an miRNA to the 3′ UTR of its target  may lead to miRISC mediated 
recruitment of the CCR4-NOT complex, which causes deadenylation of the 
target mRNA; this triggers the dissociation of the PABPC and eventual 
degradation of the target mRNA. (C) Imperfect pairing of an miRNA to the 3′ 
UTR of its target may lead to the inhibition of translation initiation. The 
precise mechanisms remain unclear but may involve preventing mRNA 
circularization or blocking assembly of the 80S ribosome. (D) Steps after 
translation initiation may be targeted by miRNAs. Proposed mechanisms 
involve encouraging ribosomal drop-off and degradation of nascent peptide. 
(E) Positive regulation of translation by miRNAs has been documented. For 
instance miR-369 binds to TNF-α mRNA and recruits Ago2 and FMR1 to 
stimulate translation. 
A 
B 
C D 
E 
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Most animal miRNAs are believed to impair various stages of translation and/or decrease 
mRNA stability. A number of studies have documented the ability of animal miRNAs to 
reduce the levels of mRNA targets, even when mismatches and bulges are present in the 
duplex (118, 138-140). Examples include lin-4/miR-125 mediated destabilization of lin-28 in 
nematodes/humans (138, 140). This mechanism appears to involves initial destabilization of 
mRNA targets followed by degradation (Fig. 1.3B) (118, 130, 141-145). Briefly miRISC 
associated protein GW182 recruits the CCR4-CAF1-NOT and PAN2-PAN3 complexes, 
which mediate deadenylation of the mRNA target. This in turn leads to the dissociation of the 
poly-A binding protein (PABP) and de-capping of the target by the DCP1:DCP2 complex. 
This renders the target mRNA susceptible to cellular exonucleases such as the 5′-3′ 
exonuclease Xrn1 and 3′-5′ exosome complexes. Most proteins involved in this pathway 
locate to processing bodies (P bodies), suggesting that these structures could be sites where 
miRISC targeted mRNAs are stored and/or degraded (146-150). Ribosome profiling of human 
and mouse cells recently demonstrated that as much as 84% of miRNA induced protein 
changes could be explained by reductions in  mRNA levels (151).  
Several lines of evidence suggest that miRNAs can inhibit translation initiation; furthermore 
this mechanism appears dependent on the target mRNA having a functional 5′ m7G cap (Fig. 
1.3C). Substitution of the 5′ m7G cap with a non-functional analog ablates miRNA mediated 
repression while mRNA generated from an internal ribosome entry site (IRES) is not subject 
to miRNA regulation (152, 153). The latter point can be convincingly demonstrated with a 
single reporter expressing firefly and Renilla reniformis luciferase in a 5′ m7G cap dependent 
and independent manner respectively (153). One mechanism by which this might occur is 
through binding of Ago or GW182 to the 5′ m7G cap structure (127, 154). This would serve 
to prevent the assembly of the initiation complex (eIF4) and circularization of the mRNA 
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target; note that both these events are necessary in order for efficient translation to take place.  
Whether or not Ago or GW182 are capable of interacting with the 5′ m7G cap remains 
controversial (126, 127, 129, 155, 156). Another possibility is that miRISC might recruit the 
ribosome anti-association factor, eIF6, which in turn impairs assembly of the 80S ribosome 
(157, 158). Interestingly the CCR4-CAF1-NOT deadenylase complex has been implicated in 
the inhibition of translational initiation by a mechanism which seemingly does not involve 
target deadenylation. Mutational  studies of this complex in Xenopus laevis oocytes revealed 
that CAF1 lacking deadenylase activity could inhibit reporter mRNAs providing they had a 
functional 5′ m7G cap structure (159). In contrast repression by deadenylation did not require 
a functional 5′ m7G cap. 
It has also been suggested that miRNAs can inhibit translation elongation (Fig. 1.3D). This 
mechanism was first indicated by the C. elegans lin-4 mediated repression of lin-14 and lin-
28; target mRNAs were associated with polysomes indicating translation initiation had 
already occurred (160, 161). Using human cells, artificial miRNAs and a mRNA reporter 
system, it has since been shown that repression of translation can occur at the post-initiation 
step (162). This is evidenced by the observation that IRES translated mammalian mRNA can 
be targeted by miRNAs and that repressed mRNAs are associated with active polysomes. 
Proposed mechanisms to address these observations include premature ribosomal drop-off 
during elongation (162), as well as  degradation of nascent peptide by unknown mechanisms 
(163).  
While most miRNAs are believed to antagonize their target, some have the opposite effect of 
stabilizing their target (Fig. 1.3E). For instance miR-369 targets AU-rich repeats in TNF-α 
mRNA under conditions of serum starvation (164). It then recruits Ago2 and FMR1 to 
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mediate translational activation as opposed to repression. Another miRNA, miR-328, binds 
hnRNP E2 in a seed independent manner and consequently relieves E2 mediated repression of 
certain targets such as CEBPA (165). 
 
1.5 miRNAs in normal cells 
In the current section we will provide a discussion on the roles of miRNAs in the context of 
normal cells, with an emphasis on cellular pathways such as differentiation, apoptosis and cell 
growth. 
A number of studies on Dicer mutant animals highlighted the in vivo importance of miRNAs. 
C.elegans and D. melanogaster Dicer mutants are both sterile and develop small ovaries and 
ruptured vulva respectively (43, 166, 167). Dicer negative zebra fish and mice in turn all die 
at varying stages of embryonic development (168, 169). Some of the earliest studies on 
miRNAs highlighted a role for these molecules in regulating developmental processes. Lin-4 
and let-7 miRNAs control stem cell fate during C. elegans development by repression of lin-
14, lin-28, lin-41 and hbl-1 during the appropriate larval stage (2, 3, 8, 9, 170-172). This 
ensures that transcription factor lin-29 accumulates at the right time and at the right quantities, 
to mediate terminal differentiation and transition towards the adult developmental stage (173, 
174). The Lin-4 and Let-7 miRNAs and their targets were found to be highly conserved and 
implicated in the development of mice (175, 176), zebra fish (177), fruit flies (178, 179) and 
humans (180).  
MiRNAs are now well established as mediators of embryonic stem cell (ESC) fate. Some 
miRNAs act to antagonize ESC maintenance. During differentiation miR-145 silences 
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transcription factors (Oct4, Sox2, Klf4) required to maintain the non-committal phenotype of 
ESC (181). The let-7 family in turn were shown to down-regulate other targets required for 
stem cell maintenance such as c-myc (182). Other miRNAs function in deciding into which 
cell type an ESC develops. The muscle-specific miRNA miR-1 silences an ESC-associated 
Notch ligand (Dll-1) to promote differentiation towards cardiomyocytes (183, 184). The 
brain-specific miRNA, miR-9, represses stathmin to promote proliferation and suppresses 
migration in human neural progenitor cells (hNPCs) (185). Finally miR-34a, miR-100 and 
miR-137 target a number of genes needed to maintain an undifferentiated ESC phenotype 
such as SIRT-1 and SMARCA5 (186).  
MiRNAs are also heavily involved in apoptosis (programmed cell death) (187). As reviewed 
by Ola et al. apoptosis can occur via the intrinsic or the extrinsic pathway (Fig. 1.4) (188). 
The intrinsic pathway is regulated by Bcl-2 family member proteins (Fig. 1.4B). Normally 
anti-apoptotic Bcl-2 members (i.e. Bcl-2, Bcl-XL etc) bind and maintain Bak and Bax in an 
inactive state. Stimuli such as metabolic or genomic stress cause the pro-apoptotic Bcl-2 
members (i.e. Bim, Puma, Bid etc) to bind and inactivate the anti-apoptotic members. This 
releases Bak and Bax and allows them to trigger pore formation in the mitochondrial 
membrane which in turn results in the release of pro-apoptotic proteins. One of these proteins, 
cytochrome c, interacts with the apoptotic protease-activating factor (Apaf1) and dATP to 
form the apoptosome and activates a series of caspases which ultimately cause cell death.  
MiRNAs target a number of Bcl-2 family members. For instance both miR-15a and miR-16 
target anti-apoptotic Bcl-2 which leads to apoptosis in a chronic lymphocytic leukaemia 
(CLL) cell line model (189). miR-34a targets Bcl-2 directly in neuroblastoma cell line models 
(190) and indirectly up-regulates pro-apoptotic PUMA via SIRT1 (191). Both miR-221 and 
B A 
Fig. 1.4. Apoptosis occurs through the extrinsic (A) and intrinsic (B) 
pathways (see text for detail). Image taken from Ola et al (188). 
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miR-222 in turn directly target PUMA to promote cell survival in glioma cells (192). The 
miR-17-92 family, which has essential roles in B cell development, cooperates with the miR-
106b-25 family to down-regulate the pro-apoptotic protein Bim (193). Formation of the 
apoptosome is also regulated by miRNAs. Pro-apoptotic miR-1 targets anti-apoptotic proteins 
HSP60 and HSP70 which function to prevent Bax-mediated pore formation pro-caspase 9 
recruitment respectively (194-196). Anti-apoptotic miR-133 targets caspase 9 which is needed 
for downstream activation of caspases 3 and 7 (188, 196). Both miR-1 and miR-133 serve to 
regulate apoptosis in cardiomyocytes (196).  
The extrinsic pathway is regulated via cell-cell signalling and is triggered by binding of 
ligands to the Fas and TNF-α receptors (Fig. 1.4A) (188). Thereafter both receptors become 
activated and recruit their respective death domain proteins FADD and TRADD; this in turn 
activates the death-inducing signalling complex (DISC). Downstream signalling continues via 
caspases and results, as before, in cell death. Examples of miRNAs which target this pathway 
include miR-21 and miR-182 which target Fas ligand and FADD respectively (197, 198).  
MiRNAs are also involved in regulating cellular proliferation (Fig. 1.5). As reviewed by 
Bueno and Malumbres, before resting cells (G0 phase) can re-enter the cell cycle, they must 
inactivate the retinoblastoma protein (pRB) and synthesize machinery required for DNA 
replication (S phase) and mitosis (M phase) (199). This process begins with transcription of 
D-type cyclins which activate cyclin dependent kinases 4 and 6 (CDK4/6). CDK-mediated 
inactivation of pRB triggers E2F release and consequent transcription of E2F regulated genes. 
This commits the cell to undergo DNA replication. Entry into the M phase requires CDK1 
and CDK2 which are activated by A or B type cyclins. Additional kinases such as Polo-like 
kinase 1 (PLK1) or Aurora regulate events during mitosis. Each phase of the cell cycle is 
Fig. 1.5. Multiple stages of the cell cycle are subject to miRNA regulation 
(image adapted from Bueno and Malumbres) (199). Proliferation can be 
favoured (red) or antagonized (blue) by cellular miRNAs. Individual 
miRNAs and miRNA clusters are shown in normal text and italics 
respectively. All miRNAs illustrated in green boxes are discussed in the 
text. Note that most of the interactions listed have only been validated by 
luciferase assay. 
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controlled by checkpoints which arrest or delay cell division in the event of DNA damage or 
mitotic abnormalities. Such stimuli trigger the activation of anti-proliferative CDK inhibitors 
such as members of the INK4 and Cip/Kip family.  
The relationship between miRNAs and the cell cycle is very complex (Fig. 1.5) and generally 
involves the G1 to S phase transition (199). Most miRNAs exert an anti-proliferative effect, 
which may be achieved by targeting cyclins and members of the CDK family. For instance 
CDK1, CDK2, CDK6, cyclin D1, cyclin D3 and cyclin E1 are all targeted by miR-15a and 
miR-16 (200-203). On the other hand miRNAs may exert a proliferative effect by targeting 
CDK inhibitors. For instance both miR-24 and miR-31 target p16INK4a, an inhibitor of 
CDK4 and CDK6 (204, 205).  
Some miRNAs regulate cell cycle events after DNA replication. The anti-proliferative miR-
125b, miR-24 and let-7 mediate repression of cyclin A and cyclin B, which in turn prevents 
CDK1 activation and G2/M progression (206-208). Conversely the proliferative miR-195, 
miR-128 and miR-516-3p target WEE1, an inhibitor of the cyclinB-CDK1 complex (209, 
210). There is little evidence for miRNA mediated regulation during mitosis although PLK1 
might be a miR-100 target (211). 
 
1.6 microRNAs in cancer cells 
Considering the broad range of biological pathways in which miRNAs are involved, it is not 
difficult to see how their deregulation could contribute to human disease. In the current 
section, we shall discuss the concept of oncomiRs, i.e. miRNAs which act as oncogenes or 
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tumour suppressors. Thereafter we will consider the mechanisms by which miRNA 
deregulation takes place in the context of human disease. 
Two early investigations used different methods to characterize expression of over 200 human 
miRNAs in a broad range of cancers i.e. solid tumours, lymphomas etc (212, 213). Both 
studies found that miRNAs were extensively deregulated in cancer compared to normal tissue. 
These findings were supported by a number of further studies, reviewed by Wang and Lee 
(214), which showed that certain miRNAs are consistently over expressed (miR-21, miR-155, 
miR-222 etc.) while others are consistently under expressed in cancer (miR-143, miR-145, 
let-7 etc.). Additionally different tumours as well as tumour subtypes may be distinguished 
based on their miRNA signature (212, 213, 215).  
When deregulation of a given miRNA promotes tumour progression it is referred to as an 
oncomiR. Such miRNAs may act as oncogenes or tumour suppressors. For example miR-155 
is an oncogenic oncomiR, frequently over expressed in B cell lymphoma (213, 216, 217); it 
causes lymphoproliferative disease in mouse models when over expressed from a B cell 
specific transgene (218). Another oncogenic oncomiR, miR-21, encourages disease 
progression in colorectal and lung cancer by targeting suppressors such as PDCD4 and TPM1 
(214, 219-222).  
The let-7 family of miRNAs serve as examples of tumour suppressor oncomiRs (89, 90, 92, 
223-227) as their expression impairs growth of a number of tumours e.g. colorectal and lung 
cancer cells, presumably by targeting oncogenes such as RAS and HMGA2. MiR-34a is 
another tumour suppressor oncomiR which mediates an anti-proliferative and/or pro-apoptotic 
state in neuroblastoma and brain tumours (190, 228), presumably by repression of c-myc, bcl-
2 and c-Met. The respective roles of let-7 and miR-34a in differentiation, apoptosis and 
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proliferation were discussed in section 1.5. A database (miR2Disease) has been set up in order 
to accumulate information on the importance of miRNA deregulation in human disease (229).  
There are a number of mechanisms through which miRNAs can be deregulated. MiRNA 
transcription for instance can be regulated by transcription factors such as c-myc or p53. C-
myc is over expressed in a number of tumours (230) while p53 is frequently inactivated by 
mutations (231). For instance p53 usually activates the tumour suppressive miR-34a cluster 
(63-65), while c-myc activates the human oncogenic miR-17-92 cluster (66, 67). Additionally 
miRNA transcription may be affected by aberrant DNA methylation i.e. inactivation of miR-
124 and miR-34a in colon and prostate cancer respectively (232, 233). MiRNA transcription 
in cancer cells is often affected by chromosomal rearrangements and aberrations. One study 
demonstrated that, out of 283 miRNA coding genes, 85.8%, 37.1% and 72.8% had altered 
copy number  in melanoma, ovarian and breast cancer, respectively  (223, 234). Interestingly 
41 of those genes were similarly altered in all three cancers investigated. Gene amplification 
of the 17q23 region housing oncogenic oncomiR miR-21 in neuroblastoma (235) and deletion 
of the 13q14 region housing anti-proliferative/pro-apoptotic miR15a and miR-16-1 miRNAs 
in chronic lymphocytic leukaemia CLL (189, 200-203, 236) are just some examples.  
MiRNA deregulation may also be mediated by aberrant expression of the miRNA processing 
machinery. Altered Drosha expression is observed in many cancers (237-239). Interestingly 
high Drosha levels indicates poor disease outcome in esophageal squamous cell carcinoma 
(ESS) while the opposite is true in ovarian cancer (237, 239). As previously mentioned 
defects in exportin-5 can lead to retention of pre-miRNAs (77). Exportin-5 has been described 
as a potential tumour suppressor in a subset of stomach and colon cancer (78). Deregulation 
of Dicer has also been described in a range of cancers (237, 240-242) with under expression 
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prognostic of poor disease outcome in lung and ovarian cancer (237, 242). Many components 
of the nuclear and cytoplasmic miRNA processing machinery, including Drosha and Dicer, 
can be regulated by tumour suppressors such p53, p63 and p73 (243).  
Finally, point mutations either in the miRNA or the 3′ UTR target can interfere with the 
miRISC silencing pathway. For instance a single G:C change in pre-miR146 reduces mature 
miR-146a production; this results in an increased risk of developing some types of thyroid 
and brain cancers whilst reducing the risk of prostate cancer (244-246). Conversely 
translocation of the normal HMGA 3′ UTR prevents let-7 mediated repression (91). High 
expression of HMGA2 contributes to disease progression in lung cancer and dually serves a 
prognostic marker for survival (224, 247, 248).  
 
1.7 Introduction to Epstein - Barr virus (EBV) 
Epstein–Barr virus (EBV), a widespread human gammaherpesvirus, is a potent transforming 
agent of resting B-lymphocytes and is aetiologically linked to several malignancies of 
lymphoid and epithelial cell origin including Burkitt lymphoma (BL) and nasopharyngeal 
carcinoma (NPC) (249). EBV was the first virus found to encode its own set of miRNAs 
(250). This raises questions as to their roles in the virus life cycle as well as how they might 
contribute to virus mediated oncogenesis. In the next few sections we will cover a few basics 
of EBV biology including how the virus was discovered and classified (section 1.7), how the 
viral genome is organized (section 1.8) and the tissue tropism of the virus (section 1.9). 
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1.7.1 A historical perspective 
The path to discovering EBV began in 1958 in Kampala (Uganda) where   surgeon Dennis 
Burkitt investigated a sarcoma affecting the jaws of children (251). The tumour (eventually 
named Burkitt lymphoma) (252) mapped almost exclusively to equatorial Africa (251) and 
appeared dependent on climatic factors like rainfall and temperature (253). Therefore it was 
proposed that transmission of the tumour could occur through a climate dependent vector, 
thereby opening the possibility of a viral role in disease development (253).  
In 1964 Michael Epstein, Bert Achong and Yvonne Barr (London) used electron microscopy 
to demonstrate the presence of herpes-virus like particles in continuous cell lines grown from 
BL biopsies (254); a series of collaborations with Werner and Gertrude Henle (Philadelphia) 
subsequently led to its classification as a novel herpes virus in 1965 (255). Over the next 
decade EBV research greatly expanded. Newly developed immunofluorescence assays 
revealed the virus was restricted neither to BL nor equatorial Africa; it was ubiquitous, 
infecting 90% people by adulthood (256). It was in fact the mosquito transmitted Plasmodium 
falciparum parasite, another co-factor in BL development, which was geographically 
restricted and climate dependent (257, 258). In the general population, EBV was identified as 
the causative agent of infectious mononucleosis (259, 260). Its potential to act as a cancer 
causing agent was demonstrated both in vitro and in vivo. Lethally irradiated BL cells induced 
growth transformation in peripheral leukocytes (261), while cell free virus induced 
lymphomas in immune-suppressed primates (262).  Nowadays EBV is an established member 
of human oncogenic (cancer causing) viruses. 
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1.7.2 A scientific classification 
EBV is formally referred to as human herpesvirus 4 (HHV4) and belongs to the family 
Herpesviridae within the order Herpesvirales (263). The Herpesviridae family contains 
primate herpesviruses, 8 of which are associated with humans, and comprises the alpha-, 
beta- and gammaherpesvirinae subfamilies. EBV is a gammaherpesvirus and the type species 
of the Lymphocryptovirus (LCV) genus. LCVs are mainly considered B lymphotrophic and, 
with the exception of EBV, exclusively infect non-human primates.  
 
1.8 Structure and genome of EBV 
The EBV particle measures ~180 nm in diameter and is surrounded by a glycoprotein (gp)-
rich envelope (264). It contains a protein tegument, a capsid with 162 capsomers, and a 
protein-DNA core organized in the form of a torus (255, 265). The genome itself consists of a 
linear double stranded DNA (dsDNA) genome roughly 175 kilobase pairs (kbp) in length 
(266).  
EBV was the first herpesvirus to have its genome fully sequenced; this was achieved with 
fragments generated by BamHI and EcoRI digestion of the B95-8 strain (267-269). Genes 
were named according to the BamHI fragment (denoted A-Z and a-e in descending order of 
size) in which they start i.e. BRLF1 is the first leftward reading frame starting in BamHI 
fragment R. A representative map of the B95-8 genome can be seen in Fig. 1.6 taken from 
Kalla and Hammerschmidt (270). Presently there are five available complete or partial 
genomes sequences (B95-8, AG876, GD1, GD2 and HKNPC1) (267, 271-274).  
Fig. 1.6. Schematic of the B95-8 prototype strain of EBV (image taken from 
Hammerschmidt and Kalla) (270). The viral genome is divided into multiple 
BamHI fragments (A-Z, a-e). The origin of plasmid replication (oriP), the 
origin of lytic replication (oriLyt), and the terminal repeats (TR) are illustrated 
with blue boxes. The12kb deletion fragment deleted in the B95-8 strain but 
present in all field strains of EBV is illustrated in the top left inset. Also shown 
are the EBV latent genes (turquoise and purple boxes), the C, W, Q and LMP 
promoters (black arrows) and the viral non-coding RNAs (red arrows). Lytic 
genes expressed shortly after de novo infection of resting B cells with EBV are 
illustrated with yellow boxes.  
 
B95-8 deletion 
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All EBV strains share a near identical genome organization. EBV has ~100 open reading 
frames (ORFs), with most of the genome’s coding capacity being shared between two unique 
domains: a short 9000 bp (US or U1) and a long 150000 bp (UL) sequence (267, 275-279). 
Most of these genes are in turn dedicated to productive cycle infection (267). EBV also has a 
large number of reiterated direct repeat sequences interspersed throughout the genome. The 
major internal repeat (IR1), which consists of multiple copies of a 3.1 kbp sequence, separates 
the US from the UL domain (268, 280, 281); the latter domain is further subdivided into four 
regions (U2-U5) by additional IRs (282, 283). The ends of the genome are flanked by the 
terminal repeats (TR), multiple copies of a 500 base pair (bp) sequences (284, 285).  
Generally the EBV genome is highly conserved. The majority of documented strain 
associated sequence variation occurs in the EBNA2 and EBNA3 genes; the amino acid 
identity of EBNA2, 3A, 3B and 3C genes differs for the two major EBV subtypes – Type I 
and Type II – by 45%, 16%, 20% and 28% respectively (286-288). Both subtypes may be 
further subdivided into many strains based on the number of repeats within their latent genes 
(289, 290). Additional polymorphisms within the EBNA and LMP genes have been identified 
some of which correlate with defined geographical locations, suggesting evolutionary drift in 
separate populations (291-294).  
 
1.9 Tissue tropism of EBV 
EBV predominantly infects B lymphocytes by targeting and binding of the C3d complement 
receptor, CD21, which is expressed on B cells of all developmental stages except terminally 
differentiated plasma cells (295-299). CD21 is the primary EBV receptor on B cells. Binding 
is mediated via the viral gp350 protein which bears two short regions of homology with the 
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natural CD21 ligand, C3dg (299-301). Subsequently EBV binds a co-receptor on B cells, 
MHCII, via the viral gp42 protein; this triggers fusion and entry (302-304). Generally 
infection of B cells results in latent infection although productive infection can occur in a 
small number of infected cells (305).  
EBV also appears capable of infecting a range of CD21 negative cell types including 
epithelial (306), natural killer (NK) (307) and T cells (308) as evidenced by direct association 
of EBV with malignancies deriving from these cell lineages. Epithelial cells can be infected in 
vitro via a process termed transfer infection, in which B cell – bound EBV is “transferred” to 
an epithelial cell via cell to cell contact (309, 310); like B cells, they are also capable of 
supporting productive infection (311, 312). While some 30% to 40% of T lymphocytes do 
express low levels of CD21 (ten times lower than B cells) (313) CD21 negative T 
lymphocytes are still capable of binding EBV via an uncharacterized receptor (314). The 
natural role of epithelial, T and NK cells in of the viral life cycle remains unclear. 
 
1.10 In vitro infection, transformation and immortalization of B cells  
The ability of EBV to act as a cancer causing agent was initially demonstrated during in vitro 
infection (261). Specifically, lethally irradiated BL cells induced growth transformation in 
peripheral leukocytes. The current section will outline the events that take place between de 
novo infection of cultured resting B cells and the outgrowth of an immortalized cell line. 
The expression of the full latent gene repertoire is interchangeably termed Latency III or the 
growth transforming program (Fig. 1.7) (315). Cells infected with EBV in vitro express the 
full range of EBV gene products discussed previously, including 6 nuclear antigens (EBNA-
Fig. 1.7. The growth transforming program of LCLs. The location of viral 
promoters and splice structures of viral transcripts are shown relative to a 
linear representation of the EBV genome. Growth transformed LCLs express 
all six EBNAs and BHRF1, predominantly from highly spliced transcripts 
initiated at the BamHI C promoter (Cp), along with the LMPs which are 
transcribed from separate promoters in the BamHI N region. Epstein-Barr 
virus-encoded small RNAs (EBERs) and BamHI A rightward transcripts 
(BARTs) are expressed from their own respective promoters.  Also shown are 
the positions of the BHRF1 and BART miRNAs, latent origin of replication 
(oriP) and the terminal repeat region (TR). Note that the growth transforming 
program is interchangeable referred to as Latency III (Lat III). 
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LP, EBNA1, EBNA2, EBNA3A, EBNA3B and EBNA3C) driven by promoters C and W 
(316-319), 3 membrane proteins (LMP1, LMP2A and LMP2B), the EBER and BART RNA 
species, and a viral Bcl-2 homolog (BHRF1) (320). Also expressed are two groups of viral 
miRNAs located in the BHRF1 and BART region of the genome termed the BHRF1 and 
BART miRNAs respectively (250). These molecules will be discussed in more detail 
throughout later sections (section 1.14.9).  
Once inside a B cell the linear EBV genome circularizes via the terminal repeats; episomes 
appear roughly 16-20 hours post infection (284, 321). This is a key event in transformation 
and immortalization as it allows the genome to persist in infected B cells. Note that multiple 
copies of the circular EBV genome can be found per latently infected cell (322). Viral 
transcription initiates much earlier however and follows a set sequence. Initially the W 
promoter (Wp) generates large RNA polymerase II driven transcripts which give rise to the 
EBNA-LP and EBNA2 proteins (detectable at 12h-24 hours) (323-327). Note that that 
different EBV strains possess a variable number of W repeats and consequently multiple 
copies of Wp (319, 328). Nonetheless a minimum of 5 copies of Wp are required for optimal 
transformation (328).  
EBNA2 transactivates the C promoter (Cp); at this point levels of Wp transcription start to 
decrease whilst Cp becomes predominantly responsible for EBNA gene transcription (24h-
48h post-infection) (325, 329-332). Cp transcripts are differentially spliced and capable of 
generating the complete set of EBNA proteins (EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C and EBNA-LP). EBNA2 further activates the latent membrane protein (LMP) 
promoters; LMP1 and LMP2 transcripts are both readily detectable by 5 days post-infection 
(325). A number of non-coding RNAs are also expressed from their respective promoters 
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early after primary infection. The BART RNAs are readily detectable by 24h whilst the EBER 
RNAs (EBER1 and EBER2) can be detected after 3 days (325). Finally a Bcl-2 homolog, 
BHRF1, is also expressed at low levels in transformed B cells (320).  
EBV has innate growth transforming and immortalization properties. De novo infection of 
resting B cells induces unlimited proliferation (261, 333) and ultimately gives rise to the 
outgrowth of an immortal cell line termed lymphoblastoid cell line (LCL). The process of 
transformation is B cell specific (334). It begins early post-infection and is characterized by a 
number of morphological changes i.e. increases in cell size, irregular shaping and clumping 
(261, 333). Cell cycle entry and progression occurs as a result of cellular changes including 
the stimulation (cyclin D2, cyclin E, cdk1, cdk2, cdk4, cdk6) and inactivation (pRb, p107) of 
specific cell cycle regulatory proteins (335-337). EBV is believed to drive and maintain 
proliferation by mimicking antigen driven B cell activation with T cell help in the absence of 
T cell signalling or the B cell receptor (338). In agreement with this, a number of genes and 
cell surface molecules involved in signalling and growth regulation are collectively up 
regulated. These include growth factors IL-5 (339), IL6 (340), and IL-10 (341, 342) as well as 
receptors such as CD21, CD23 (343-345), CCR7 (346, 347), and the TNF-α receptor (348). A 
number of adhesion molecules and proteins involved in cytokine formation are also 
stimulated (346, 349).  
Transformation requires several EBV proteins. EBNA2, LMP1 and EBNA3C are absolutely 
essential for transformation (350, 351). EBNA-LP, EBNA3A and EBNA1 are also very 
important; EBNA-LP deleted mutants have reduced transformation efficiencies (352), 
EBNA3A deleted LCLs are severely growth impaired and sensitised to apoptosis (353) whilst 
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EBNA1 is needed to maintain the viral genome in proliferating cells (354). The precise 
functions of the various EBV gene products are discussed elsewhere (section 1.14).  
EBV transformed lymphoblastoid cells require additional mutations to achieve 
immortalization, key to which is telomerase activation (355-358). Non-immortalized LCLs 
have negligible telomerase activity (359, 360), thus telomere shortening occurs with each cell 
division until a critical length is reached (typically by 180 passages). At this point cells 
undergo crisis and only those which have managed to stabilize their telomeres (via telomerase 
activation) survive. These cells grow out to form an immortalized population characterized by 
chromosomal aberrations (361). As they become more tumour-like, immortalized LCLs gain 
the ability to form colonies on agarose and grow in nude mice (362). Other changes are 
associated with immortalization and tumourigenesis including mutations in p53 (362) and an 
altered responses to cytotoxic drugs (363). The processes of transformation and 
immortalization (within context of the LCL model of infection) are important as they have not 
only provided us with insight into the biology of the Epstein-Barr virus but also clues as to the 
mechanisms underlining EBV tumourigenesis.  
 
1.11 In vivo infection of B cells 
EBV is usually contracted during childhood where it causes an asymptomatic infection. Some 
50% of EBV infections contracted during adolescence or later result in infectious 
mononucleosis (IM), a self limiting lymphoproliferative disease (260, 364). The virus is 
transmitted by saliva and enters the body through the lymphoepithelium lining the oral cavity 
(365). EBV is believed to initially infect and replicate in tonsillar B lymphocytes (305, 366, 
367). It is unclear if and to what extent epithelial cells are involved during the natural biology 
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of EBV. Evidence suggests that epithelial cells are not infected during primary infection but 
instead might serve as sites of viral amplification and subsequent shedding in healthy EBV 
carriers (368-371). Nonetheless primary EBV infection results both in shedding of new virus 
into the oral cavity and the latent colonization of the host B cell pool.  
Primary EBV infection elicits a potent CD8+ cytotoxic T lymphocyte (CTL) response, which 
both controls the infection and causes the symptoms of IM (372, 373). EBV is not cleared 
entirely however and may be isolated as infectious virus in throat washings and in latently 
infected B cells (374, 375). On that note EBV is able to persist within memory B cells where 
it expresses a very restricted form of latency termed the latency program (Lat 0) where only 
non-coding RNA species are expressed i.e. the EBERs, BARTs and in theory the BART 
miRNAs (376, 377).  
The mechanism by which EBV gains access to the memory pool is controversial. One widely 
accepted model is that EBV colonizes naïve B cells and then mirrors antigen driven B cell 
maturation, allowing for germinal centre (GC) transit in the absence of  external stimuli (377). 
The GC model can be seen in Fig. 1.8A taken from Young and Rickinson (378). EBV 
primarily infects resting naïve B cells. Subsequently it expresses the full range of latent 
antigens (Lat III), which causes the naïve B cells to become activated B blasts. Activated B 
blasts travel to the follicles whereupon EBV gene expression is down regulated to a 
Hodgkin’s lymphoma-like (Lat II) antigen profile termed the default program (379, 380). Two 
viral antigens, LMP1 and LMP2, are sufficient to allow for GC formation and differentiation 
of the activated B blast to a memory B cell. LMP1 functions as a constitutively active CD40 
receptor thus activating proliferation and survival (381, 382) while LMP2 is capable of 
providing BCR-like survival signals (383, 384). The LMPs will be discussed in more detail 
Fig. 1.8. In vivo infection and persistence of EBV (image taken from Young 
and Rickinson) (378). (A) Two possible mechanisms through which EBV gains 
access to the memory B cell reservoir. In the Germinal centre (GC) model EBV 
infects naïve B cells and mirrors antigen driven differentiation of naïve B cells 
to memory B cells. In the direct infection model EBV infects pre-existing 
memory B cells (B) Summary of EBV persistence. EBV persists latently in 
memory B cells until antigen stimulation drives them to differentiate into 
plasma cells. Plasma cells migrate to the mucosal epithelium and release 
infectious virus into the saliva. 
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later (section 1.14.5). In circulating memory B cells viral antigen expression is further 
suppressed to Lat 0, consequently avoiding immune detection (377). Note that EBNA1 is 
occasionally expressed to allow for maintenance of the viral genome during cell division 
(385).  
Another possible mechanism is the direct infection of memory B cells in the absence of GC 
transit (379, 386). This model is supported by a number of observations. Firstly X-linked 
lymphoproliferative (XLP) patients can be latently infected with EBV; note that XLP patients 
can not form fully functional germinal centres (387). Secondly EBV is detectable in the non-
isotype-switched memory B cells (IgD+ CD27+) of immunocompetent IM patients and 
persistently infected individuals (388); note this particular B cell subset is believed to arise in 
a GC-independent manner (389-391). Finally EBV-infected B cells in IM tonsils do not 
localize to the germinal centre but to extrafollicular areas instead (305, 379, 392). Such B 
cells lack GC markers such as CD10 and CD77 (388); it is true that they are positive for 
CD38, also a GC marker, however this may be a consequence of growth activation rather than 
GC transit (388).  
EBV reactivation from latently infected memory B cells in vivo is thought to be triggered by 
antigen driven differentiation of the memory B cell to an antibody secreting plasma B cell 
(393, 394). Plasma cells naturally migrate to the mucosal surface where infectious virus is 
released into the tonsils (395-397). As discussed earlier epithelial cells may play a role in 
amplifying the amount of virus released into the saliva (368, 369). The reactivation process 
can be seen in Fig. 1.8B taken from Young and Rickinson (378).  
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1.12 EBV productive infection 
Previously we have discussed the establishment of latency both in vitro and in vivo; in both 
scenarios a Lat III program of latent gene expression can be observed. The majority of the 
EBV coding capacity is dedicated to productive infection (267, 270) which may be divided 
into immediate early, early and late genes. The switch to productive infection depends on two 
immediate early transcription factor genes, BZLF1 and BRLF1 (398, 399). These 
transcription factors are responsible for early gene induction; BZLF1 and BRLF1 can auto- 
and cross- stimulate one another in order to amplify their activities (400-404). BZLF1 is a 
viral AP-1 homolog (405) that interacts with targets containing Z-response elements (ZRE) 
(406, 407). Early genes include machinery necessary for DNA replication such as the viral 
polymerase BALF5 (408-410). By comparison late cycle genes primarily include structural 
proteins required for virus assembly (408-410).  
Productive infection within in vitro cultured B cell lines can be triggered through mechanisms 
such as phorbol ester treatment and immunoglobulin cross linking (411-415). One thing to 
note however is that significant productive infection does not occur in de novo infected 
cultured B cells, even though BZLF1 is expressed in the majority of cells within the first few 
hours post-infection (416). BZLF1 expression has been suggested in these circumstances to 
promote the proliferation of resting B cells. The failure to produce viral progeny is linked to 
the fact that de novo infecting viral genomes are unmethylated; a number of key downstream 
targets of BZLF1 require promoter methylation in order to be efficiently activated by BZLF1 
(417, 418). Production of infectious virus in vivo occurs in B cells of the oropharynx, possibly 
during primary infection or viral reactivation (366, 367, 393, 419); it has been suggested that 
the source of infectious virus are terminal differentiating plasma B cells (393, 394).  
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The EBV genome is exponentially amplified by rolling circle replication and expresses an 
extensive number of genes (267, 408). Consequently EBV has developed a number of 
mechanisms to subvert immune surveillance. For instance the non-structural late protein 
BCRF1 acts as a viral IL-10 homolog (vIL-10) (420); BCRF1 may provide pro-survival 
signals (420-424) and/or interfere with T cell mediated immune surveillance (425-428). 
Furthermore a number of other gene products such as BILF1, BGLF5 and BNLF2a may also 
interfere with viral targeting by T cells (429-431). Two early genes, BHRF1 and BALF1, are 
bcl-2 homologs which have previously been shown to inhibit apoptosis in culture (320, 432). 
These may further assist in the survival of cells infected with actively replicating EBV. 
 
1.13 EBV-associated B cell lymphomas 
EBV is aetiologically linked to a number of malignancies of lymphoid and epithelial cell 
origin; these include Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant 
lymphoproliferative disease (PTLD), nasopharyngeal carcinoma (NPC) and a range of T cell 
and NK lymphomas (249). In the current section we will discuss a selection of malignancies 
specific to B cells. We will focus first on a number of proliferative diseases found in immune 
compromised individuals; thereafter we will focus on Hodgkin and Burkitt lymphoma. 
 
1.13.1 Proliferative disease in immune compromised hosts 
The in vivo oncogenic properties of EBV are clearly evidenced by a collection of 
lymphoproliferative diseases in the immune suppressed or compromised. One such disease is 
post-transplant lymphoproliferative disease (PTLD). It affects patients who are receiving 
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immune suppression to prevent graft vs. host disease of transplanted tissue. As reviewed by 
Nalesnik, PTLD occurs in at least 1.4% of transplants although the precise rate depends on 
factors such as the type of tissue and level of immune suppression received (433). For 
instance heart transplants (2%-10%) carries a higher risk of PTLD than renal transplants (1%) 
(433). Rarely (less than 2%) PTLD may also occur in human stem cell transplant (HSCT) 
patients; note that such patients would have had their own immune system ablated as part of 
the medical procedure (434-436). PTLD lesions have been described as early, polymorphic 
and monomorphic (437). The relationship between EBV infection and PTLD is well 
established (433). Patients with high EBV loads or those undergoing primary EBV infection 
are at greatest risk (438, 439). PTLD lesions in turn are almost always EBV positive (437). It 
is believed that PTLD lesions derive from germinal centre (GC) or post-GC B cells; the 
majority of EBV positive B cells in a PTLD lesion carry mutated Ig gene rearrangements 
(440). Several lines of evidence point to a loss of the virus-specific CD8+ cytotoxic T cell 
(CTL) response as the reason for PTLD formation. PTLD lesions display a latency III pattern 
of EBV gene expression, consistent with EBV infection in the absence of immune 
surveillance (441-443). Furthermore PTLD lesions are devoid of activated T cell infiltrate 
(444). Additionally the risk of PTLD throughout bone marrow transplantation rises from 1% 
to nearly 24% upon ablation of EBV specific T cells from donor marrow (445). Finally PTLD 
can be reversed via a reduction of immune suppressive therapy; recovery coincides with the 
appearance of virus specific CD8+ CTLs (446-448).  
Another example of an EBV associated lymphoproliferative disease is AIDS-associated 
lymphoma. As reviewed by Gaidano et al. HIV infected individuals have a higher risk of 
developing a range of B cell lymphomas, especially during end stage disease (449, 450). EBV 
association with tumour cells varies between 30% and 100% depending on the nature of 
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lymphoma involved. One of the more prevalent types of AIDS-lymphoma presents with 
PTLD-like lesion (451). Tumour cells within these lesions seem to derive from memory B 
cells, are characterized by a Lat III pattern of gene expression and also appear to  result from a 
loss of virus specific T cell monitoring (450, 452-455).  
 
1.13.2 Hodgkin lymphoma 
Hodgkin lymphoma (HL) is a common form of lymphoma in the West with 3 cases per 
100000 each year (456). It is an unusual disease in that more than 98% of the total tumour 
mass consists of non-malignant infiltrate, which in turn surrounds a minor population of 
malignant mononuclear Hodgkin cells and multinuclear Reed-Sternberg cells (H-RS) (457). 
HL is subdivided into classical HL (cHL) and lymphocyte predominant HL (lp-HL) groups 
(457). While EBV association in the latter subtype is rare, it is associated with ~35% of cHL 
in the west and more than 60% of cases in developing countries (458).  
Differences in the onset and peaks of childhood and adult HL between western and 
developing countries mirror IM prevalence thus suggesting a possible role for EBV in HL 
progression (459, 460). Several pieces of evidence favoured this hypothesis. Firstly a history 
of IM increased the risk of developing HL three fold (459). Secondly monoclonal EBV 
genomes were not only detected in tumour biopsies (southern blotting, terminal repeat 
assays), but specifically located to H-RS cells (in situ hybridization) (461-463). Ultimately 
every H-RS cell of a given tumour was found to carry the exact same EBV genome (464).  
EBV gene expression in HL is more restricted than latency III. Antibody staining at the single 
cell level only revealed the presence of EBNA1 (465), LMP1 (466, 467) and LMP2A (392) 
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while transcriptional analysis also demonstrated the presence of EBER and BART RNA 
(468). This pattern of latent antigen expression is termed latency II. H-RS cells were found to 
derive from somatically hypermutated germinal centre B cells with nonsense Ig gene 
rearrangements (469-472). Such cells would normally undergo apoptosis but are rescued by 
two EBV latent antigens termed LMP1 and LMP2. The functions of LMP gene products were 
briefly discussed in section 1.11 and will be discussed in more detail later (section 1.14.5).  
 
1.13.3 Burkitt lymphoma 
Burkitt lymphoma (BL) is a tumour derived from germinal centre B cells which can be 
separated into three groups: endemic, sporadic and AIDS-associated (473). Endemic BL 
(eBL) predominantly presents as a mass of the jaw and is the BL group originally described 
by Dennis Burkitt (251-253, 257). It maps almost exclusively to equatorial Africa and Papua 
New Guinea and is nearly always EBV associated, suggesting a role for the virus in the 
disease process (473, 474). Sporadic BL (sBL) presents mainly as an abdominal mass and is 
~15% EBV associated (475-477). In contrast to eBL it occurs worldwide, albeit with a much 
lower incidence (475, 476). AIDS associated BL (AIDS-BL) usually occurs in otherwise 
healthy HIV carriers and is around 40% EBV associated (450, 477-479). Due to HIV 
prevalence it is the most common form of BL.  
All three groups of BL (eBL, sBL and AIDS-BL) share characteristic gene rearrangements 
between the c-myc region of chromosome 8 and the immunoglobulin genes (477, 480, 481). 
For most BL (~80%) this involves a translocation with the heavy chain genes on chromosome 
14, but can also involve the lambda or kappa genes on chromosomes 22 and 2 respectively. In 
all three, over expression of c-myc by the immunoglobulin locus (480-483) leads to aberrant 
Chapter 1 
 
 
33 
 
cell growth and proliferation (484-489). It also triggers a heightened sensitivity to apoptosis 
(490, 491).  
Each tumour cell in EBV positive BL is monoclonal in origin; thus EBV precedes and could 
be responsible for clonal expansion in BL (254, 492). Studies on the contribution of EBV to 
the disease progression of BL have investigated a number of latent antigens (493). EBNA1 is 
the only latent antigen expressed in conventional EBV positive BL and is expressed from 
promoter Q (Fig 1.9) (494, 495); note that the W, C and LMP promoters are silent in this 
tumour (496-498). Additionally both the EBER and BART RNA species are expressed (473, 
499). This form of latency is termed latency I and it is even more restricted than latency II 
seen in HL. The observation that EBV positive BL cells are more resistant to apoptosis than 
spontaneous EBV loss counterparts suggests that EBV might provide survival signals to 
tumour cells (500). On that note EBNA1 has been shown to destabilize p53 by targeting 
HAUSP (501). It is unclear how relevant this is as p53 is frequently mutated in BL cell lines; 
nonetheless there is evidence to suggest such mutations may be less frequent in vivo (502, 
503). EBERs may also contribute to BL as they have been implicated in driving tumour 
growth and resisting IFN-α mediated apoptosis (500, 504-508).  
Around ~15% of EBV associated BL tumours display a more extensive pattern of antigen 
expression where promoter W drives expression of EBNA1, EBNA3A, -3B, -3C, BHRF1 and 
a truncated form of EBNA-LP (t-EBNALP) from an EBNA2 deleted genome (Fig. 1.9) (320, 
509, 510); note that these tumours also carry a silent wild type genome. This particular type of 
BL is termed Wp-restricted BL (Wp-BL) and is more resistant to apoptosis than its latency I 
BL counter part (510). A number of reports have investigated the contributions of BHRF1, t-
EBNA-LP and the EBNA3s to the Wp-BL survival phenotype (320, 511, 512). Briefly, 
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Fig. 1.9. Patterns of latent gene expression in BL cell lines and LCLs. The 
location of viral promoters and splice structures of viral transcripts are shown 
relative to a linear representation of the EBV genome. Conventional Latency I 
BLs express a single latent antigen EBNA1 transcribed from a viral promoter 
in the BamHI Q region(Qp). Wp-restricted BLs are characterised by the 
presence of an EBNA2-deleted EBV genome; these BLs express EBNAs 1, -
3A, -3B, -3C and –LP, along with BHRF1, all transcribed from the Latency III 
BamHI W promoter (Wp), but in the absence of EBNA2 and the latent 
membrane proteins (LMPs). Latency III BL lines and growth transformed 
LCLs express all six EBNAs and BHRF1, predominantly from transcripts 
initiated at the BamHI C promoter (Cp), along with the LMPs which are 
transcribed from separate promoters in the BamHI N region. EBERs (not 
shown) and BamHI A rightward transcripts (BARTs) are present in all three 
forms of latency.  Also shown are the positions of the BHRF1 and BART 
miRNAs, latent origin of replication (oriP) and the terminal repeat region (TR).  
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BHRF1 acts as an anti-apoptotic Bcl-2 homolog (320, 513), while t-EBNA-LP antagonizes 
caspase-mediated apoptosis via inactivation of protein phosphatase 2A (PP2A) (512).  
EBNA3A and 3C in turn can down regulate pro-apoptotic Bim and members of the anti-
proliferative INK4 family (353, 511, 514). As such EBV may act to counter the sensitisation 
to apoptosis caused by c-myc deregulation.  
 
1.14 Functions of EBV Latent Gene Products  
In sections 1.10 and 1.11 we described the full repertoire of latent gene expression found in 
transforming B cells both in vitro and in vivo. In the following sections we will cover in detail 
the functions of each of these latent gene products and how they contribute towards the viral 
life cycle.  
 
1.14.1 EBNA1 
EBNA1 is a DNA binding protein with essential roles in replication and maintenance of the 
EBV episome in infected cells (385). It is encoded within the BamHI-K region of the genome 
and can be transcribed from four different promoters: the C and W promoters in the LCL 
model (515), the Q promoter in classical Burkitt lymphoma (516) and the F promoter during 
productive infection (517-519).  
EBNA1 directly binds three areas of the viral genome: the dyad symmetry (DS) and the 
family of repeats (FR), which together form the plasmid origin of replication (oriP), as well as 
a more distal area located in BamHI-Q (385, 520-524). The DS contains 4 EBNA1 binding 
sites; it is the site of replication initiation and functions as an EBNA1-dependent replicator 
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(525-527). FR contains a variable number of EBNA1 binding sites (20 in B95-8) and 
functions to prevent EBV loss from actively dividing cells by attaching them to the human 
chromosome (528, 529). EBNA1 is the only viral protein able to associate with the human 
chromosome (530), which it does via a cellular binding partner EBP2 (EBNA1-binding 
protein) (531-533). Note that EBNA1contains an AT-hook domain which might allow for 
EBP2 independent binding (534). 
Deletion studies have revealed that genome maintenance is the key essential function of 
EBNA1 (535). EBNA1 deleted virus can only transform resting B cells if the entire viral 
genome integrates into the human chromosome. Other functions of EBNA1 involve acting as 
a transcriptional enhancer or repressor. By binding oriP, EBNA1 can enhance the C and 
LMP1 promoters (520, 536). Similarly by interacting with the EBNA1 binding site in the 
BamHI-Q region of the genome EBNA1 can negatively regulate its own expression during 
Latency I (518, 519, 537, 538). EBNA1 is also capable of binding to and affecting the 
promoters of many cellular genes; the nature of genes affected appears to be tissue specific 
(539, 540). Furthermore EBNA1 appears to have a mechanism for avoiding immune detection 
by CD8+ T cells. This is mediated by a glycine-alanine repeat in its N-terminus which can (a) 
negatively regulate the efficiency of EBNA1 translation and (b) interfere with EBNA1 
degradation by cellular proteosomes (541, 542). Both activities would reduce the amount of 
EBNA1 derived epitopes available for antigen presentation. Finally EBNA1 might inhibit 
apoptosis and promote G1-S cell cycle progression (500, 543) by sequestering HAUSP/USP7 
(501), a deubiquitylating enzyme involved in protecting p53 from MDM2-mediated 
degradation. 
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1.14.2 EBNA2 
The EBNA2 gene is located in the BamHI-Y region of the genome and encodes a 487 amino 
acid protein with an 84kDa molecular weight. (544, 545). It is a viral transcriptional activator 
protein which acts on a number of viral and cellular promoters (499). Its importance in 
transformation was demonstrated through reconstitution experiments on an EBNA2 deleted 
virus (P3HR-1) lacking immortalizing properties (544-546). Indeed the differences in 
transforming efficiencies observed between EBV type 1 vs. type 2 virus (547) are attributed to 
changes in their EBNA2 genes; these changes predominantly map to the EBNA2 C-terminus 
(548, 549).  
EBNA2 contains three regions crucial to transformation and immortalization: domains either 
side of an N-terminal proline repeat motif which facilitate homodimer formation and 
transcription factor recruitment (550, 551); an acidic 14 amino acid C-terminal region which 
functions as a trans-activation domain (552); an RBP-Jκ interaction domain which facilitates 
DNA contact (553-555). Other functionally important regions include the Arg-Gly repeat and 
C-terminal Lys-Arg-ProArg motifs which both serve as nuclear localization signals (NLS) 
(556) as well as the large central region which mediates self-association (557). In essence 
EBNA2 contains a number of features common to cellular transcription factors.  
The transforming properties of EBNA2 are directly tied to its ability to potently activate 
transcription (552) of genes involved in proliferation. The RBP-Jκ interaction domain allows 
EBNA2 to bind DNA indirectly via the adaptor protein RBP-Jκ (553-555, 558, 559). RBP-Jκ 
is a ubiquitously expressed and highly conserved cellular DNA-binding protein (560, 561) 
and forms part of the Notch signalling pathway (562). In non-proliferating cells RBP-Jκ 
interferes with gene expression  as part of a co-repressor complex (SMRT/N-CoR, CIR, 
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SKIP, Sin3A, SAP30 and HDAC1) (563). In proliferating cells, activated Notch receptor 
binds RBP-Jκ and displaces the co-repressor complex (564, 565), enabling RBPJ-κ to 
participate in gene activation (566, 567). The RBP-Jκ interaction domain allows EBNA2 to 
interact with RBP-Jκ in a similar way to Notch (568, 569), essentially making EBNA2 a 
functional equivalent to a constitutively active Notch receptor. This is further evidenced by 
the observation that activated Notch can transiently substitute for EBNA2 in driving 
proliferation (570).  
The C-terminal activation domain of EBNA2 is functionally equivalent to herpes simplex 
antigen VP16 (556, 571) and allows for similar interactions with cellular transcription factors 
such as TFIIB, TFIIH, TFIIE and p100 (572-574). EBNA2 also interacts with transcriptional 
co-activators p300, CBP and PCAF (575) as well as hSNF5/INI1 (576), suggesting the 
mechanism underlying EBNA2 function involves both histone acetyltransferase (HAT) 
activity and chromatin restructuring. Three viral (LMP1, LMP2A and C promoters) (577-579) 
and numerous cellular promoters (including CD21, CD23, CD25, C-FGR, c-myc) (499, 580) 
have EBNA2 response elements and are thus subject to its regulation.  
An additional function of EBNA2, separate from its role in trans-activation, is to counter 
apoptosis via an interaction with nuclear protein Nur77 (581). Nur77 functions as a 
transcription factor in the nucleus but as a cytochrome c release signal in the cytoplasm (582, 
583). EBNA2 prevents the latter function by retaining Nur77 in the nucleus (581).  
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1.14.3 EBNA3A/3B/3C 
The EBNA3 proteins (EBNA3A, 3B and 3C) were originally discovered by western blotting 
using rheumatoid arthritis patient sera (584-588). They are encoded by three separate genes 
arranged in tandem within the BamHI-E region of the genome. EBNA3A, 3B and 3C mRNAs 
are all processed from the same transcript, but may differentially accumulate due to alternate 
splicing of the primary transcript (316-318, 589).  
EBNA3A, 3B and 3C proteins are highly stable proteins of 944, 937 and 992 amino acids in 
length, respectively, and are remarkably similar in amino acid sequence (590-593). EBNA3 
proteins all have short hydrophilic N-termini, a region extensively conserved between all 
three EBNA3 proteins (homology domain), and C-termini rich in proline residues and repeat 
motifs. Thus it is unsurprising that they share a degree of functional homology. EBNA3 
proteins can all sequester RBP-Jκ via specific binding sites in their homology domains (594-
596). This suggests they function to negatively regulate the trans-activating functions of 
EBNA2. Indeed EBNA3A has been found to antagonize the expression of EBNA2 stimulated 
genes i.e. CD21, CD23 and c-myc (597). Similarly EBNA3C represses both the LMP1 and C 
promoters in an RBP-Jκ dependent manner (593, 598). There is also evidence that EBNA3A 
and EBNA3C can function as transcriptional activators (594, 599). EBNA3C might enhance 
LMP1 expression under certain conditions (594, 600, 601), while EBNA3A helps activate the 
Aryl hydrocarbon receptor (AhR), a transcription factor involved in cell proliferation (602, 
603).  
The ability of the EBNA3 proteins to act as transcriptional repressors and activators appears 
to be indispensible for growth transformation. EBNA3C deleted recombinant virus can not 
immortalize resting B cells and withdrawal of conditionally expressed EBNA3C from 
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proliferating blasts results in growth arrest (351, 604). EBNA3A is not essential as previously 
thought but does appear to provide important functions in cell growth and survival (351, 353, 
605).  
One way by which EBNA3 proteins maintain the proliferating phenotype is through 
interference with cell cycle checkpoints. EBNA3A and 3C can both down regulate members 
of the anti-proliferative INK4 family such as p16 (353, 604) thus favouring cell cycle 
progression. Additionally all three EBNA3 proteins are each capable of bypassing the G2/M 
checkpoint, possibly by inactivating the checkpoint kinase chk2 (606). Finally EBNA3C can 
antagonize the formation of pRb-E2F1 complexes thus freeing transcription factor E2F1 (607, 
608), as well as stabilize c-myc to ensure continued expression c-myc stimulated genes (609).  
EBNA3 proteins have also been shown to modulate the levels of proteins involved in cell 
death. EBNA3B can cause the up regulation of anti-apoptotic protein bcl-2 when expressed in 
the EBV negative BL line DG75 (610). Likewise EBNA3A and EBNA3C cooperate in the 
epigenetic silencing and CpG methylation of pro-apoptotic protein Bim (514). This may 
prove a novel means by which EBV infection can influence cellular gene expression even 
after their viral expression is silenced (as would be the case in vivo).  
EBNA3 may additionally function to modulate the host immune response in vivo. Recently it 
was demonstrated by array analysis that EBNA3C regulates as many as 169 genes, many of 
which were involved in migration, adhesion and chemotaxis (611). In particular CXCL10 and 
CXCL11 were shown to be down regulated. Both function to attract CXCR3 expressing cells 
i.e. NK and T lymphocytes to sights of inflammation; the migration of CXCR3 expressing 
cells was revealed to be impaired in a number of EBNA3C expressing B cell lines (611). 
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Remarkably a recent report suggests that up to 1000 cellular genes may be regulated by one or 
more of the EBNA3 proteins (612).  
 
1.14.4 EBNA-LP 
EBNA-LP is expressed together with EBNA2 early post-infection (8-12 hours) and 
predominantly serves as a co-activator for EBNA2 mediated trans-activation (499). The N-
terminus component is located in the W repeat region with each repeat containing two exons 
(W1W2) which together encode a 66 amino acid sequence. The C-terminus consists of a 
single stretch of 45 unique amino acids derived from two exons (Y1Y2) in the long unique 
region of the genome (316, 317, 613, 614). EBNA-LP size is affected by a number of factors 
(615). Each W repeat contains a functional W promoter capable of initiating EBNA-LP; thus 
W promoter initiated EBNA-LP varies in size according to the number of W repeats in the 
viral genome and the specific W promoter used to initiate transcription (319, 499, 616). In 
addition to this both C and W promoter initiated EBNA-LP are subject to alternate splicing 
which involves the differential skipping of the W1W2 exons (499, 617).  
Evolutionarily conserved regions in the repeat region appear to be necessary for EBNALP 
mediated co-activation; consequently there is a link between EBNA-LP size and function 
(618, 619). EBNALP activity is regulated by phosphorylation (620) with serine 35 in the W2 
exon being especially important. Serine to alanine substitutions resulted in a reduced 
induction of EBNA2 trans-activated LMP1 in an Akata cell line model (620). EBNA-LP 
trans-activating functions are important in the formation of an LCL, since a mutant virus 
lacking the two C-terminal exons is severely impaired for immortalization (352, 545).  
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EBNA-LP also appears to be involved in cell cycle regulation. This is suggested by the 
observation that EBNA-LP phosphorylation is cell cycle dependent (621). EBNA-LP and 
EBNA2 can cooperate in promoting cell cycle progression by inducing cyclin D2 (622). 
EBNA-LP also forms stable complexes with p53 and MDM2 which appears to result in the 
functional inactivation of p53 (623, 624). The inability of p53 to induce p21, a CDK inhibitor, 
may contribute to cell cycle progression. 
As mentioned in section 1.13.3, a truncated form of EBNA-LP (t-EBNA-LP) is produced in 
Wp-restricted Burkitt lymphoma (Wp-BL); specifically, t-EBNALP lacks the terminal Y1Y2 
exons. EBNA-LP can not function as a co-activator in these tumour cells due to an EBNA2 
deletion in the active viral genome (512, 625). The role of t-EBNA-LP in Wp-BL may be to 
antagonize caspase-mediated apoptosis by inactivating protein phosphatise 2A (PP2A) thus 
acting as a pro-survival factor (512).  
 
1.14.5 LMP1 and LMP2 
LMP1 and LMP2 are integral membrane proteins encoded in the BamHI-N region of the 
genome, adjacent to the terminal repeats. LMP1 is transcribed from three promoters: an 
EBNA2 activated latency III promoter (626), a STAT regulated latency II promoter (627) and 
a designated late lytic promoter encoding truncated LMP1 (628). LMP1 consists of three 
functional domains: a cytoplasmic N terminus which anchors LMP1 to the plasma membrane 
(629, 630), a trans-membrane region which mediates self-aggregation (631-633) and a 
cytoplasmic C-terminus which engages in cell signalling via three activation domains termed 
CTAR1-3 (634, 635). CTAR1 is responsible for initiating cell proliferation while CTAR2 is 
necessary for immortalization.  
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LMP1 is essential to in vitro transformation of B cells (350, 636) and is sufficient to mediate a 
range of tumour-associated cellular changes (637-641). The LMP1 C-terminus essentially 
mimics a constitutively active tumour necrosis factor receptor capable of providing CD40 
signalling in B cells (381, 382) and as such engages the NFκB, AP-1, JAK/STAT and PI-
PLC-PKC pathways (642, 643). LMP1 can promote cell cycle progression (644) via an NFκB 
dependent up-regulation of cyclin-D1 (645) and an AP-1 dependent inhibition of INK4 family 
member p16 (646). It can also promote immortalization by regulating human telomerase 
reverse transcriptase (hTERT) in an NFκB, AP-1 and c-myc dependent manner (647-650). 
LMP1 can protect against apoptosis by increasing levels of Survivin, an inhibitor of apoptosis 
protein (IAP), in an NFκB, AP-1 and c-myc dependent manner (651-653). A broader range of 
LMP1 functions is  reviewed by Dawson et al (652).  
The LMP2 gene encodes two products, LMP2A and LMP2B, neither of which are essential to 
transformation (654-662). The role of LMP2A in EBV associated malignancies has been 
studied using LCL and transgenic mice models (383, 659, 660, 663-667). The N-terminal 
domain of LMP2A was found to engage in BCR associated signalling pathways (668) and has 
previously been shown to promote the survival of BCR negative mouse and human B cells 
(383, 669, 670). The survival phenotype is in part mediated by NF-κB dependent increases in 
Survivin (671, 672) and Bcl-2, as well as NF-κB or Ras dependent increases in Bcl-XL (669, 
673, 674). An additional function of LMP2A appears to be maintenance of viral latency in the 
presence of reactivation stimuli i.e. CD19 cross-linking. LMP2A mediates these effects by 
engaging with src family tyrosine kinases (663, 664). The functions of LMP2B have not been 
fully elucidated. It cannot engage in BCR signalling as it lacks the N-terminal domain of 
LMP2A (654, 656, 657, 661). Two possible roles for LMP2B may be to negatively regulate 
LMP2A activity (675-677), and to promote turnover of interferon receptors (678). 
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1.14.6 BHRF1 and BALF1 
The intrinsic or mitochondrial apoptosis pathway is controlled by a number of pro- and anti-
apoptotic Bcl-2 family members (see Fig. 1.4) (188). EBV encodes two Bcl-2 homologs 
termed BHRF1 and BALF1. While predominantly productive cycle antigens (267, 679), both 
have been identified as latency associated in LCL and tumour cell lines (320, 680). BHRF1 is 
the main viral Bcl-2 homolog and is considered an important contributor to the survival 
advantage of Wp-BL over latency I BL (320, 681). Despite similarities to Bcl-2, BHRF1 does 
not appear to associate with Bax or Bak (682, 683). BHRF1 has however been shown to 
protect from apoptosis by sequestering the pro-apoptotic protein Bim (684). Much less is 
known about the function of BALF1. Viral transformation can take place in the presence of 
individual BHRF1 or BALF1 deletions but not if both are deleted (513, 685, 686), suggesting 
a degree of redundancy between both proteins. Nonetheless studies on the roles of BALF1 in 
cell survival were conflicting (680, 687, 688). A recent study has however demonstrated the 
ability of BALF1 to promote tumour formation in nude mice as well as protect from apoptosis 
in culture (432). 
 
1.14.7 EBERS 
EBER1 and EBER2 are highly conserved small non-polyadenylated RNA species encoded in 
the BamHI-C region of the EBV genome (267, 689, 690). They are 167 and 172 nucleotides 
long respectively and are separated by 161 base pairs. EBER RNAs are transcribed from 
separate promoters containing both polymerase II and III associated elements (691). EBER1 
and EBER2 share 54% sequence homology and even greater similarities in secondary 
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structures, which is characterized by extensive base-pairing and stem-loop formation (692, 
693).  
EBERS are predominantly nuclear (694-696) though conflicting literature suggests they also 
locate to the cytoplasm (697-699). EBERS are expressed across a wide range of EBV-
associated malignancies (700-703) and often constitute the most abundant transcripts (704). 
They appear to be latency associated as their expression is diminished during productive 
infection (705). Other factors influencing EBER expression are EBV load (704), cell 
background (706) and differential turnover; EBER1 is more stable than EBER2 thus 
accumulates to 10-fold higher steady state levels (707, 708).  
EBERS are believed to modulate cell immunity and apoptosis. They can hold the double 
stranded RNA (dsRNA) regulated protein kinase (PKR) in an inactive state (709, 710) as well 
as up-regulate anti-apoptotic protein Bcl-2 (504). Both these actions counteract an antiviral 
INF-α signalling cascade which would ultimately result in cell death. Gene expression studies 
using a range of EBV loss BL, EBV negative BL and epithelial cell lines confirm a protection 
from IFN-α mediated apoptosis in the presence of EBERS (500, 505, 507, 508).  
EBERS have also been implicated in stimulating cell growth. When expressed in EBV loss or 
EBV negative BL they confer both an ability to grow in soft agar as well as form tumours in 
SCID mice (504, 506, 508). These effects may be mediated by IL-10 which is produced in 
response to EBER interactions with RIG-I (711). RIG-I is another dsRNA responsive protein 
which forms an upstream component of the same IFN-α signalling cascade involving PKR. 
The presence of IL-10 correlates with EBER positivity in BL cells and both can stimulate cell 
growth (712). Different growth promoting cytokines are stimulated in different cell types i.e. 
IL-9 in T cell lines or IGF-I in NPC and GC (713-715).  
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Finally there have been reports that EBERS support growth transformation (716). Specifically 
EBER2 appears to mediate this effect in an IL-6 dependent manner. The literature concerning 
EBER function remains conflicting and contains a number of inconsistencies. For instance 
there is evidence to suggest that EBER mediated cell survival in BL may PKR independent 
(717). The involvement Bcl-2 is also questionable as it is not expressed in most BL (718). 
 
1.14.8 BARTS 
BART transcripts are encoded within the BamHI-A region of the genome. Originally 
discovered in a nude mouse NPC line (719, 720), they are known to be expressed in all forms 
of EBV infection both in vitro and in vivo (719-726). BARTS are a diverse group of heavily 
spliced RNA species (4kb to 8kb in size), with a common 3′ sequence and poly-A signal (719, 
720, 727, 728). They are predominantly generated from promoter P1 but may be generated by 
P2. P1 and P2 are regulated by different cellular factors and respond differently to alternate 
cell backgrounds (729). They are dispensable for transformation; indeed most of the BART 
region is deleted in the transforming B95-8 prototype strain  (267).  
BART transcripts give rise to a number of open reading frames (BARF0, RK-BARF0, A73 
and RPMS1) which can be translated in vitro (721, 727, 728, 730-734). A number of studies 
using artificially translated proteins have revealed regulatory roles for RPMS1 and RK-
BARF0 in stimulating and antagonizing Notch signalling respectively (724, 730, 731). A73 
on the other hand binds the RACK1 adaptor protein with unknown consequences (731, 735). 
The relevance of these interactions is questionable as there is little evidence to suggest the 
BART proteins are natural expressed in latently infected cells (721, 735-737). More recently 
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the BART transcripts have been shown to encode a large number of miRNAs (BART 
miRNAs) (250, 738-741) as well as a small nucleolar RNA (v-snoRNA1) (742), both of 
which could be important in the virus life cycle. 
 
1.14.9 MicroRNAs 
EBV encodes at least 40 miRNAs; three are generated from the UTRs either side of the 
BHRF1 ORF (miR-BHRF1s), while the rest locate to the intronic regions of the BART 
transcripts (miR-BARTs) (250, 738-741). All three BHRF1 miRNAs are generated during the 
growth transforming program, likely from the C and W promoters (250, 738, 743-745). 
During productive infection, two of three BHRF1 miRNAs (miR-BHRF1-2 and miRBHRF1-
3) are expressed from the BHRF1 promoter (BHRF1p) (744, 746, 747); miRBHRF1-1 
overlaps the BHRF1p and thus is not included in the transcript. BART miRNAs are expressed 
from the BART promoters in all forms of EBV infection, although steady state levels are 
especially high in EBV positive NPC tumours and epithelial cell lines (250, 738, 739, 741, 
743, 745, 748, 749).  
EBV miRNAs are highly conserved among EBV strains and therefore probably mediate 
important functions in the viral life cycle (738). BHRF1 miRNAs are believed to assist in 
transformation, cell cycle progression and in resisting apoptosis throughout early EBV 
infection (750, 751). However neither deleting the BHRF1 miRNAs nor most of the BART 
miRNAs can prevent LCL formation (267, 750, 751). Cellular BHRF1 miRNA targets may 
include tumour suppressor p53 (miR-BHRF1-1) and T cell attracting chemokine CXCL11 
(miR-BHRF1-3) (752, 753). Cellular BART miRNA targets may include Dicer (miR-
BART6-5p) and MICB (miR-BART2-5p), which function in miRNA processing and NK cell 
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immunity respectively, TOMM22 (miR-BART16) and IPO7 (miR-BART3), which function 
in protein transport across the mitochondrial and nuclear membrane, respectively, as well as 
the pro-apoptotic Bcl-2 family members PUMA (miR-BART5) and Bim (miR-BART 1, 3, 9, 
11 and 12) (754-758). Viral BART miRNA targets may include BALF5 (miR-BART2), 
LMP1 (miR-BART 1-5p, 16-5p and 17-5p; miR-BART9) and LMP2A (miR-BART22) (759-
762). Thus EBV miRNAs appear to have roles in apoptosis, proliferation, immune evasion 
and viral gene expression. 
The contributions of the EBV miRNAs towards oncogenesis and the viral life cycle remain 
largely unknown. For instance there are currently no confirmed target genes for the majority 
of EBV miRNAs.  Furthermore it is very likely that individual EBV miRNAs possess more 
than just one target (754, 755, 759, 760, 763, 764). Finally the literature concerning predicted 
or validated EBV miRNA targets is conflicting. Different groups can not necessarily validate 
the same targets (755, 760, 763); likewise there is little overlap between published targetomes 
(758, 763-765).  
 
1.15 Aims and objectives 
We wanted to perform our own investigation into the function of EBV encoded miRNAs, in 
order to better understand how they contribute towards oncogenesis and the viral life cycle. 
To do this we first needed a good understanding of when and under what circumstances EBV 
miRNAs are expressed.  Studies released prior to the present work largely relied on Northern 
blotting, arrays or cloning for detection (250, 738, 744, 745, 748, 749). Unfortunately such 
methods require large amounts of RNA, have limited sensitivity and only provide qualitative 
data. Thus the first goal of this thesis was to quantitatively assess viral miRNA expression in 
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different types of EBV infection. The second goal of this thesis was to establish if and how 
EBV miRNAs contribute to the oncogenesis of Burkitt lymphoma.  
In results chapter I there are three aims. Firstly we will validate a commercial quantitative 
PCR (QPCR) system for the detection and quantification of EBV miRNAs. Secondly we will 
use these QPCR assays to characterize EBV miRNA expression in a range of different 
latently infected BL cell lines and LCLs. Thirdly we will investigate a number of factors 
determining EBV miRNA steady state levels, such as differential turnover rates and levels of 
BHRF1 and BART gene transcription. 
In results chapter II we continued our study on viral miRNA expression by focusing on two 
further types of EBV infection. Our first aim was to investigate viral miRNA expression 
during the early events of EBV mediated B cell transformation. Thus we infected resting B 
lymphocytes de novo with a strain of virus (2089) similar to the B95-8 prototype. Our second 
aim was to focus on viral miRNA expression following the induction of EBV replication. 
This was investigated using the AKBM cell system in which EBV-positive Akata-BL cells 
are stably transfected with a GFP reporter gene under the control of the EBV lytic cycle 
BMRF1 promoter; these cells enter lytic cycle following Ig cross linking and can be identified 
by GFP expression. 
In results chapter III we had two broad aims. Our first aim was to establish a methodology 
with which we could study the functions of the BHRF1 miRNAs. In order to achieve our first 
aim we undertook two complementary approaches. In the first we attempted to knock down 
the BHRF1 miRNAs in Wp BL lines using antisense oligonucleotide inhibitors. In the second 
we attempted to express the BHRF1 miRNAs in a panel of EBV negative and Lat I BL lines 
using a lentivirus. Our second aim was to perform three different investigations into the 
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function of the BHRF1 miRNAs. First we assessed the effects of the BHRF1 miRNAs on the 
transcriptome of a BL cell line using array analysis. Secondly we investigated the effects of 
the BHRF1 miRNAs on cell growth. Thirdly we determined the effects of the BHRF1 
miRNAs on cell death by (a) measuring cell viability in the presence of apoptosis inducing 
drugs and (b) using western blot to look for changes in the protein levels of individual Bcl-2 
family members. 
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2. Materials and Methods 
2.1 Cell culture 
2.1.1 Lymphoid and epithelial cell lines 
Most cell lines used in this study were derived from BL tumour cells. EBV-positive BL lines 
included Latency I Dante-BL, Sav-BL, Ezema-BL, Akata-BL, Kem-BL, Chep-BL and MutuI-
BL cl.59 (291, 766); the group III BL lines MutuIII-BL and GlorIII-BL which have drifted in 
culture to a Latency III form of infection; the Wp-restricted BL lines Oku-BL, Sal-BL and 
Ava-BL (625); and Latency I and Wp-restricted sublines derived from Awia-BL (767). EBV-
negative BL lines include DG75, BL41, BL30, Ramos-BL and two EBV genome loss BL 
clones isolated by single cell seeding of MutuI-BL cl.59 and Akata-BL (kindly provided by 
Dr Gemma Kelly and Leah Fitzsimmons). BJAB is an EBV-negative B lymphoma cell line. 
Jurkat is an EBV negative T leukaemia cell line (768).   
In addition a range of virus transformed LCLs were also used in this work. LCLs carrying 
natural EBV isolates included IM51.1, IM81.1, IM83.1 and IM93.1 and were established by 
spontaneous transformation of peripheral blood derived B cells from EBV-infected infectious 
mononucleosis patients (769), while EH LCL1 and EH LCL2 were generated by in vitro 
infection of EBV-naïve B cells with the recombinant 2089 EBV genome (770).  
The following reference cell lines served as standards for quantifying EBV and/or human 
transcripts: X50/7 LCL (771), CD+Oku LCL (625), the spontaneously permissive Sal tr-LCL 
(containing 2% BZLF1 positive cells), the EBV-positive nasopharyngeal cell line C666-1 and 
the EBV-negative NK leukaemia cell line NKL (772). AKBM is a derivative of Akata-BL 
stably transfected with GFP reporter plasmid under the control of the early BMRF1 promoter 
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(773). Standard HEK293 cells were used in the production of infectious EBV while the 
293FT cell line was used to package lentivirus stocks (Invitrogen). 
 
2.1.2 Maintenance of lymphoid and epithelial cell lines 
B cell lines and standard HEK293 cells were maintained in exponential growth in RPMI/10% 
selected foetal calf serum (FCS) (Biosera) supplemented with 2 mM L-glutamine (Life 
Technologies) and penicillin/streptomycin (Sigma). Oku-BL, Sal-BL, Ava-BL, and Awia-BL 
clones (k and m) were maintained in B cell medium supplemented with 1mM sodium 
pyruvate (Sigma), 50 mM alpha-thioglycerol (Sigma) and 20 nM bathocupronine disulfonic 
acid (Sigma). 293FT cells were maintained in B cell medium supplemented with heat 
inactivated FCS (56°C for 1 hour) and 200μg/ml G418 (Life Technologies) if required. 
Suspension cells were cultured in 25cm
2
 flasks and adherent cells in 100mm plates; all cells 
were grown at standard incubator conditions (37°C, 5% CO2). Where indicated, RNA 
transcription was inhibited by the addition of 5µg/ml Actinomycin D (Sigma) to the cell 
culture medium and cells harvested for analysis at the indicated time points.  
 
2.1.3 Cryopreservation and recovery of lymphoid and epithelial cell lines 
Between five and ten million cells were taken at log phase (suspension cells) or 80%-90% 
confluence (adherent cells), spun down by centrifugation for 5 minutes at 450 x g and 
resuspended in ~0.75 ml RPMI/40% FCS supplemented with 2 mM L-glutamine (Life 
Technologies) and 10% dimethylsulphoxide (DMSO). Cells were transferred to a cryovial and 
placed in a freezing container surrounded by a propan-2-ol soaked sponge (Mr Frosty). The 
freezing container was stored overnight at -80°C to allow for a controlled cooling rate of -
Chapter 2 
 
52 
 
1°C/minute. Cryovials were subsequently removed and transferred to the vapour stage of 
liquid nitrogen (-180°C) for long term storage.  
Upon removal from liquid nitrogen, cells were thawed quickly at 37°C in a water bath and 
added drop wise to 15 ml of suitable pre-warmed media in order to minimize exposure to 
DMSO. Cells were spun down by centrifugation for 5 minutes at 1400 rpm using a Heraeus 
8155 rotor, resuspended in 10 ml suitable media and transferred either to a 25cm
2 
flask 
(suspension cells) or a 100mm plate (adherent cells). 
 
2.2 Reactivation of EBV in AKBM cells and isolation of cells in lytic cycle 
Viral reactivation in AKBM cells was induced by crosslinking surface immunoglobulin (Ig) 
with 100 µg/ml goat anti-human IgG antibody (Cappel) as described (773). Cells were 
transferred into fresh medium, plated out at 0.5 x 10
6
 cells per ml in a 24 well plate and 
harvested at each indicated time point. To monitor induction of virus lytic cycle, an aliquot of 
cells was assayed by flow cytometry, either directly for GFP expression or after staining with 
the BZLF1-specific mAb BZ.1, as described (773). Where indicated, induced AKBM cultures 
were sorted into GFP-positive (lytic) and GFP-negative (latent) populations using a MoFlo 
cell sorter (Dako).  
To monitor the changes in EBV viral load in induced AKBM cultures, genomic DNA was 
extracted using the GenElute Mammalian Genomic DNA kit (Sigma). EBV genome load was 
then determined by QPCR using primer/probe combinations to amplify EBV DNA 
polymerase (BALF5) and cellular beta 2-microglobulin sequences, as described (774). Where 
indicated, EBV genome replication was inhibited by the addition of 200 µg/ml 
acycloguanosine (Sigma) to the culture medium. 
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2.3 Primary infection of B Cells 
2.3.1 Production of recombinant EBV (2089) from 293 cells 
In preparation for the production of recombinant 2089 EBV (770), 293 producer cells 
carrying the 2089 BAC were split into each well of a 6 well plate and grown to 70% 
confluence. Cells were transfected with plasmids encoding the BALF4 and BZLF1 gene 
products (0.5 μg each per well) (770, 775) using Lipofectamine (Invitrogen) in Opti-MEM® 
reduced serum media (Invitrogen) according to manufacturer’s instructions. Cells were then 
placed in a 37°C incubator for 3 hours, topped up with an additional 1 ml of B cell medium 
per well, and returned to the incubator for a further 72 hours. Virus containing supernatant 
was subsequently harvested, debris removed by centrifugation for 5 minutes at 2000 rpm 
using a Heraeus 8155 rotor and the supernatant subjected to filter sterilization using a 0.45 μm 
filter. Aliquots of supernatant were frozen at -80°C until required.  
 
2.3.2 Quantifying recombinant EBV (2089) titre 
Virus titre quantification was determined using Q-PCR. Briefly, virus containing supernatant 
was mixed with an equal volume of lysis buffer (10mM Tris-HCL pH 8.8, 1.5mM MgCl2, 
50mM KCl:, 100mg/ml proteinase K (Roche) and 0.1% v/v Triton X-100) and incubated for 1 
hour at 55°C followed by 10 minutes at 99°C. Real time PCR amplification of the BALF5 
gene was performed as in section 2.2, using 5 μl supernatant as input. 
 
Chapter 2 
 
54 
 
2.3.3 Isolation of human primary B cells from whole blood 
Lymphocyte enriched buffy coats (NHS Blood and Transplant, Birmingham) were mixed 1:1 
with PBS and gently layered over 15ml warmed Lymphoprep solution (Axis Shield) in a 50 
ml tube. Tubes were spun for 30 minutes at 1800 rpm using a Heraeus 8155 rotor (without 
brake to avoid disturbing the interface). Note that peripheral blood mononuclear cells 
(PBMCs) form a layer at the interface between the upper plasma and lower Lymphoprep 
solution. PBMCs were isolated and washed three times in 50 ml PBS for 10 minutes at 1600 
rpm, 1200 rpm and 1000 rpm, respectively, using a Heraeus 8155 rotor and then resuspended 
in cold RPMI/1% FCS. A total B cell estimate was made using the assumption that the B cell 
population accounts for 5% of total PBMCs. B cells were subsequently isolated from PBMCs 
using magnetic CD19 pan B Dynabeads® and CD19 pan B DETACHaBEAD® (Invitrogen) 
according to manufacturer’s instructions. B cells were used immediately for in vitro infection 
experiments described below. 
 
2.3.4 Infection of human B cells with recombinant EBV (2089) 
Primary B cells were exposed to preparations of recombinant 2089 EBV at a multiplicity of 
infection (moi) of 100 using published methods (326). Briefly, isolated B cells were 
centrifuged for 5 minutes at 328 x g and resuspended in virus supernatant at the correct moi. 
After incubating the B cells and virus supernatant together for 2 hours at 37°C, the virus 
supernatant was removed via centrifugation at 5 minutes at 1200 rpm using a Heraeus 8155 
rotor. The infected B cells were resuspended at 2 x 10
6
 cells/ml in fresh B cell medium, 
seeded in a 24 well plate and harvested at the indicated time points.  
 
Chapter 2 
 
55 
 
2.4 Quantitative RT-PCR analysis of viral and cellular transcripts  
2.4.1 RNA extraction 
RNA samples used for RT-PCR analysis of viral and cellular transcripts were prepared as 
follows. Approximately 1-3 x 10
6 
cells were harvested and washed once in PBS. Total RNA 
was subsequently prepared using the Nucleospin RNA Isolation kit (Machery-Nagel) 
according to manufacturer’s instructions. All RNA samples were eluted in 50-60 μl of 
nuclease free water (Ambion), quantified using a Nanodrop spectrophotometer (Thermo 
Scientific) and where possible diluted to 100 ng/μl. RNA samples were either used directly or 
stored at -80°C.  
Since the majority of QPCR primer/probe combinations used in this study were designed to 
span across exon-exon splice junctions, residual contaminating DNA was unlikely to yield a 
false positive signal. However for assays which amplified within a single exon, an additional 
DNAse I treatment was performed on a 1μg aliquot of RNA using DNA-free™ (Ambion) 
according to manufacturer’s instructions. 
 
2.4.2 Reverse transcription  
For the detection of EBV transcripts, RNA was reverse transcribed using a mixture of 
previously described gene-specific cDNA primers (320, 769) or new cDNA primers described 
later (section 2.4.3). Five hundred nanogram total RNA was denatured at 90°C for 5 minutes 
and added to a reaction mix containing 5u AMV-RT (Roche), 1 x AMV reverse transcriptase 
reaction buffer, 1 μM each cDNA primer, 200 μM each of dATP, dTTP, dCTP and dGTP 
(Roche) and nuclease free water in a total volume of 20 μl. The reaction incubated for 1 hour 
at 42°C and then 5 minutes at 90°C.  
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For the detection of cellular transcripts, 500 ng total RNA was reverse transcribed using the 
qScriptTM cDNA supermix (Quanta Biosciences), according to manufacturer’s instructions. 
The reaction mix was incubated as above, albeit with an initial 5 minutes incubation at room 
temperature (RT) to allow for optimal primer annealing. After completion of the cDNA 
reaction, all reaction mixes were made up to 100 μl with nuclease free water and stored at -
20°C. 
 
2.4.3 QPCR 
Relative levels of Qp-, Cp- and Wp-initiated transcripts, BARTs (exon 6-7 splice junction), 
lytic and latent BHRF1 transcripts and immediate early BZLF1 transcripts were determined 
by QPCR using published primers and Taqman probes (320, 769). In addition, three new 
assays were designed to detect novel viral transcripts. The first assay detected both latent and 
lytic BHRF1 transcripts using the following primers and probe: cDNA primer 5'-
TCTTGCTGCTAGCT-3', forward primer 5'-CCCTCTTAATTACATTTGTGCCAGAT-3', 
reverse primer 5'-TCCCGTATACACAGGGCTAACAGT-3', probe 5'-Fam 
TAGAGCAAGATGGCCTATTCAACAAGGGAGA Tamra-3'. Two further assays were also 
designed to detect alternatively spliced BART transcripts, either by amplifying across the 
exon 2-3 splice junction in conventional BART mRNAs (BART 2-3) or across the exon 1-3 
splice junction in the variant lacking exon 2 (BART 1-3). These assays used the following 
primers and probes: common cDNA primer 5'-TCTAAAGTCATACGCCC-3' (exon 3), 
BART 2-3 forward primer 5'-TCCACTTTGTGTTACAGGTCCG-3' (exon 2-3 junction), 
BART 1-3 forward primer 5'-CTCTTCATGTGAGGTCCGGC-3' (exon 1-3 junction), 
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common reverse primer 5'-TGTGTCCGGTAAACGCCATA-3' (exon 3) and BART probe 5'-
Fam CCACGGAGACTCGGACGTAGCCCTT Tamra-3' (exon 3).  
Relative levels of cellular transcripts (MYC, Drosha, Dicer, ADAM18, DSCR8, ASZ1, 
HSPA4L, GRM5, CELF2, CRYBG3, FCRL2, IQSEC2, ITGA5, MAN1B1, MIPEP, MMP14, 
OCA2 and TDRD7) were determined by QPCR using commercially available Taqman gene 
expression assays (Applied Biosystems); further details are shown in Table 2.1. 
Relative quantification of gene expression was performed using an Applied Biosystems 7500 
Sequence Detection System using the following conditions: 95°C for 10 minutes, followed by 
40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Each PCR run included duplicate 
test cDNA samples and serial cDNA dilutions prepared from a suitable reference line (Akata-
BL, Qp; X50/7, Wp; CD+Oku LCL, Cp and latent BHRF1; Sal tr-LCL, BZLF1 and lytic 
BHRF1; C666.1, BARTs) which were used to construct relative standard curves. EBV gene 
expression data was normalised either to cellular glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or phosphoglycerate kinase (PGK) expression, both quantified using commercially 
available assays (Applied Biosystems). Normalised data were expressed relative to the 
appropriate reference line which was assigned an arbitrary value of one. Note that in the case 
of lytic transcripts, the data were further adjusted such that the final values were expressed 
relative to a culture containing 100% BZLF1-positive cells.  
 
2.5 Quantitative PCR analysis of EBV miRNAs  
All EBV miRNA sequences were obtained from the Sanger miRNA database version 12 
(http://microRNA.sanger.ac.uk/) (22). Real time PCR assays to quantify EBV miRNAs were 
based on the stem-loop RT primer method described by Chen et al. (776). Stem-loop RT 
Table 2.1. Commercially available TaqMan (Applied Biosystems) 
assays used for measuring human transcripts and EBV miRNAs 
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primers and primer/probe combinations for each target miRNA were either designed using the 
Custom Taqman Small RNA Assay service (miR-BART5, miR-BART7, miR-BART22, miR-
BART13, miR-BART2-5p) or obtained commercially (miR-BHRF1-1, miR-BHRF1-2, miR-
BHRF1-3, miR-BART3, miR-BART4, miR-BART1-3p, miR-BART15) (Applied 
Biosystems); further details are shown in Table 2.1. 
For miRNA analysis, RNA was prepared using the mirVana miRNA Isolation Kit (Applied 
Biosystems) according to the manufacturer’s instructions. Input RNA (10 ng) was reverse 
transcribed in a 20 µl reaction volume containing up to 7 RT stem-loop primers using the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems).  
QPCR reactions (20 μl) were performed using an Applied Biosystems 7500 Sequence 
Detection System. In each PCR, duplicate aliquots of each test cDNA were run alongside 
serial cDNA dilutions prepared from a suitable reference line (X50/7, miR-BHRF1 miRNAs; 
C666.1, miR-BART miRNAs) which were used initially to construct relative calibration 
curves.  
To convert from relative to absolute quantitation, target miRNAs were obtained as synthetic 
oligonucleotides (Eurogentec), pooled and reverse transcribed as above. Aliquots of cDNA 
corresponding to 10
8
 to 10
2 
miRNA copies were then subjected to PCR amplification and the 
data used to generate calibration curves from which the absolute number of EBV miRNA 
molecules in reference X50-7 and C666.1 cells could be determined. Expression data was 
normalised to RNU48 as a loading control (Applied Biosystems). 
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2.6 Western blotting 
2.6.1 Protein quantification 
Approximately 5-10 x106 cells were spun down and washed twice in phosphate buffered 
saline (PBS).  Pellets were maintained on ice, lysed in 50 μl 9M Urea buffer (9M Urea, 5mM 
EDTA, 5mM EGTA, 1% DTT, 2-4% CHAPS) and sonicated for 15- 20 seconds. Aliquots of 
lysates were diluted 5-fold with Urea buffer, vortexed, and 5 μl was loaded, in duplicate, onto 
a 96 well plate. BSA standards of 5, 2, 1, 0.5, 0.2 and 0.1 mg/ml were also vortexed and 
loaded in duplicate.  
Total protein concentrations were determined using BioRad DC protein assay reagents A and 
B added in a 1:4 ratio, as per manufacturer’s instructions. The reaction plate was incubated for 
15 minutes at room temperature and the resulting colour change analysed using a 96 well 
plate reader set at 630nm wavelength. The protein concentration was then determined using 
line of best fit generated from the standards.  All protein samples were subsequently diluted to 
2mg/ml in Gel Sample Buffer (0.4M sodium 2-mercaptoethanesulfonate (MESNA), 125mM 
Tris-HCL pH 6.8, 20% v/v glycerol, 4% v/v SDS and 0.004% v/v bromophenol blue). Diluted 
samples were boiled for 10 minutes to denature protein and then stored at -20°C. 
 
2.6.2 Protein electrophoresis and membrane transfer 
Protein electrophoresis was performed using the Novex XCell SureLock mini cell system 
(Invitrogen) and NuPAGE 4-12% Bis-Tris gels (Invitrogen). The system was set up as per 
manufacturer’s instructions with 1x NuPAGE MES SDS running buffer (Invitrogen) prepared 
in distilled water. Protein samples were defrosted and resolubilised for 5 minutes at 80°C. 
Chapter 2 
 
60 
 
Twenty μg of protein sample was loaded per well, with one well being used for 10 µl SeeBlue 
Plus2 Prestained standard (Invitrogen). Samples were electrophoresed at 100 V, 250 mA for 
90 minutes. When the run had completed, the apparatus was disassembled and the Bis-Tris 
gel was placed into an XCell II blot module (Invitrogen) with a PVDF membrane pre-soaked 
in 100% methanol and then equilibrated with transfer buffer (0.192M Glycine (Sigma), 
2.5mM Tris-Base (Fisher Chemicals), 20% Methanol). Protein transfer was performed as per 
manufacturer’s instructions at 30 V for 100 minutes.  
 
2.6.3 Membrane blocking, antibody binding and detection  
After transfer, the PVDF membrane was removed from the blotting module and washed in 
PBS with 0.1% Tween-20 (PBS-T). The membrane was then blocked in 5% dried milk 
diluted with PBS-T for 1 hour with gentle agitation on a rocking platform. Primary antibodies 
were diluted in 5% dried milk and incubated with the membrane for 2 hours at room 
temperature or overnight at 4°C with gentle agitation. After antibody binding, the antibody 
was removed and the membrane was washed with seven times with PBS-T over a period of 
20 minutes. The membrane was then incubated for 1 hour at room temperature with a specific 
secondary antibody conjugated to Horseradish Peroxidise (Sigma) diluted in 5% milk. After 
incubation with the secondary antibody, the membrane was washed as above; view Table 2.2 
for a full list of primary and secondary antibodies.  
Protein visualisation was carried out using an ECL western blotting kit (GE Healthcare) 
according to the manufacturer’s instructions. Finally the membrane was placed inside a film 
cassette with a sheet of CL Xposure X-ray film (Thermo Scientific), exposed for between 30 
seconds and 20 minutes, and then developed using a Kodak X OMAT 1000 film processor.   
Table 2.2. Antibodies used in western blotting 
558 
443 
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2.7 Sequencing of BHRF1 miRNAs 
Genomic BHRF1 sequences spanning all three BHRF1 miRNAs were PCR amplified using 
the primers 5′-GGACTTGGGGTGATTTTCTATGT-3′ and 5′-
CCCACACTCACCTCAGTTATTTC-3′ under the following conditions; 94°C for 5 mins, 35 
cycles of 94°C for 60s, 56°C for 60s and 72°C for 2 mins, and a final extension of 72°C for 
10 mins. The 1600bp product was then gel purified and sequenced using an automated 
Applied Biosystems 3730 (Functional Genomics and Proteomics Services, School of 
Biosciences, University of Birmingham).  
BHRF1 miRNA sequences were aligned to the prototype B95-8 sequence (RefSeq 
NC_007605.1) using BioEdit sequence alignment editor 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). The pre-miRNA secondary structure 
prediction through free energy minimisation was calculated using the software programs 
Mfold (http://mfold.rna.albany.edu/) (777) and RNAfold (http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi) (778, 779). 
 
2.8 Construction of plasmid vectors 
2.8.1 Preparation of cloning inserts 
DNA oligonucleotide sequences representing individual BHRF1 miRNA binding sites were 
cloned into pMIR-REPORT
TM
 as described in section 5.2. Individual binding sites (see Fig. 
5.1) were custom ordered as two separate single stranded sequences (Alta Bioscience Ltd). 
Annealing of the two single stranded sequences was achieved in a reaction mix containing 2 
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μg of each oligonucleotide and 1 x SuRE/Cut Buffer A (buffer) in a final reaction volume of 
50 μl. The reaction mix was heated 90°C for 3 minutes in a heating block and subsequently 
left to cool slowly over several hours.  
Lentiviral vectors for the stable expression of the BHRF1 miRNAs were cloned as described 
in section 5.4. Genomic BHRF1 sequences spanning miR-BHRF1-2 and miR-BHRF1-3 were 
PCR amplified using the primers 5′-AAAGGATCCTTTAACCAAACAGTGGTCGTGAG-3′ 
and 5′-AAAGAATTCTTAATTAATCCCAAAACCTACTACCCCATT-3′. Genomic BHRF1 
sequences spanning miR-BHRF1-1 were PCR amplified using the primers 5′-
AAAGGATCCCCATGAGCCCCGCCTTTA-3′ and 5′-
AAAAGATCTGGCTAAACCTAATCCCCAACCTTT-3′. Both fragments were amplified 
under the following conditions; 94°C for 5 mins, 35 cycles of 94°C for 60s, 56°C for 60s and 
72°C for 1 mins, and a final extension of 72°C for 10 mins.  
 
2.8.2 Restriction digestion 
PCR-amplified or vector-derived inserts and recipient plasmid vector DNA were digested 
with the appropriate restriction enzymes following the manufacturer’s guidelines (standard 
enzymes from Promega and Roche, or Fast Digest enzymes from Fermentas). Typically 1μg 
plasmid DNA was digested in a 20 μl reaction volume with 1μl (10 units) restriction enzyme 
and 1 x concentration of the appropriate restriction enzyme buffer. Digests were performed at 
37°C for 30-60 minutes (FD enzymes) or 3 hours (standard enzymes). After digestion, 
recipient plasmid vector DNA was treated twice with 1 unit Calf Alkaline Phophatase (Roche) 
for 30 minutes at 37°C to remove 5′ terminal phosphate groups; this prevents religation and 
circularization of vector DNA, unless the vector is ligated to a suitable DNA insert (digested 
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PCR product or released vector-derived insert) possessing 5′ phosphate groups. Note that 
when inserting annealed oligonucleotides lacking 5′ phosphate groups, vector capping was not 
performed on recipient plasmid vector DNA.   
 
2.8.3 Agarose gel electrophoresis 
Plasmid derived DNA insert fragments were separated and purified from their backbone 
vector fragments using agarose gel electrophoresis. Agarose gels were prepared using 0.8-
1.0% agarose (Eurogentec) resuspended in 1x TBE (88.9mM Tris-Base, 2.49mM EDTA and 
88.9mM Boric Acid in distilled water). Agarose suspensions were heated to 100°C until the 
slurry had fully dissolved and then poured into a casting chamber and allowed to set. Digested 
DNA products were mixed with 6x gel loading dye (0.25% w/v xylene cyanol, 0.25% w/v 
bromophenol blue, 30% v/v glycerol) and loaded into each well, with one well being used for 
loading a DNA size marker (1kb Plus DNA Ladder, Invitrogen). The samples were 
electrophoresed at 80-100 V for 1-2 hours in a horizontal Flowgen tank containing 1x TBE.  
When the run was complete, the agarose gel was soaked for 20 minutes in a bath of distilled 
water containing 1-5 μl 10mg/ml ethidium bromide (Fisher Scientific) and the DNA 
visualised under UV light. The appropriately sized inserts were excised manually using a 
scalpel and subsequently recovered using the QIAquick Gel Extraction kit (Qiagen) as per 
manufacturer’s instructions.  
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2.8.4 Purification of vector and insert DNA. 
In some cases it was not necessary to isolate DNA fragments using gel electrophoresis but 
instead vector DNA, insert DNA or PCR products were simply purified using a High Pure 
PCR product purification kit (Roche) as per manufacturer’s instructions.  
In other cases, DNA products were extracted using organic solvents. Briefly, the sample was 
increased to a volume of 200μl with DEPC treated nuclease free water (Ambion), mixed with 
an equal volume of phenol: chloroform: isoamyl alcohol (25:24:1 pH8.0, Sigma) and then 
vortexed for 15 seconds. After centrifugation at 16000 x g for 2 minutes, the upper layer 
containing DNA was removed to a fresh tube. The DNA was precipitated by the addition of 
2.5 volumes of 100% ethanol and 1/10 volumes of 3M Sodium Acetate pH 5.2 and stored at -
20°C overnight. The next day, the sample was centrifuged at 16000 x g for 15 minutes at 4°C, 
the DNA pellet washed in cold 70% ethanol and allowed to dry at room temperature. In some 
cases, 0.5 μg glycogen (Roche) was added during the precipitation in order to help visualize 
the location of the DNA pellet. Finally the DNA pellet was resuspended in DEPC treated 
water and the DNA concentration was determined using a NanoDrop. 
 
2.8.5 Ligation of inserts into recipient plasmid vectors 
The quantity of vector and insert DNA used in each ligation reaction was determined using 
the following calculation: ((ng of vector × kb size of insert) / kb size of vector) x molar ratio 
of insert:vector = ng of insert. Ligation reactions were performed using the Rapid Ligation kit 
(Roche) in a 10 µl reaction volume containing the appropriate ratio of vector and insert 
fragments, 1 x ligation buffer and 1 unit T4 DNA ligase. The ligation mix was incubated for 
2-3 hours at room temperature or overnight at 4°C. Note that annealed oligonucleotide 
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sequences and purified PCR amplification products were added to cut vector DNA at a 5 x 
molar surplus.     
 
2.8.6 Bacterial transformation of plasmid DNA 
Ligated DNA products were transformed into chemically competent E.coli using standard 
methods. For most purposes, DH5α cells were used as the host strain. However Stabl3 cells 
(Invitrogen) were used for cloning of lentivirus plasmids to reduce the frequency of unwanted 
homologous recombination events between the long terminal repeat regions.  
Aliquots of chemically competent DH5α or Stabl3 cells were defrosted slowly on ice. 
Approximately 100 μl competent cells were subsequently added to each DNA sample, gently 
mixed and incubated on ice for 30 minutes. In all cases, a no DNA negative control was used 
and in the case of ligation reactions, an unligated vector sample was included to control for 
inefficient digestion and/or contamination of ligation reagents. Samples were then heat 
shocked at 42°C for 90 seconds and returned to ice for a further 2 minutes. Finally 1 ml of 
sterile LB (25g/L, Fisher Scientific) was added and cells incubated for a further 1 hour at 
37°C on a shaker.  
Before plating out, the cells were concentrated by centrifugation at 16000 x g for 60 seconds, 
the supernatant discarded and the cells resuspended in the residual LB liquid. The cells were 
then aseptically spread onto the surface of a 100mm LB agar plate containing 100 μg/ml 
ampicillin (Roche). Agar plates were incubated at 37°C overnight to allow the growth of 
transformants.  
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2.8.7 Growth of bacterial cultures 
To screen for the presence of the desired recombinants, individual colonies were used to 
inoculate 3ml LB (containing 100 μg/ml ampicillin) and grown overnight at 37°C in a shaking 
incubator. Plasmid DNA was extracted from these small scale cultures using a QIAprep Spin 
Miniprep kit (Qiagen), according to the manufacturer’s instructions. Recombinant plasmids 
were digested with suitable restriction enzymes and then screened by gel electrophoresis for 
the presence of the correct sized insert (see section 2.8.3). Where appropriate, plasmid 
constructs were confirmed by DNA sequencing using appropriate primers.  
Large scale plasmid preparations were made by transforming the desired plasmid DNA 
constructs into DH5α or Stabl3 cells, inoculating single colonies into 400ml LB (containing 
100 μg/ml ampicillin) and shaking the cultures at 37°C overnight. Plasmid DNA was 
extracted using a Qiagen Plasmid Maxi kit, as per manufacturer’s instructions. The 
concentration of plasmid DNA was determined using a NanoDrop spectrophotometer. 
 
2.9 Generation of BL lines stably transduced with lentiviral vectors 
2.9.1 Preparation of lentivirus stocks 
293FT virus producer cells were split 1:3 with fresh medium without G418 in 100mm plates 
(see section 2.1.2). The next day, the cells were monitored until they had reached a confluence 
of 70-90%. Subsequently the medium was replaced again with fresh medium lacking G418 
and the cells transfected with 2μg envelope plasmid (pMD2G), 6μg packaging plasmid 
(psPax2) and 4μg of the appropriate lentiviral vector using Lipofectamine (Invitrogen) in 
Opti-MEM® reduced serum media (Gibco). Briefly, all three plasmids were added to 1.5 ml 
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Opti-MEM® while 26μl Lipofectamine was added to a separate aliquot of 1.5 ml Opti-
MEM®. After 5 minutes incubation at room temperature, the two mixes were combined and 
left for a further 20 minutes. Subsequently the combined transfection mix was added to the 
293FT cells and left overnight at 37°C, 5% CO2. Thereafter the 293FT cells were given a 
fresh change of 293FT medium without G418. At this point the cells will not have undergone 
any morphological changes.  
After 48-72 hours the virus supernatant was harvested into a 50 ml tube and centrifuged for 5 
minutes at 1200 rpm using a Heraeus 8155 rotor to remove cellular debris; note the presence 
of virus is indicated by the formation of numerous budding vesicles. The supernatant was 
subsequently filtered using a 0.45 μm filter and the virus stored at -80°C, or concentrated and 
used in downstream applications. Virus supernatant was concentrated at 19500 rpm for 2 
hours at 16°C using a Beckman SW40 rotor. After removing most of the medium, the virus 
pellet was resuspended in ~1 ml residual liquid. Concentrated virus stocks were used 
immediately to infect target cells or stored overnight at 4°C.  
 
2.9.2 Spin infection of BL lines with lentiviral vectors 
Approximately 1 x 10
5
 BL cells in 100 μl B cell medium was mixed with 1 ml of 
concentrated virus in a 1.5 ml microfuge tube and supplemented with polybrene (1 μl per ml). 
The virus:cell mix was incubated for 30 minutes at 37°C, transferred to a 15 ml tube and spun 
for 2 hours at 2200 rpm using a Heraeus 8155 rotor (28-30°C). At this point, most of the 
supernatant was removed and the cell pellet resuspended in the residual medium. The cells 
were subsequently mixed with 1 ml pre-warmed B cell medium and transferred to one well of 
a 48-well plate. The efficiency of lentivirus transduction was assessed by GFP expression at 
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one and two weeks post-transduction using an Accuri C6 flow cytometer (BD Biosciences). 
Transduced BL cells were sorted on the basis of GFP expression using a MoFlo cell sorter 
(Dako). 
 
2.10 Electroporation of BL lines 
One day prior to transfection, cultures were split 1:3 in fresh medium to ensure the cells were 
actively growing. Cells were washed once in PBS and resuspended in Opti-MEM® reduced 
serum media (Gibco) at 16-20 x 10
6
 cells per ml. In parallel, electroporation cuvettes were 
prepared with appropriate amounts of DNA to be transfected. 0.5 ml of Opti-MEM®/cell mix 
was added to each cuvette (8-10 x 10
6
 cells), and each sample was electroporated at 270V and 
950μF using a BioRad Gene Pulser II Electroporation system. The contents of each cuvette 
were then quickly transferred to 7ml pre-warmed medium in one well of a 6 well plate and 
placed in an incubator at 37°C, 5% CO2.  
All reporter and control plasmids (pMIR-REPORT
TM
 Luciferase, pMIR-REPORT
TM
 β-Gal 
and pRL SV40 Renilla) were used at 4 μg per transfection. FTGW and FTGW derived 
BHRF1 miRNA expression vectors were used at 16 μg per transfection. Anti-miRNA 
oligonucleotides were added, where indicated, at concentrations shown in Chapter 5.3; note 
that these concentrations were relative to the volume of cells in the cuvette, not the final 
volume in the 6 well plates.  
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2.11 Measuring the activity of reporter constructs  
Firefly luciferase and Renilla luciferase activities were measured using the Dual-Luciferase® 
Reporter Assay System (Promega). Briefly transfected BL cells were harvested 24 hours post-
transfection, washed twice in PBS and the cell pellets kept on ice. Cells were lysed by the 
addition of 1x passive lysis buffer, incubated on ice for 15 minutes and then centrifuged to 
remove cell debris.  
Luciferase activities were measured using an ORION L Microplate Luminometer (Berthold 
Detection Systems) with a preset programme optimised for Dual Luciferase Assays. Replicate 
20 μl aliquots of each lysate were transferred to a 96-well plate which was then loaded into 
the luminometer. Firefly luciferase activity was measured following the addition of 100 μl 
Luciferase Assay Reagent II (LAR II) to each sample. The Stop & Glo® reagent was then 
added in order to both quench the firefly luciferase reaction and initiate the measurements of 
Renilla luciferase activity.  
In some experiments, pMIR-REPORT
TM
 β-Gal was used instead of pRL SV40 Renilla to 
normalise for transfection efficiency. In these cases, cells were lysed by the addition of 0.5 ml 
lysis solution (10 ml 1M Hepes pH 8, 2 ml 100mM MgCl2, 0.5 ml 1M DTT and 2 ml Triton 
X-100 made to 100 ml using distilled water) and incubated for 15 minutes on ice. Firefly 
luciferase activity was determined using a Sirius single tube luminometer (Berthold Detection 
Systems). Briefly 100 μl luciferase assay reagent (LAR) was added manually to 100 μl of cell 
lysate, the sample placed inside the luminometer and the data collected for 10 seconds. To 
prepare LAR, 2.5 ml 1M glycylglycine, 5 ml 100mM MgCl2, 20 μl 500mM EDTA, 50.8 mg 
DTT, 27.8 mg ATP and 21.3 mg co-enzyme A were diluted to 100 ml with distilled water; 
immediately prior to use, 250 μl luciferin stock was added to 5 ml LAR. In parallel, β-Gal 
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activity was measured on a separate aliquot of lysate using the Galacto-Light Plus
TM
 System 
(Applied Biosystems) according to manufacturer’s instructions. Following heat inactivation of 
the cell lysate at 50°C for 1 hour, a 20 μl aliquot was manually added to 200 μl β-gal substrate 
(Galacton-Plus substrate diluted 1:100 in reaction buffer diluent) and incubated for 1 hour at 
room temperature. β-gal activity was then measured for 1 second following addition of 300 μl 
Accelerator-II on a Sirius single tube luminometer. 
 
2.12 Cell growth assays 
Approximately 2 x 10
6
 lentivirus transduced BL cells were plated out in a 24 well plate and 
either induced with 1μg/ml doxycycline (Sigma Aldrich) or left untreated. Cell viability was 
tested at 48 hours using Trypan blue. Briefly a 10μl aliquot of cells was mixed 1:1 with 0.4% 
trypan blue (Sigma Aldrich), the stained cells were loaded into a dual chamber counting slide 
and the cell number and percentage viability measured using a TC10 automated cell counter 
(BioRad). A threshold of 80% viability for Akata BL derived lines and 70% viability for 
BL41 lines was used.  
Cell lines were then diluted in fresh B cell medium to a final concentration of 2 x 10
5
 cells/ml 
and 0.5 ml (1 x 10
5
) cells plated out, in triplicate, into a 48 well plate. To each well was then 
added 0.5 ml B cell medium containing (a) no drug or (b) 1μg/ml doxycycline. Cultures were 
then incubated at 37°C, 5% CO2 and harvested daily over the next 72 hours. The total number 
of live cells was determined by measuring GFP. Readings were collected from each well in 
FL1 using an Accuri C6 Flow Cytometer (BD Bioscience) from a minimum of 10000 cells. 
Data was expressed as fold change in live cell count relative to the number of cells at day 0.  
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2.13 Apoptosis assays 
Approximately 2 x 10
6
 lentivirus transduced BL cells were plated out in a 24 well plate and 
either induced with 1μg/ml doxycycline or left untreated. Cell viability was tested at 48 hours 
using Trypan blue as before (section 2.12). A threshold of 80% viability for Akata BL derived 
lines and 70% viability for BL41 and BL30 lines was used. Cell lines were then diluted in 
fresh B cell medium to a final concentration of 3 x 10
5
 cells/ml and 100 μl (3 x 104) cells 
plated out, in triplicate, into a flat bottomed 96 well plate. To each well was then added 100μl 
B cell medium containing (a) no drugs, (b) 1μg/ml doxycycline only, (c) the appropriate 
concentration of ionomycin only or (d) 1μg/ml doxycycline and the appropriate concentration 
of ionomycin (Sigma). The final concentration of ionomycin was 2μg/ml for Akata, 0.5μg/ml 
for BL41 and 1μg/ml for BL30 derived lines. Cultures were then incubated at 37°C, 5% CO2 
for 48 hours (Akata and BL41) or 72 hours (BL30) before analysis.  
Live and dead cells were distinguished following staining with Syto 17 (which stains live 
cells) and propidium iodide (which is membrane impermeable and stains late apoptotic or 
dead cells). Initially Syto17 (Invitrogen) was added to each well at a final concentration of 
50nM and incubated at 37°C for 1 hour. The plate was then put on ice and propidium iodide 
(PI, Invitrogen) added to each well at a final concentration of 0.5 ng per ml. Single and 
unstained samples for Syto17 and PI were also included for the purpose of colour 
compensation.  
Readings were collected from each well using an Accuri C6 Flow Cytometer from a 
minimum of 10000 cells. Syto17 is detected in FL4, while PI is detected in FL3. Live cells 
can be described as Syto17 positive, PI negative; early apoptotic cells as Syto17 negative, PI 
negative; and late apoptotic or dead cells as Syto17 negative, PI positive. The following 
Chapter 2 
 
72 
 
equation was used to calculate the amount of induced cell death as a result of ionomycin 
treatment: (Total number of dead cells in ionomycin treated sample – mean of total number of 
dead cells in untreated sample) / mean number of live cells in untreated sample.  
 
2.14 Affymetrix gene expression arrays 
RNA samples for the Affymetrix microarray analysis were prepared from approximately 5-10 
x 10
6
 lentiviral transduced cells. After harvesting, cells were washed once in PBS. Total RNA 
was prepared using TRIzol® reagent (Ambion) according to manufacturer’s instructions. 
RNA quality was confirmed by a 2100 Bioanalyzer (Agilent Technologies) and all samples 
were found to have RNA integrity numbers (RIN) between 9.8 and 9.9. Note that RIN is 
measured on a scale of 1 (heavily degraded) to 10 (intact RNA). 
Whole transcript profiling was performed by Sim Sihota (Affymetrix Microarray Facility, 
School of Cancer Sciences, University of Birmingham). Briefly biotinylated RNA was 
fragmented and hybridised to Affymetrix Human Gene ST1.0 Gene Chip according to the 
Affymetrix protocol. After washing and staining using an Affymetrix FS450 fluidics station, 
arrays were scanned using a GeneChip 3000 7G scanner. Probe level quantile normalisation 
and robust multi-array analysis on the raw CEL files were performed by Dr. Wenbin Wei 
using the AltAnalyze software package (http://www.altanalyze.org/) (780). Differentially 
expressed probe sets were identified using Limma analysis. The p-value cut off was set to 
0.01 and the fold change cut off to 1.5. 
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3. Quantitative study of EBV encoded miRNAs in BL cell lines 
3.1 Introduction 
In earlier sections (1.5, 1.6) we discussed both the broad range of cellular pathways in which 
miRNAs participate and the potential roles of miRNA deregulation in tumour development. 
The observation that EBV encodes a set of highly conserved viral miRNAs suggests that they 
are (a) important to the virus life cycle and (b) likely contribute to the pathogenesis of EBV 
associated malignancies (738). At the start of our study however only a handful of potential 
EBV miRNA targets had been validated (CXCL11, LMP1 and BALF5) (753, 759, 760) thus 
their functions remained largely unknown. By studying the BL cell line model, we aimed to 
establish if and how virally encoded miRNAs contribute to the oncogenic potential of EBV. 
Before we could study the function of the EBV miRNAs, we needed to gain an understanding 
of when and to what degree they are expressed. Studies published prior to the present work 
have provided us with some insight into EBV miRNA expression in EBV positive cell lines 
(250, 738, 740, 744, 745, 748)  and primary tumour material (749).  
Most of the 40 known EBV miRNAs were collectively discovered by Pfeffer (250), 
Grundhoff  (740) and Cai (738) along with their respective colleagues. These groups used 
methods such as cloning/sequencing (250, 738) or software prediction (740) to identify 
candidate miRNAs which were confirmed either by  array (740) or northern blotting (250, 
738, 740). Cai and co-workers  analyzed a larger selection of EBV positive cell lines by 
northern blot than the other two groups; consequently they were able to draw a number of 
interesting conclusions (738). The BHRF1 miRNAs were generated during the growth 
transforming program, specifically in cell lines expressing Cp and Wp initiated transcripts. 
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The BART miRNAs in turn were detected in all forms of EBV infection and their expression 
correlated with BART transcription; levels of both were notably elevated in epithelial cell 
lines. Cai and co-workers also performed the first investigation into EBV miRNA expression 
during lytic replication. They noticed that at 48h post induction the levels of all 4 BART 
miRNAs tested, as well as miR-BHRF1-2, were increased. Levels of miR-BHRF1-1 in 
contrast remained unchanged; this was somewhat predicted as miRBHRF1-1 overlaps the 
lytic BHRF1p and thus is not included in the transcript (744, 746, 747). 
Other studies by Cameron et al and Xing and Kieff gave broadly comparable results using 
northern blots (744) and arrays (745), respectively, to measure EBV miRNA expression. 
However Xing and Kieff made two interesting observations regarding EBV miRNA 
expression during lytic cycle which conflicted somewhat with data from Cai and co-workers 
(738, 744). First, Xing and Kieff could not detect an increase in the levels of the 2 BART 
miRNAs tested following induction of lytic replication; second, miR-BHRF1-1 levels did 
increase, but only after 48h, and appeared to correlate with the expression of Lat III latent 
antigens. Note that these two studies shared just one BART miRNA in common and used 
entirely different cell backgrounds (738, 744).  
Two additional northern blot studies have provided further insights into BART miRNA 
expression. Kim et al. demonstrated that BART miRNAs, but not BHRF1 miRNAs, could be 
detected in gastric carcinoma cell lines, animal models and patient tumour samples (749). Not 
only was this study the first to look at EBV miRNA expression in tissue samples, but it 
suggested that observations made in cell lines can be representative of the tumour from which 
they derived. Finally Edwards et al. extended the observation that the BART miRNAs 
correlate with BART transcription (748). They noticed that a particular BART exon splice 
variant (direct joining of exons 1 and 3) favoured BART miRNA accumulation. Furthermore, 
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they included an extensive panel of BART miRNAs in their study and so were able to 
convincingly demonstrate that individual BART miRNAs accumulate to different levels 
within the same cell line.  
Thus in summary we know that all three BHRF1 miRNAs are expressed from C and W 
promoter initiated transcripts during latency III, while miR-BHRF1-2 and 1-3 are expressed 
from the lytic BHRF1 promoter during productive infection. BART miRNAs in turn are 
expressed in all forms of EBV infection, and are preferably expressed in epithelial cell lines 
and NPC tumour cells as compared to cells of lymphoid origin (250, 738, 740, 744, 745, 748, 
749).  
Unfortunately these studies largely relied on northern blotting, arrays or cloning for detection. 
Such methods unfortunately require large amounts of RNA, have limited sensitivity and only 
provide qualitative data. In contrast we wanted to develop a methodology which was 
sensitive, specific and capable quantifying absolute EBV miRNA copy numbers.  
Thus in the first part of our study we aim to address these issues by validating a commercial 
quantitative PCR (QPCR) system for the detection and quantification of EBV miRNAs. 
Thereafter we confirm and extend the previous literature by characterizing EBV miRNA 
expression in a range of different BL cell lines and LCLs. Finally we investigate a number of 
factors determining EBV miRNA steady state levels, such as differential turnover rates and 
levels of BHRF1 and BART gene transcription.  
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3.2 Validating QPCR assays for the detection of EBV miRNAs 
Our QPCR assays were based on the stem-loop reverse transcriptase (RT) method described 
by Chen et al (776). Stem-loop RT primers are more efficient and possess greater target 
specificity than conventional RT primers. They also exclusively bind the mature form of a 
target miRNA. Furthermore stem-loop RT primers unfold during reverse transcription to 
produce a template sequence much longer than the mature miRNA target. This enables the 
generation of cDNA large enough to accommodate the full primer-probe set required for 
QPCR amplification. In a series of preliminary experiments, we validated both the specificity 
and sensitivity of a panel of QPCR assays designed to quantify selected EBV miRNAs. These 
included all three miRNAs derived from the BHRF1 region (miR-BHRF1-1, 1-2 and 1-3), 
five miRNAs from BART cluster 1 (miR-BART3, 4, 1-3p, 15 and 5), three miRNAs from 
BART cluster 2 (miR-BART7, 22 and 13) and miR-BART2-5p.  
Although it is recommended that each miRNA is reverse transcribed using its specific RT 
primer in a separate reaction, we first tested if it was possible to reverse transcribe several 
miRNAs at once by pooling several RT primers in a single reaction. Therefore in initial 
experiments we optimised a multiplex cDNA synthesis method incorporating up to 7 miRNA-
specific RT primers; this would enable us to assay several miRNAs from the same cDNA 
pool. Representative amplification plots for miR-BHRF1-1 and miR-BART3 produced from 
this multiplex method are shown in Fig. 3.1A, alongside data from cDNA made in a single 
reaction. Multiplex cDNA synthesis resulted only in a small (2 cycles or less) reduction in the 
sensitivity of QPCR detection, as compared to singleplex cDNA synthesis.  
Using cDNA prepared by this multiplex protocol, we then carried out a series of control 
experiments. First we used RNA from eight EBV-negative cell lines to test the specificity of 
miR-BART4 
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X50/7 
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miR-BHRF1-1 miR-BART3 
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Fig. 3.1. (A) Optimization of a multiplex cDNA synthesis method. cDNA was 
generated from a suitable reference line using either one (singleplex) or a pool 
of seven (multiplex) miRNA-specific RT primers. Shown are PCR 
amplification plots for miR-BHRF1-1 and miR-BART3.  (B) Specificity of 
QPCR assays to detect EBV miRNAs. Four EBV negative BLs (DG75, BJAB, 
BL41 and Ramos), EBV loss clones derived from two Latency I BLs (Mutu 59 
and Akata), an EBV negative T cell and NK cell line (Jurkat and NKL 
respectively) and an EBV positive LCL (X50/7) were used to test the 
specificity of each QPCR assay. Shown are representative PCR amplification 
plots for miR-BHRF1-1, miR-BHRF1-2, miR-BART4 and miR-BART5. (C) 
Sensitivity of QPCR assays to detect EBV miRNAs in cell mixtures containing 
serial dilutions of an EBV-positive LCL (100 – 0.1 cells) in an EBV-negative 
cell background. Shown are PCR amplification plots for miR-BHRF1-1 and 
miR-BART3 
Multiplex 
Singleplex 
Multiplex 
Singleplex 
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our assays. Data from representative amplification plots for miR-BHRF1-1, miR-BHRF1-2, 
miR-BART4 and miR-BART5 are shown in Fig. 3.1B. We found that all but three assays 
gave a negative PCR result; the exceptions were miR-BHRF1-1, miR-BART3 and miR-
BART4 which occasionally yielded extremely weak signals (Fig. 3.1B; also see Fig. 3.13B-D 
later). Second, we used our assays to detect EBV miRNAs in cell mixtures containing serial 
dilutions of an EBV-positive LCL (100 – 0.1 cells) in an EBV-negative (BJAB) cell 
background. Amplification plots for miR-BHRF1-1 and miR-BART3 are shown in Fig. 3.1C. 
All assays tested reproducibly and detected a single EBV-infected cell.  
Finally, the absolute sensitivity of each assay was determined by using cDNA prepared from 
serial dilutions of a pool of synthetic oligonucleotides containing all 12 target miRNAs. Data 
from representative amplification plots for 10-fold serial dilutions (10
8
 copies – 101 copies) of 
miR-BHRF1-1 and miR-BART3 are shown in Fig. 3.2., while standard curves for all 12 
assays are shown in Fig. 3.3. All assays demonstrated an excellent correlation between cycle 
threshold (Ct) values and RNA input over at least a 5-log range, and had a lower detection 
limit of between 100-1000 miRNA copies. 
 
3.3 Defining EBV latent gene expression in a panel of EBV positive B cell 
lines 
Having validated our QPCR assays we proceeded to characterize EBV miRNA expression in 
a panel of B cell lines with different patterns of latency. Our test lines included eight 
conventional Latency I BL lines (Lat I BL), five Wp-restricted BL lines (Wp BL), two 
Latency III BL lines (Lat III BL) and seven virus-transformed LCLs. These latency programs 
are summarized again in Fig. 3.4. While most if not all our cell lines had been previously 
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Fig. 3.2. Sensitivity of QPCR assays to detect EBV miRNAs. cDNA samples 
containing known numbers of synthetic miRNAs (108 – 102 copies) were used 
to test the absolute sensitivity of each QPCR assay. Shown are representative 
PCR amplification plots for miR-BHRF1-1 and miR-BART3.  
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Fig. 3.3. Sensitivity of QPCR assays to detect EBV miRNAs. Standard curves 
obtained for all 12 miRNAs obtained by plotting the cycle threshold (Ct) 
values against log input RNA copy number. Open circles indicate absence of a 
detectable signal (Ct=40).  
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Fig. 3.4. Patterns of latent gene expression in BL cell lines and LCLs. The 
location of viral promoters and splice structures of viral transcripts are shown 
relative to a linear representation of the EBV genome. Conventional Latency I 
BLs express a single latent antigen EBNA1 transcribed from a viral promoter 
in the BamHI Q region(Qp). Wp-restricted BLs are characterised by the 
presence of an EBNA2-deleted EBV genome; these BLs express EBNAs 1, -
3A, -3B, -3C and –LP, along with BHRF1, all transcribed from the Latency III 
BamHI W promoter (Wp), but in the absence of EBNA2 and the latent 
membrane proteins (LMPs). Latency III BL lines and growth transformed 
LCLs express all six EBNAs and BHRF1, predominantly from transcripts 
initiated at the BamHI C promoter (Cp), along with the LMPs which are 
transcribed from separate promoters in the BamHI N region. EBERs (not 
shown) and BamHI A rightward transcripts (BARTs) are present in all three 
forms of latency.  Also shown are the positions of the BHRF1 and BART 
miRNAs, latent origin of replication (oriP) and the terminal repeat region (TR).  
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characterized, it was necessary to ensure they had not drifted towards an unexpected pattern 
of latency, as is occasionally seen in BL cell lines (781).  
 
3.3.1 Assessing latent promoter usage 
Conventionally latency is defined by latent promoter usage. Thus we first verified that our test 
lines showed the expected pattern of latent viral promoter usage by quantifying levels of Qp-, 
Cp- and Wp-initiated EBNA transcripts by QPCR using established assays (Fig. 3.5) (769). 
As expected the Lat I BL lines exclusively used Qp with only trace or undetectable levels of 
Cp/Wp activity. In contrast, the Wp BL lines were distinguished by high levels of Wp 
activity, usually in the absence of the other latent promoters. Lat III BLs and LCLs in turn 
showed variable levels of both Cp and Wp usage, with the exception of X50/7 which lacks Cp 
sequences (771). Note that Chep-BL was originally defined as a Lat I BL line (781) but 
appeared to have drifted to Lat III during passage in vitro. Finally, all test cell lines were 
tightly latent since immediate early BZLF1 transcripts were either undetectable or present at 
very low levels, equivalent to less than 1% BZLF1 positive cells (see Fig. 3.8A later). 
 
3.3.2 Expression of latent proteins 
As an additional confirmation of latency we probed for EBNA1, EBNA2, BHRF1 and LMP1 
expression in the same lines by western blot (Fig. 3.6). Protein expression correlated broadly 
with latent viral promoter usage as expected. Thus EBNA1 alone was detected in Lat I BL 
lines. Both EBNA1 and BHRF1 were detected in Wp BL lines, although BHRF1 protein 
levels in Awia-BL sub-clones (k, m) were barely detectable. Finally Lat III BL lines and 
LCLs expressed EBNA1, EBNA2 and variable levels of LMP1; BHRF1 could only be 
Fig. 3.5. Expression of latent transcripts in EBV-positive B cell lines. Latency 
I-associated Qp transcripts and Latency III-associated Cp- and Wp-initiated 
transcripts were quantified by QPCR in seven Latency I BLs (Dante, Sav, 
Ezema, Akata, Kem and Awia cl. a), five Wp-restricted BLs (Awia cl. k and m, 
Oku, Sal and Ava), three Latency III BLs (Chep, Mutu III and Glor III) and 
seven LCLs (X50-7, IM51, -81, -83, -93, EH LCL1 and EH LCL2); DG75 was 
included as a negative control. Data were normalised to cellular PGK levels 
and expressed relative to a suitable positive reference line which was assigned 
an arbitrary value of one. Shown in separate panels are two replicate assay 
measurements obtained from a single preparation of RNA.  
-ve Lat I BL Wp BL LCL Lat III BL 
Cp 
Qp 
Wp 
-ve Lat I BL Wp BL LCL Lat III BL 
Cp 
Qp 
Wp 
EBNA 1 
EBNA 2 
BHRF1 
B-ACTIN 
Calregulin 
LMP1 
-ve Lat I BL Wp BL LCL Lat III BL 
Fig. 3.6. Expression of latent proteins in EBV-positive B cell lines. EBNA1, -
2, BHRF1 and LMP1 protein was detected by western blot in the same cell 
lines shown in Fig. 4. DG75 was included as a negative control. Detection of 
either β-Actin or Calregulin was performed as a loading control. Molecular 
weight markers and sizes in kDa are provided on the side of each gel.   
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detected in one LCL (IM 81.1). Surprisingly Chep-BL expressed EBNA1 in the absence of 
EBNA2 and LMP1, despite the presence of Cp/Wp initiated EBNA transcription (Fig. 3.5). 
Due to these contradictory results, we removed Chep-BL from further studies.  
 
3.4 Investigating BHRF1 miRNA expression in EBV positive B cell lines 
At this point we have successfully validated our QPCR assays and confirmed the latency 
pattern of our B cell lines. Thus in the next series of experiments we launched an investigation 
into the expression of the BHRF1 miRNAs in the same lines. According to earlier reports the 
BHRF1 miRNAs are processed from the introns of large Cp and Wp initiated EBNA 
transcripts (738, 744), though they could in theory be processed from the 5′ and 3′ UTRs of 
latent BHRF1 transcripts (Fig. 3.7A). To further investigate these possibilities, we determined 
both the copy numbers of all three BHRF1 miRNAs in our test lines and the levels of BHRF1 
transcription to determine how well it correlates with BHRF1 miRNA expression.  
 
3.4.1 Correlating BHRF1 miRNA expression and BHRF1 transcription   
BHRF1 transcripts were measured using two different primer/probe combinations, one 
designed to specifically amplify Cp/Wp-initiated latent BHRF1 transcripts and the other 
designed to detect total (lytic and latent) BHRF1 transcripts. As shown by the data in Fig. 
3.8A, the BHRF1 expression profiles were comparable using both assays, and correlated with 
the presence of Cp and/or Wp promoter activity (Fig. 3.5). Consistent with the very low 
BZLF1 signals, negligible levels of lytic BHRF1 transcripts were observed in these test lines 
(data not shown), thus excluding the possibility that a small population of productively 
infected cells were making a significant contribution to the total levels of BHRF1 transcripts.  
Fig. 3.7. Detailed structure of EBV transcripts and miRNAs. (A) BHRF1 
transcripts and location of BHRF1-derived miRNAs. All three BHRF1 
miRNAs may be generated during latency either by processing of an intron 
present within the Cp/Wp initiated primary EBNA transcript or by processing 
of the 5′ and 3′ untranslated regions within latent BHRF1 transcripts with the 
W2-Y1-Y2-BHRF1 structure. (B) Detailed structure of the highly spliced 
BARTs and location of the BART-derived miRNAs (adapted from Edwards et 
al. ) (748). The BART miRNAs form two clusters within the BART introns, 
with the exception of mirBART2 which lies further downstream. The 
prototype B95-8 EBV strain carries a 12kb deletion in this region which 
removes several cluster 1 miRNAs and all cluster 2 miRNAs (shown in 
italics).  
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Fig. 3.8. Expression of BHRF1 transcripts and BHRF1 miRNAs in EBV-
positive B cell lines. (A) Total BHRF1 transcripts, Cp/Wp-initiated latent 
BHRF1 transcripts and immediate early BZLF1 transcripts were quantified by 
QPCR in the same cell lines as shown in Fig. 3.5. BHRF1 values are expressed 
relative to a reference LCL, while BZLF1 values are expressed relative to a 
spontaneous LCL and adjusted so that a value of one is equivalent to 100% 
positive cells.  (B) Expression of BHRF1 miRNAs in the same cell lines 
determined by QPCR. Data were normalised to RNU48 expression and 
expressed as absolute copy numbers per pg total RNA. Shown in separate 
panels are two replicate assay measurements obtained from a single 
preparation of RNA. Note that Sal-BL is deleted for miR-BHRF1-1, as 
indicated by the † symbol. 
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We then went on to measure the levels of BHRF1 miRNAs in the same panel of cell lines 
using our newly-developed QPCR assays. The data (Fig 3.8B) show that BHRF1 miRNA 
expression varied widely, ranging from 0-5 copies per pg RNA in Lat I BL lines to more than 
300 copies per pg RNA in Lat III LCLs. Interestingly levels of the BHRF1 miRNAs in the 
LCLs were at least as high as in the Wp BL lines, despite the latter having much higher levels 
of BHRF1 transcripts. In most cases, we noted that all three BHRF1 miRNAs were co-
ordinately expressed within a cell line, with no more than 3-fold variation in absolute values 
between individual miRNAs. One exception was Sal-BL, which expressed abundant levels of 
mir-BHRF1-2 and mir-BHRF1-3 but is known to be deleted for miR-BHRF1-1 (625). 
Another exception was Ava-BL, where levels of miR-BHRF1-2 were unusually low 
compared to the other BHRF1 miRNAs.  
To determine if BHRF1 transcription correlates with the BHRF1 miRNA expression, we 
plotted the entire latent BHRF1 data set against that of miR-BHRF1-1, miR-BHRF1-2 or 
miR-BHRF1-3 and performed linear regression analysis (Fig. 3.9). Cell lines expressing latent 
BHRF1 also expressed the BHRF1 miRNAs and vice versa. Nonetheless linear regression 
analysis revealed a startling lack of correlation between the two data sets, with R
2
 values 
falling below 0.1 for each comparison.  
 
3.4.2 BHRF1 miRNA sequence variation 
Previous studies have revealed that sequence changes can interfere with miRNA processing 
(743, 748); such changes could in theory also affect the efficiency of the PCR reaction. 
Therefore we considered the possibility that EBV strain polymorphisms might account for 
some of the variation in BHRF1 miRNA levels. To this end, we determined the sequence of 
miR-BHRF1-1 vs. Latent BHRF1 
miR-BHRF1-2 vs. Latent BHRF1 
miR-BHRF1-3 vs. Latent BHRF1 
R2 =  0.09299 
R2 =  0.00008 
R2 =  0.00175 
Fig. 3.9. Correlating levels of BHRF1 transcripts and BHRF1 miRNAs in 
EBV-positive B cell lines. Collective data from Fig. 3.8. were redrawn to plot 
each BHRF1 miRNA individually against latent BHRF1. Each point on the 
graph represents data from a single cell line. Linear regression analysis was 
performed to calculate R squared values.  
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the BHRF1 pre-miRNAs in 12 EBV isolates and compared the sequences with the published 
B95-8 genome; the number and position of any sequence changes are summarised in Fig. 3.10 
through Fig. 3.12. We also calculated the minimum free energy ΔG associated with each 
polymorphic variant separately using both Mfold (777) and RNAfold (778, 779). While each 
program calculated different absolute ΔG values per pre-miRNA sequence, the differences in 
free energy between a given test sequence and the B95-8 sequence were near identical for 
both programs.  
Overall miR-BHRF1-1 and miR-BHRF1-2 sequences were highly conserved in the BL lines 
tested. In two cases (Kem-BL and Sav-BL), we found a single change in the mature miR-
BHRF1-1 miRNA; however the effect of this mutation on pre-miRNA processing or PCR 
detection is unclear as the BHRF1 region is not transcribed in these Latency I lines (Fig. 
3.10). One cell line, Ava-BL, contained a single polymorphism in the mature miR-BHRF1-2 
sequence which disrupts a G-C base pair in the stem-loop (Fig. 3.11). This G to A substitution 
is predicted to significantly destabilise the pre-miRNA hairpin loop structure and therefore 
may account for the low levels of miR-BHRF1-2 detected in this cell line (Fig. 3.8B). Finally, 
five cell lines contained six common nucleotide changes in the miR-BHRF1-3 pre-miRNA 
(Fig. 3.12). Surprisingly these changes only marginally affected the minimum free energy 
structure of the BHRF1-3 pre-miRNA, and are therefore unlikely to affect folding or 
processing of this pre-miRNA.  
 
3.5 Investigating BART miRNA expression in EBV positive B cell lines 
The majority of EBV miRNAs form two intronic clusters within the BART region of the 
genome. The BART transcripts are expressed from two promoters and are reportedly found in 
mir-BHRF1-1 
UUAACCU
GA
UCAG
C
CCCGG
A
GUUG
CC
UG
UU
U
5′UA
3′AAC
AGUUGGA
GA
AGUC
C
GGGCC
C
CAAU
C
AC
UA
C
U (Kem, Sav)
B95-8 Kem 
                  ΔG (Mfold)                  -21.2 kcal/mol                     -18.7 kcal/mol 
                  ΔG (RNAfold)             -25.5 kcal/mol                     -22.5 kcal/mol 
Fig. 3.10. Sequence variation in miR-BHRF1-1. (A) The prototype B95-8 
sequence of the pre-miRNA is shown with the mature miRNA indicated in 
bold text. Sequence changes are marked by the arrows with the cell line 
indicated in brackets. (B) Structures of the folded B95-8 and Kem pre-
miRNAs were predicted using Mfold. Minimum free energy ∆G was 
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Fig. 3.11. Sequence variation in miR-BHRF1-2. (A) The prototype B95-8 
sequence of the pre-miRNA is shown with the mature miRNA indicated in 
bold text. Sequence changes are marked by the arrows with the cell line 
indicated in brackets. (B) Structures of the folded B95-8 and Ava pre-miRNAs 
were predicted using Mfold. Minimum free energy ∆G was determined 
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Fig. 3.12. Sequence variation in miR-BHRF1-3. (A) The prototype B95-8 
sequence of the pre-miRNA is shown with the mature miRNA indicated in 
bold text. Sequence changes are marked by the arrows with the cell line 
indicated in brackets. (B) Structures of the folded B95-8 and Ava pre-miRNAs 
were predicted using Mfold. Minimum free energy ∆G was determined 
separately with Mfold and RNAfold.  
 
 
Chapter 3 
 
82 
 
all forms of latency. Since particular BART splice variants may favour the production of 
BART miRNAs (748), we quantified BART transcription in our test lines using two different 
PCR assays; the first specific for the conventional transcript containing exons 1, 2 and 3 (exon 
2-3 assay) and the second specific for the exon 2-deleted variant (exon 1-3 assay).  
Subsequently we quantified a select panel of 9 BART miRNAs spanning both clusters 1 and 2 
in the same lines. 
 
3.5.1 Correlating BART miRNA expression and BART transcription 
In contrast to BHRF1, BART transcripts were detected across all forms of latency, albeit at 
highly variable levels (Fig. 3.13A); BART transcripts containing exon 2-3 and exon 1-3 splice 
junctions appeared to be co-ordinately expressed. Screening the same samples for the 
presence of nine representative BART miRNAs, we found levels ranging from less than 10 to 
more than 400 copies per pg RNA (Figs. 3.13B-D). Overall it is clear that the B cell lines 
expressed lower levels of BART miRNAs than the epithelial cell line C666-1 (data included 
in Figs. 1.13B-D for comparison). Interestingly we observed up to a 50-fold variation between 
different BART miRNAs within a given cell line. BART miRNA levels also varied widely 
between cell lines but all showed the same hierarchy of BART miRNA expression, with miR-
BART7 usually the most abundant and miR-BART13 the most scarce. Of note, EH LCL1 and 
EH LCL2 were generated from a recombinant prototype EBV strain which, like B95-8, lacks 
many of the BART miRNAs (Fig. 3.7B). 
We next investigated how well BART transcription correlates with BART miRNA 
production. To this end we plotted the data sets of either the 1-3 or the 2-3 BART exon splice 
variant individually against miR-BART15 (cluster 1), miR-BART22 (cluster 2) or miR-
BART2-5p (Fig. 3.14). Linear regression revealed that both BART exon splice variants 
Fig. 3.13. Expression of BART transcripts and BART miRNAs in EBV-
positive B cell lines. (A) BART transcripts were quantified by QPCR using 
assays specific for either the exon 1-3 or 2-3 splice variants in the same cell 
lines as shown in Fig. 3.5. Data were normalised to PGK expression and 
results are expressed relative to the EBV-positive epithelial tumour cell line 
C666-1. (B) and (C) show expression of cluster 1 and cluster 2 BART 
miRNAs, respectively while (D) shows miR-BART2-5p expression. Data were 
normalised to RNU48 expression and expressed as copy numbers per pg input 
RNA. Shown in separate panels are two replicate assay measurements 
obtained from a single preparation of RNA. Data points highlighted with † 
correspond to cell lines carrying a BART deletion. For comparison, copy 
numbers of BART miRNAs per pg C666-1 RNA are shown in parentheses in 
each histogram.  
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Fig. 3.14. Correlating levels of BART transcripts and BART miRNAs in EBV-
positive B cell lines. Collective data from Fig. 3.13. were redrawn to plot 
either a cluster 1 (miR-BART15), a cluster 2 BART miRNA (miR-BART22) or 
the miR-BART2-5p miRNA individually against (A) BART (1-3) or (B) BART 
(2-3). Each point on the graph represents data from a single cell line. Linear 
regression analysis was performed to calculate R squared values.  
Chapter 3 
 
83 
 
correlated similarly with each of the three BART miRNAs examined, with R
2
 values ranging 
between 0.3 and 0.4. These values indicate a closer relationship between BART transcription 
and BART miRNA production than is the case for latent BHRF1 and the BHRF1 miRNAs. 
 
3.6 Quantifying Drosha and Dicer transcription in EBV positive B cell lines 
Neither BHRF1 nor BART transcription could account for (a) the variation in EBV miRNA 
expression between different cell lines and (b) the wide variation in levels of individual 
miRNAs within a cell line. To address the former, we asked whether differences in the levels 
of Drosha and Dicer could account for some of the variation in BHRF1 or BART miRNA 
levels between our test lines. As discussed earlier (sections 1.2 and 1.5) Drosha and Dicer are 
key components of the miRNA biogenesis pathway whose levels impact on cellular miRNA 
accumulation. Therefore we performed QPCR for Drosha and Dicer transcripts in a select 
panel of B cell lines (Fig. 3.15A). Levels of Drosha and Dicer transcripts were within a 4 – 5 
fold range in the cell lines tested. For comparison, we also calculated the mean copy number 
of BHRF1 and BART miRNAs for the same cell lines (Fig. 3.15B; using data from Fig. 3.8 
and Fig. 3.13). It is clear that changes in miRNA levels are greater than changes in 
Drosha/Dicer, and show no correlation. 
 
3.7 Stability of viral transcripts and miRNAs in EBV positive B cell lines 
It has previously been reported that some miRNAs are intrinsically less stable than others, 
while conversely certain cell backgrounds have overall faster miRNA turnover rates (93, 95). 
Either scenario could account for some of the variation in the steady state levels of BHRF1 
and BART miRNAs observed in our test lines. To investigate this theory in more detail, we 
A 
-ve Lat I BL LCL Lat III BL 
Drosha 
Dicer 
Fig. 3.15. Comparing levels of EBV miRNAs to Drosha and Dicer expression. 
(A) Drosha and Dicer transcripts were quantified by QPCR in a select panel of 
cell lines. Data were normalised to PGK expression and expressed relative to a 
reference LCL. Shown are the averages of two replicate assay measurements 
obtained from a single preparation of RNA (B) Data from Fig. 3.8. and Fig. 
3.13. were used to generate mean BHRF1 and BART  miRNA values for the 
same cell lines.  
 
  
B 
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examined the half-life of selected miRNAs in three cell lines Sal-BL, X50/7 LCL and Ava-
BL; these lines were chosen since they showed overall high, intermediate and low levels of 
BART miRNA expression (Fig. 3.13). Cells were cultured in the presence of the RNA 
synthesis inhibitor Actinomycin D and then harvested for analysis at various time points after 
treatment. Residual levels of BHRF1 and BART transcripts and derived miRNAs were then 
monitored by QPCR (Fig. 3.16, Fig. 3.17); as a control, we also assayed c-myc RNA since 
this transcript has been reported to have a very short half-life of around 12 minutes (782).  
Fig. 3.16A and Fig. 3.17A show the individual data points from Sal-BL cells up to 24h post 
treatment, while Fig. 3.16B and Fig. 3.17B summarise the data from all three cell lines. In the 
case of Sal-BL, c-myc RNA levels decreased rapidly to less than 10% after 4h exposure to 
Actinomycin D while the latent BHRF1 transcripts also decreased but to a lesser extent (Fig. 
3.16A). By contrast, the BHRF1 miRNAs decreased by less than 2-fold even at 24h post 
treatment. When we examined the BARTs, both the BART (1-3) transcript and three 
representative BART miRNAs were all relatively constant up to 24h (Fig. 3.17A). Similar 
data for the stability of the transcripts and miRNAs were obtained from X50/7 and Ava-BL 
(Fig. 3.16B, Fig. 3.17B). Although we have only tested a limited number of miRNAs, these 
data suggest that the EBV miRNAs are very stable and therefore changes in miRNA turnover 
cannot account for the observed differences in miRNA levels. 
 
 
miR-BHRF1-2 
miR-BHRF1-3 
Latent BHRF1 
C-MYC 
A 
B 
∆ 
Fig. 3.16. Stability of EBV transcripts and miRNAs. (A) Sal-BL cells were 
treated with 5µg/ml actinomycin D, harvested at the indicated time points and 
then analysed for BHRF1 transcripts and miRNAs. Error bars indicate standard 
deviation of 3 replicate experiments (B) Summary of data from Sal-BL, Ava-
BL and X50/7. The histograms indicate the expression of the indicated 
transcripts and miRNAs measured at 12 h after the addition of actinomycin D. 
Shown in separate panels are two replicate assay measurements obtained from 
a single preparation of RNA. Cellular c-myc RNA is unstable and served as a 
positive control for RNA decay. All data were normalised to RNA input. 
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∆ 
Fig. 3.17. Stability of EBV transcripts and miRNAs. (A) Sal-BL cells were 
treated with 5µg/ml actinomycin D, harvested at the indicated time points and 
then analysed for BART transcripts and miRNAs. Error bars indicate standard 
deviation of 3 replicate experiments. (B) Summary of data from Sal-BL, Ava-
BL and X50/7. The histograms indicate the expression of the indicated 
transcripts and miRNAs measured at 12 h after the addition of actinomycin D. 
Shown in separate panels are two replicate assay measurements obtained from 
a single preparation of RNA. Cellular c-myc RNA is unstable and served as a 
positive control for RNA decay. All data were normalised to RNA input. 
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3.8 Discussion 
3.8.1 Preliminary validation experiments 
EBV miRNAs have attracted a lot of interest in recent years as they potentially contribute to 
the B cell growth transformation and the pathogenesis of EBV-associated tumours. However 
there was little information on the quantitative expression of these molecules in different 
types of infection. In the first part of our work we validated a panel of real time PCR assays to 
quantify expression of three BHRF1 miRNAs and nine representative BART miRNAs 
(including all five BART miRNAs present in the B95-8 prototype EBV genome). In a series 
of control experiments these assays were shown to be both specific and highly sensitive (Fig. 
3.1 through Fig. 3.3).  
In contrast to some earlier studies of EBV miRNAs, we carefully characterized latent viral 
promoter usage and protein expression in our 22 EBV-positive test cell lines (Fig. 3.5 and Fig. 
3.6). The vast majority of our lines displayed the expected pattern of latent infection. One 
exception was Chep-BL which appeared to display an intermediate form of latency, 
characterized by the presence of Lat III transcripts but in the absence of detectable EBNA2 
protein. The other exception was Awia-BL in which BHRF1 protein was nearly undetectable. 
We speculate that BHRF1 protein levels in these cells were too low for detection by western 
blot using the experimental conditions outlined in Table 2.2. Nonetheless these examples both 
highlight the importance of carefully validating cell lines before using them in research.  
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3.8.2 Viral miRNA expression in EBV positive B cell lines 
Next we characterized the expression of 3 BHRF1 and 9 BART miRNAs in 21 EBV-positive 
lymphoid cell lines with well defined forms of latency. While this issue has been addressed in 
earlier studies, data have only been reported for a very limited number of lymphoid cell lines 
and these were not fully characterised in terms of virus gene expression (250, 738, 740, 744, 
745, 748, 749).  
Our work revealed that all three BHRF1 miRNAs are robustly expressed at comparable levels 
in Latency III cell lines which use Cp and/or Wp to drive EBNA transcription. While this 
finding is consistent with earlier Northern blot-based studies discussed in section 3.1 (738, 
744), our data provide a number of novel findings. We demonstrate that the BHRF1 miRNAs 
are also abundantly expressed in a range of Wp BL lines (Fig. 3.8B). While the biological 
significance of this finding remains to be determined, it has previously been reported that Wp 
BL lines are much more resistant to cell death stimuli than standard Lat I BL lines (681). A 
number of recent reports (320, 511, 512) have focussed on the role of BHRF1, EBNA-LP and 
the EBNA3 proteins in providing a pro-survival signal in Wp BLs, but the current work now 
adds the BHRF1 miRNAs to the list of candidate genes which may mediate this phenotype. 
We also found that while some Lat I BL lines express extremely low levels of BHRF1 
miRNAs, these signals are always accompanied by similar trace levels of Wp- and Cp-
initiated transcripts, suggesting that a small population of cells have drifted to Latency III 
during passage in vitro. This finding further underlines the importance of carefully validating 
the patterns of virus promoter usage before drawing conclusions on miRNA expression.  
Extending our studies to the BART region, our quantitative analysis confirms earlier reports 
that the BART miRNAs are readily detectable in all forms of virus latency, albeit at lower 
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levels than in EBV infected epithelial cell lines (250, 738, 743, 748). Our data also highlight 
the huge variation in overall BART miRNA levels between different cell lines. However, in 
sharp contrast to the coordinate expression of the BHRF1 miRNAs, different BART miRNAs 
were found to be expressed at dramatically different levels within a cell line, with miR-
BART7, miR-BART4 and miR-BART15 frequently the most abundant and miR-BART2-5p 
and miR-BART13 consistently the least abundant (Fig. 3.13). While a similar hierarchy of 
miRNA expression has been noted in previous studies of B cells (743) and epithelial cells 
(739), it was unclear if this pattern reflected PCR artefacts arising from miRNA sequence 
polymorphisms or differences in miRNA processing and stability.  
While this work was in progress, Pratt and co-workers (743) described a similar quantitative 
PCR study of EBV miRNA expression in EBV positive lymphoid cell lines. While their 
conclusions are broadly similar to those of the present work, our analysis included a larger 
collection of cell lines and examined a different panel of miRNAs. We also noted a number of 
discordant results between the two studies. Overall we found that the absolute level of 
BHRF1 and BART miRNAs were 5-20 fold higher than previously estimated (743).  
Our data suggest that individual EBV miRNAs are expressed at a range of 100 – 4000 copies 
per cell, assuming that 1 cell contains 10 pg of RNA. For comparison, individual cellular 
miRNAs are expressed at a median of 633 copies per mouse liver cell and at a median of 178 
copies per human hematopoietic progenitor cell (HSC) (783). Thus it is likely that EBV 
miRNAs are expressed at physiologically significant levels.  
A number of recent studies have relied on deep sequencing techniques to profile miRNA 
expression in EBV positive lymphoid cell lines and tumours (763, 764, 784). The concept 
behind deep sequencing is reviewed in more detail elsewhere (785). Essentially millions of 
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small sequence reads are generated; individual miRNAs can then be quantified based on the 
number of times their sequence appears in the data set. Next generation sequencing 
techniques also appear capable of distinguishing between miRNA variants containing 3′ 
modifications; there is increasing evidence to suggest such reads are not just an artefact of 
sequencing (741, 763, 786). Sequencing is also suited for expression of individual miRNAs as 
a fraction of the total cellular miRNA pool. Thus Skalsky and co-workers found that up to 
22% of all miRNA reads in a panel of B95-8 derived LCLs (Lat III) were virus associated 
(763). Imig and co-workers in turn found that around 1.7% of miRNA reads in EBV positive 
diffuse large B-cell lymphoma (DLBCL; Lat I) were virus associated (784).  
There are a number of similarities between the present work and studies conducted by 
Skalsky, Imig and their respective co-workers (763, 784). They all agree with the notion that 
BHRF1 miRNAs are expressed during Latency III while BART miRNAs are found in all 
forms of latency. Furthermore they all found that the BART miRNAs were expressed at 
dramatically different levels within a given cell line or tumour. Finally, where examined there 
was a huge variation in overall EBV miRNA levels between different cell lines (763).  
Nonetheless there were drastic differences concerning which EBV miRNAs were highest and 
lowest expressed within a given tumour background. We found that miR-BART7, miR-
BART4 and miR-BART15 were frequently the most abundant and miR-BART2-5p and miR-
BART13 consistently the least abundant of the BART miRNAs (Fig. 3.13). Imig and co-
workers found that miR-BART10, miR-BART22 and miR-BART7 were frequently the most 
abundant and miR-BART15 and miR-BART20 consistently the least abundant of the BART 
miRNAs (784). Finally Skalsky and co-workers found that miR-BART1-5p (not tested in the 
present work) was frequently the most abundant of the BART miRNAs; relative levels of all 
the remaining BART miRNAs differed from one LCL to the next (763). They also noted that 
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the miR-BHRF1-1 was expressed at levels up to 16 fold greater than miR-BHRF1-2 and miR-
BHRF1-3 in the majority of LCLs examined; the present work suggest that all three BHRF1 
miRNAs are almost always expressed at similarly levels (Fig. 3.8). We speculate that these 
discrepancies are mainly due to differences in the cell line or tumour background studied, as 
opposed to differing methods of detection. Imig and co-workers demonstrated that 
quantitative data gathered by sequencing can in most cases be backed up by other techniques 
such as QPCR and northern blot (784). 
On a final note QPCR and deep sequencing have all been used to characterize EBV miRNA 
expression in NPC tumours (739, 741, 786). Comparisons between these studies revealed that 
NPC does not have a characteristic EBV miRNA profile as the relative levels of each miRNA 
differs from one tumour to the next. For instance Chen et al. found miR-BART5-5p, miR-
BART3-3p and miR-BART9-3p were the most abundant EBV miRNAs while Zhu et al. 
found miR-BART7-3p, miR-BART22 and miR-BART1-5p to be most abundant; this is 
despite both reports using a similar method of detection (sequencing) (741, 786). 
Cosmopoulos and co-workers in turn found miR-BART7, miR-BART17-5p and miR-
BART16 to be the most abundant EBV miRNAs by means of QPCR (739). Overall the 
hierarchy of miRNA expression described in the present study agrees most closely with that 
described by Cosmopoulos et al (739).  
 
3.8.3 Exploring the possible determinants of EBV miRNA accumulation 
Our data highlight that alterations in BHRF1 transcription do not necessarily correlate with 
changes in steady state BHRF1 miRNA levels. This is best exemplified by the Wp-restricted 
BL lines which on average expressed ten-fold more latent BHRF1 transcripts than LCLs, but 
did not express higher levels of mature BHRF1 miRNAs (Fig. 3.8). We note that BHRF1 pre-
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miRNAs may potentially be generated by processing of either a large BHRF1-containing 
intron present in all primary Cp/Wp-initiated EBNA transcripts (744) or from the 5' and 3' 
UTRs present within latent BHRF1 transcripts. Our data appear to suggest that this second 
pathway may be less important for determining the levels of BHRF1 miRNAs in latent 
infection. To some extent BART miRNA expression correlated with overall levels of BART 
transcription, although the correlation was better in the case of BL lines than LCLs (Fig. 
3.13). Edwards et al. reported that BART miRNA production is favoured by the 1-3 BART 
exon splice form (748). Interestingly we found that 1-3 and 2-3 BART exon splice forms were 
similar in their correlation to selected BART miRNAs (Fig. 3.14). Nonetheless we appreciate 
this does not mean BART miRNAs are generated equally from both BART exon splice forms. 
As discussed in section 1.3 there are a number of factors which affect miRNA accumulation 
aside from levels of precursor transcription (70). These factors include processing of the 
precursor miRNA as well as the inherent stability of a given mature miRNA. Similarly 
nucleotide polymorphisms in the pre-miRNA sequence have also been reported to disrupt 
processing of the mature miRNA (738, 743, 748, 787); examples include miR-BHRF1-3 in 
Raji BL or miR-BHRF1-1 in Jijoye BL.  
Therefore we performed additional experiments in order to understand the discordant 
relationship between EBV precursor transcription and miRNA production. In the first we 
investigated Drosha and Dicer transcription due to their involvement in the miRNA 
biogenesis pathway. We found that RNA levels of both genes were relatively constant in the 
selection of cell lines tested (Fig. 3.15), implying that differences in Drosha and Dicer 
transcription can not explain differences in EBV miRNA expression. Nonetheless it remains 
possible that Drosha and Dicer protein levels accumulate differentially among our test lines. 
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Indeed a recent report has implicated miR-BART6 in the post-transcriptional regulation of 
Dicer (757).  
Following this we investigated whether sequence polymorphisms in the pre-miRNA sequence 
were contributing to the variations in EBV miRNA measurements. A number of previous 
studies have already documented the high degree of sequence conservation of BART 
miRNAs in different EBV strains (738, 748). None of the nine BART miRNAs examined 
here have previously been reported to carry polymorphisms in the mature miRNA sequence, 
although some of the BART miRNAs examined here have been reported to carry 
polymorphisms in the pre-miRNA sequence; these changes were rare and predicted to have no 
effect on processing (748). Thus we argue that the differential accumulation of individual 
BART miRNAs is unlikely related to sequence variation.  
A detailed investigation into BHRF1 miRNA sequence variation among different EBV 
positive cell lines revealed that the miR-BHRF1-1 (Fig. 3.10) and miR-BHRF1-2 (Fig. 3.11) 
sequences were well conserved in 12 virus genomes tested. In contrast, several cell lines 
contained six changes in the miR-BHRF1-3 pre-miRNA sequence. Remarkably these 
mutations appeared to maintain the base pairing within the pre-miRNA hairpin loop structure 
(Fig. 3.12) and did not significantly reduce miR-BHRF1-3 expression. Collectively these 
findings strongly support the view that BHRF1 miRNAs have been functionally conserved 
during EBV evolution.  
We also note that when sequence variation occurs in the mature miRNA sequence, we cannot 
eliminate the possibility that the mutation affects PCR detection. This is compounded by the 
lack of data regarding the QPCR primer-probe sequences due to their commercial nature. Our 
data (Fig. 3.8) does however suggest that the single polymorphism seen in the mature miR-
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BHRF1-3 sequence has little or no effect on PCR amplification; miR-BHRF1-3 was readily 
detectable in three cell lines (Sal BL, Ava BL and Glor III BL) carrying the nucleotide 
change, and at levels similar to other cell lines displaying a comparable pattern of latent gene 
expression. 
Finally our data argue that variations in EBV miRNA expression are not due to differences in 
the stability of individual miRNAs within a cell line. BHRF1 transcripts and BHRF1 miRNAs 
have similar half lives in X50/7 LCL and two Wp BL lines, Sal-BL and Ava-BL (Fig. 3.16). 
Similarly all the BART miRNAs tested appeared to have half lives in excess of 12 h (Fig. 
3.17). 
Nonetheless, it is now known that many cellular miRNAs are also highly stable as compared 
to cellular transcripts (788). One study in particular found that most cellular miRNAs tested 
possess half lives in excess of 8h; miR-187, miR-224 and miR-378 in turn possessed half 
lives in excess of 48 h (93). Therefore we accept the possibility that differences in the stability 
of individual EBV miRNAs might only become apparent after 24 h.  
Two recent studies by Kim et al. have provided a number of insights into BART miRNA 
transcription (789, 790). Firstly they found the BART miRNAs were, much like cellular 
miRNAs, transcribed by pol II and processed by Drosha and Dicer. Secondly they discovered 
an inverse correlation between BART miRNA expression and BART promoter methylation 
across a panel of lymphoid cell lines. Finally they demonstrated that the BART miRNAs were 
positively regulated by C/EBP β binding upstream of the BART promoters. While these 
findings may account for some of the variation in EBV miRNA levels between cell lines, they 
fail to explain why miRNAs derived from the same transcript accumulate to such different 
levels.  
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In summary we conclude that differences in steady state BHRF1 and BART miRNA levels 
are determined primarily by variations in the efficiency of miRNA maturation from their 
respective precursor transcripts. We will discuss this possibility further in section 6. 
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4. Quantitative study of EBV encoded miRNAs during EBV mediated B cell 
transformation and lytic replication 
4.1 Introduction 
In the first part of our study we investigated EBV miRNA expression in a panel of latently 
infected lymphoid cell lines. In the current section we will investigate viral miRNA 
expression during the early events of EBV mediated B cell transformation. Thereafter we will 
focus on viral miRNA expression following the induction of EBV replication.  
 
4.2 Expression of viral miRNAs during the early events of EBV mediated B 
cell transformation 
The kinetics of EBV gene expression following primary infection of human B cells are well 
established. Wp is activated immediately post infection (323, 326, 791), leading to the initial 
expression of EBNA2, EBNA-LP and also BHRF1 (320, 323, 324, 513). Wp activity then 
falls after 24 h as Cp activity becomes dominant, concomitant with the broadening of latent 
antigen expression to the full spectrum of EBNAs and LMPs. Nonetheless when we began 
our study there was no available information on the kinetics of EBV miRNA expression 
during the same events.  
To address this issue we isolated primary B cells from peripheral blood using CD19 
Dynabeads (Invitrogen) and subsequently exposed them to preparations of recombinant 2089 
EBV at a multiplicity of infection (moi) of 100 using published methods (326). Infected cells 
were cultured in fresh medium and harvested at 0 h, 8 h, 12 h, 24 h, 48 h, 72 h and 120 h. By 
120 h abundant lymphoblast formation was clearly visible by microscopic analysis implying 
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efficient transformation. Note that the recombinant 2089 EBV strain used in this work 
contains the same 12kb BamHI A deletion as the prototype B95-8 strain (Fig. 4.1B) (267); 
therefore in this experiment it was necessary to detect the BART transcripts using an 
alternative primer/probe combination which specifically amplified sequences across the exon 
6-7 splice junction.  
The data in Fig. 4.2A show the results of this BART6-7 assay, alongside standard assays to 
measure Wp-initiated transcripts, Cp-initiated transcripts and BHRF1 transcripts. As 
expected, Wp activity was already induced by 8 h post infection, peaked at 12 h and then fell 
as the level of Cp activity began to increase; latent BHRF1 expression was also robustly 
induced by 8 h (Fig. 4.2A). By contrast lytic BHRF1 was only transiently detectable in the 
first 24 h post-infection. The appearance of the BHRF1 miRNAs was significantly delayed 
relative to BHRF1 transcription, with weak signals first detected between 12-24 h which then 
gradually increased throughout the experiment (Fig. 4.2B). Kinetic analysis of BART RNAs 
also showed a similar lag in the appearance of mature BART miRNAs relative to BART 
transcription (Figs. 4.2A and 4.2B).  
 
4.3 Expression of EBV miRNAs during lytic replication 
As discussed in section 1.12, productive infection does not occur in de novo infected cultured 
B cells, even though BZLF1 is reportedly expressed within the first few hours post-infection 
(416). BHRF1 and BART transcripts are nonetheless both induced during lytic replication 
(275, 410, 747), although if and to what extent BHRF1 and BART miRNA levels also 
increase is less clear. We note that during lytic replication, BHRF1 and its associated 
miRNAs would be transcribed from an alternative promoter BHRF1p (747); as illustrated in 
Fig. 4.1. Detailed structure of EBV transcripts and miRNAs. (A) BHRF1 
transcripts and location of BHRF1-derived miRNAs. All three BHRF1 
miRNAs may be generated during lateny either by processing of an intron 
present within the Cp/Wp initiated primary EBNA transcript or by processing 
of the 5′ and 3′ untranslated regions within latent BHRF1 transcripts with the 
W2-Y1-Y2-BHRF1 structure. In contrast lytic BHRF1 transcripts initiated 
from the alternative BHRF1p promoter only encode miR-BHRF1-2 and miR-
BHRF1-3.  (B) Detailed structure of the highly spliced BARTs and location of 
the BART-derived miRNAs (adapted from Edwards et al.) (748). The BART 
miRNAs form two clusters within the BART introns, with the exception of 
mirBART2 which lies further downstream. The prototype B95-8 EBV strain 
carries a 12kb deletion in this region which removes several cluster 1 miRNAs 
and all cluster 2 miRNAs (shown in italics).  
Cp / Wp BHRF1p BHRF1 
BHRF1-1 BHRF1-2 BHRF1-3 
A 
Latent  
p2     p1 
1 1a 1b 2 3 4 5 6 7 
B95-8 Deletion 
BART3 
BART4 
BART1 
BART15 
BART5 
BART16 
BART17 
BART6 
BART18 
BART21 BART7 
BART8 
BART9 
BART22 
BART10 
BART11 
BART12 
BART19 
BART20 
BART13 
BART14 
 BART2  
B 
Cluster 1 Cluster 2     
Lytic  
Fig. 4.2. Expression of latent transcripts and EBV miRNAs in primary B cells 
infected with EBV in vitro. (A) Wp- and Cp-initiated transcripts, BHRF1 
transcripts and BARTs were quantified by QPCR at the indicated time points 
post-infection. Since the recombinant EBV used in these experiments carries 
the same BamHI A deletion as the B95-8 strain, BARTs were detected using a 
primer/probe combination which amplified across the exon 6-7 splice junction. 
(B) Expression of selected BHRF1 and BART miRNAs measured by QPCR. 
Data were normalised to RNU48 expression and expressed as copy numbers 
per pg input RNA. Shown on each graph are representative time courses for 
two of three replicate experiments. Each data point corresponds to the average 
of two replicate assay measurements. 
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Fig. 4.1A, this lytic BHRF1 transcript overlaps the miR-BHRF1-1 sequence and therefore can 
only generate the two downstream BHRF1 miRNAs. Earlier studies have yielded 
contradictory findings on EBV miRNA expression during lytic infection (738, 743, 744). In 
order to resolve these issues we exploited the AKBM cell system in which EBV-positive 
Akata-BL cells are stably transfected with a GFP reporter gene under the control of the EBV 
lytic cycle BMRF1 promoter; following Ig crosslinking, a significant proportion of cells enter 
into lytic cycle and these cells can be identified by GFP expression (773). Note that unlike the 
B95-8 prototype strain, Akata-BL retains the entire BART region. Therefore in order to assess 
BART transcription we reverted back to the exon 1-3 assay; this assay measures the exon 2-
deleted BART splice variant which, as discussed in section 3.1, favours the production of the 
BART miRNAs (748). 
 
4.3.1 Short (24h) lytic induction of AKBM cells 
In the first instance, we monitored the production of BHRF1 and BART transcripts and 
derived miRNAs in AKBM cells at various time points up to 24 h post induction. Entry into 
lytic cycle was confirmed by quantifying both the number of GFP and BZLF1 positive 
AKBM cells by flow cytometry (Fig. 4.3). BZLF1 positive lytic cells were detected by flow 
cytometry within 4 h and increased to around 22% of the culture at 24 h. GFP positive lytic 
cells appeared with similar albeit slightly delayed kinetics. In the experiments shown in Fig. 
4.4, lytic BHRF1 transcripts appeared with similar kinetics to BZLF1 (Fig. 4.4A) and 
coincided with marked increases in miR-BHRF1-2 and 1-3 miRNAs, but not miR-BHRF1-1 
(Fig. 4.4B); this is consistent with BHRF1 transcription being initiated from the lytic 
promoter BHRF1p, rather than the latent promoters Cp/Wp, at these early time points. In 
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Fig. 4.3. Lytic induction of latent AKBM cultures over 24 hours. Lytic GFP-
positive AKBM cells were enumerated at the indicated time points post-
induction by flow cytometry. BZLF1 expression was assessed in the same 
samples by staining with BZ.1 anti BZLF1 antibody. (A) FACS plot illustrating 
the lytic GFP/BZLF1 double positive and latent GFP/BZLF1 double negative 
AKBM populations at 12 hours post-induction. (B) Percentage of lytic BZLF1 
and GFP positive AKBM cells at each time point post-induction. Shown are 
representative data from one of two experiments. 
Fig. 4.4. Expression of EBV transcripts and miRNAs in lytic AKBM cultures 
24 h post-induction. (A) BHRF1 and BART transcripts quantified by QPCR at 
the indicated time points in the same culture shown in Fig. 4.3. Latent BHRF1 
values are expressed relative to a reference LCL, while lytic BHRF1 values are 
expressed such a value of one is equivalent to 100% positive cells. (B) 
Expression of selected BHRF1 miRNAs and BART miRNAs determined by 
QPCR at the indicated time points. Data were normalised to RNU48 expression 
and expressed as copy numbers per pg input RNA. Shown on each graph are 
time courses for two replicate experiments. Each data point corresponds to the 
average of two replicate assay measurements. 
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contrast, levels of BART-derived miRNAs (here illustrated with data for miR-BART15 and 
miR-BART2-5p) barely increased during the same 24 h period despite the fact that BART 
transcript levels increased more than 45-fold (Figs. 4.4A and 4.4B). 
 
4.3.2 Extended (120h) lytic induction of AKBM cells 
To examine whether the relatively small increases in miR-BART miRNA expression might be 
due to a delay in processing the BART transcripts, we repeated the experiment but now 
analysed gene expression in the induced AKBM cells for up to 120 h post induction. Given 
the similar kinetics of GFP and BZLF1 induction in these experiments, we quantified the 
number of lytic AKBM cells by GFP alone (Fig. 4.5). The number of GFP positive AKBM 
cells detected at 24h was comparable to previous experiments (Fig. 4.3). Furthermore lytic 
BHRF1 and BART transcripts showed similar levels of induction at 24 h (Fig. 4.6A) to the 
previous experiments (Fig. 4.4) and thereafter remained relatively constant. However we now 
observed that latent BHRF1 transcripts became detectable at later time points, coincident with 
induction of the Lat III promoters Wp and Cp (Fig. 4.6A and data not shown) and broadening 
of miRNA expression to all three miR-BHRF1 miRNAs (Fig. 4.6B). Consistent with our 
earlier findings, we again noted a rapid and dramatic increase in BART transcription 
accompanied by only modest 5-8 fold increase in levels of miR-BART4, miR-BART15 and 
miR-BART2-5p.  
 
4.3.3 Analysis of sorted lytic AKBM cells 
The above findings suggested that BHRF1 miRNA production during virus replication is 
biphasic, with early lytic BHRF1 transcripts selectively generating miBHRF1-2 and miR-
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Fig. 4.5. Lytic induction of latent AKBM cultures over 120 hours. Lytic GFP-
positive AKBM cells were enumerated at the indicated time points post-
induction by flow cytometry. (A) FACS histogram illustrating lytic and latent 
populations in induced AKBM cells at 24h post-induction. Non-induced AKBM 
cells were used as negative controls. (B) Percentage of lytic GFP positive 
AKBM cells in the induced population at each time point post-induction. 
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Fig. 4.6. Extended time course showing expression of EBV transcripts and 
miRNAs in lytic AKBM cultures. (A) Wp, latent BHRF1 and lytic BHRF1 
transcripts and BARTs (exon 1-3 splice form) were quantified by QPCR in the 
same induced cells shown in Fig. 4.5. (B) and (C) show expression of selected 
BHRF1 and BART miRNAs, respectively, determined by QPCR. Shown in 
separate panels are two replicate assay measurements obtained from a single 
experiment. 
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BHRF1-3, while delayed latent BHRF1 transcripts are processed to give all three miR-
BHRF1 miRNAs. This is consistent with the appearance of Lat III transcripts during the later 
stages of virus replication (Fig. 4.6), in agreement with an earlier study (744). To further 
examine the role of Lat III transcripts in miRNA production we next confirmed that the latent 
transcripts were present in the lytic AKBM population. Briefly, AKBM cells were induced 
into lytic cycle as before and then sorted into GFP-positive (lytic) and GFP-negative (latent) 
populations at 48 h post induction. We found that both latent and lytic BHRF1 transcripts, and 
all three miR-BHRF1 miRNAs, were greatly enriched in the GFP-positive fraction relative to 
the GFP-negative population (Fig. 4.7).  
 
4.3.4 Using acyclovir to inhibit lytic replication in AKBM cells 
We speculated that the Lat III transcripts seen in lytic AKBM cultures were being transcribed 
from the very high copy numbers of newly replicated EBV genomes, since such genomes are 
unmethylated and could therefore act as templates for Wp- and Cp-initiated transcription. To 
test this hypothesis, we induced AKBM cells in the presence of acyclovir (ACV) to block 
viral DNA replication. In the absence of ACV, we confirmed that the average EBV genome 
load increased from around 50 genomes per cell to as much as 16,000 genomes per cell in 
induced control AKBM cells. The addition of ACV completely blocked this genome 
amplification (Fig. 4.8A) and also ablated induction of Latency III Wp, Cp and BHRF1 
transcripts as well as miR-BHRF1-1 (Figs. 4.8B and 4.8C); these data support the view that 
these transcripts are dependent on viral DNA synthesis. In contrast, ACV treatment only 
modestly reduced levels of lytic BHRF1 and BART transcripts (~2-fold and less than 5-fold, 
respectively) (Fig. 4.8B) and made little difference to expression of the two remaining miR-
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Fig. 4.7. GFP sorting of induced AKBM cells. AKBM cells were induced and 
sorted at 48 hours for GFP expression. (A) Wp and BHRF1 (latent and lytic) 
transcripts were quantified by QPCR. Data are expressed relative to the 48h 
GFP + ve population (set at one). (B) Expression of BHRF1 miRNAs in the 
same populations as determined by QPCR. Data were normalised to RNU48 
expression and expressed as absolute copy numbers per pg total RNA. Shown 
in separate panels are two replicate assay measurements obtained from one of 
two replicate experiments.  
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Fig. 4.8. Effect of ACV on expression of EBV transcripts and miRNAs in 
induced AKBM cultures. (A) EBV genome load quantified by QPCR 48 h post 
induction. Data were normalised to cellular beta-2-microblobulin copies and 
expressed as EBV genomes per cell. (B) Wp, Cp, latent and lytic BHRF1 
transcripts and BARTs (exon 1-3 splice) quantified by QPCR 48 h post 
induction. Data are expressed relative to values seen in the uninhibited culture.  
(C) and (D) show expression of selected BHRF1 and BART miRNAs, 
respectively, determined by QPCR. Data were normalised to RNU48 expression 
and expressed as copy numbers per pg input RNA. Shown on each graph are 
two replicate experiments. Each data point corresponds to the average of two 
replicate assay measurements. 
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BHRF1 miRNAs or the BART miRNAs tested (miR-BART4 and miR-BART2-5p) (Figs. 
4.8C and 4.8D).  
 
4.3.5 Stability of BART miRNAs in latent vs. lytic AKBM cells 
In a final experiment, we asked whether the failure to significantly increase BART miRNA 
expression during virus replication was due to changes in BART transcript or BART miRNA 
stability. Briefly, AKBM cells were induced as before and then 12 h post induction, the cells 
were either cultured in normal medium or transferred to medium containing Actinomycin D to 
block further RNA transcription. We found that the BART transcripts and the three BART 
miRNAs (miR-BART4, miR-BART7 and miR-BART2-5p) examined had similar long half 
lives in lytically induced and latent AKBM cultures (Fig. 4.9). These half lives were also 
comparable to latently infected cell lines examined previously (Fig. 3.17), arguing that the 
weak induction of the BART miRNAs was not due to increased miRNA turnover during lytic 
cycle.  
 
4.4 Discussion 
4.4.1 Viral miRNA expression during EBV mediated transformation of B 
cells  
In the first set of experiments we looked at miRNA expression during the early events of B 
cell transformation. Interestingly we found that EBV miRNA production was delayed with 
respect to the induction of BHRF1 and BART transcripts (Fig. 4.2). In the case of the BHRF1 
miRNAs, one possible explanation for the delay in miRNA production could be that the pre-
A 
B 
Fig. 4.9. Stability of BART transcripts and miRNAs in latent and induced 
AKBM cultures. AKBM cells were split into two populations and (A) cultured 
normally for 12h or (B) induced for the same duration. Both populations were 
then treated with 5µg/ml actinomycin D, harvested at the indicated time points 
and analysed for BART transcripts and miRNAs. Cellular c-myc RNA is 
unstable and served as a positive control for RNA decay. Shown in separate 
panels are two replicate assay measurements obtained from a single 
experiment. All data were normalised to RNA input. 
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miRNAs are only efficiently processed once the Wp-to-Cp switch has occurred between 24-
48h post infection (323, 326, 791). Interestingly BART transcripts can also be expressed from 
two alternative promoters,  P1, which is expressed early post-infection, and P2, which is only 
activated after 48 h (729). It remains to be tested whether BART miRNAs are preferentially 
generated from P2-initiated BART transcripts. An alternative possibility is that precursor 
miRNAs are actually transcribed much earlier than 48h but their processing is delayed. On 
that note Nourse et al. observed that EBV miRNAs are maintained as precursors (pre-
miRNAs) throughout the initial stages of B cell infection (unpublished data). 
The presence of the EBV miRNAs throughout early EBV infection means they could 
potentially contribute to B cell transformation. The lack of significant levels of EBV miRNAs 
at early time points, when EBNA2 and EBNA-LP are already abundantly expressed (323, 
324), argues that they are not essential for the initiation of B cell growth transformation. On 
this point a recent study demonstrated that EBV mutants lacking the BHRF1 miRNAs (Δ123) 
display a reduced transforming capacity (750). However they only detected discernable 
differences between wild type and Δ123 EBV after 5 days post infection at which point the 
BHRF1 miRNAs are clearly expressed (Fig. 4.2). Another study demonstrated that the 
BHRF1 miRNAs protect B cells against apoptosis and promote cell cycle progression during 
the early stages of B cell infection (751). Again these effects were observed after 5 days post 
infection.  
The contributions of the BART miRNAs throughout the early stages of B cell infection 
remain unclear. The efficient transformation mediated by the prototype B95-8 virus clearly 
demonstrates that many of the BART miRNAs are dispensable for transformation in vitro. 
Conversely reconstitution of the deleted BART miRNAs in the B95-8 strain does not result in 
noticeably increased proliferation or survival of de novo infected B cells (751). Nonetheless 
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these observations do not exclude the possibility that BART miRNAs still present in the B95-
8 virus contribute to transformation. On that note miR-BART1 and miR-BART3 have been 
found to target Bim while miR-BART2 targets the viral polymerase BALF5 (754, 759). We 
appreciate that these studies were mostly conducted using epithelial as opposed to lymphoid 
cell lines. Nonetheless it is still tempting to speculate that the BART miRNAs might provide 
survival signals to de novo infected B cells whilst suppressing viral reactivation once latency 
has been established.  
 
4.4.2 Viral miRNA expression following EBV lytic replication 
A number of previous studies have reported contradictory findings on EBV miRNA 
expression during virus replication (738, 743, 744). Northern blot studies by Cai and co-
workers showed that with the exception of miR-BHRF1-1, all BHRF1 and BART miRNAs 
tested were increased following lytic induction. By contrast similar studies by Xing and Kieff 
showed that all BHRF1 miRNAs were increased following lytic induction while levels of the 
BART miRNAs remained unchanged (744). Similar results were obtained by Pratt and co-
workers using a different detection method (QPCR) (743). Overall our data seems to agree 
most with the latter two studies. 
We clearly demonstrate that all three BHRF1 miRNAs are strongly induced in lytic cycle, 
approaching levels seen in Latency III LCLs. Our detailed kinetic studies show that both lytic 
and latent BHRF1 transcripts potentially contribute to this increase in BHRF1 miRNAs (Fig. 
4.6), thus the initial increases in miR-BHRF1-2 and miR-BHRF1-3 correlated with the 
induction of early lytic BHRF1 transcripts, while the expression of BHRF1-1 was delayed 
until after the induction of Cp/Wp-initiated transcripts (410) and dependent on new viral DNA 
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replication (Fig. 4.8). The up regulation of the BHRF1 miRNAs during viral replication 
suggest they could participate in immune evasion or in protecting virus producing cells from 
apoptosis; this would agree with the observations that miR-BHRF1-1 and miR-BHRF1-3 
target p53 and CXCL11, respectively. Alternatively the BHRF1 miRNAs may function to 
regulate EBV lytic cycle genes. 
In contrast, virus replication was associated with relatively modest (5-8 fold) increases in 
BART miRNA levels (Figs. 4.4 and 4.6), in agreement with two earlier studies (743, 744). 
However this latter finding is difficult to reconcile with the much bigger increases in overall 
BART transcription during lytic cycle. As the BART miRNAs are very stable in both latent 
and lytic cycle, we conclude that the BART transcripts which accumulate during replication 
are inefficiently processed into mature miRNAs. These observations raise the question as to 
the role of the BARTs in the context of virus replication. On this point, several open reading 
frames (RPMS1, A73) have previously been identified within the BART transcripts and a 
number of studies have proposed that these may give rise to functional proteins (727, 731). 
While there is no evidence to date to support the view that these protein products are naturally 
expressed in latently infected cells (721, 732, 735, 736), our data would suggest that such 
protein products might be detectable in productive infection where there are dramatically 
elevated levels of BART transcripts. Alternatively, the BARTs might have other roles, such as 
encoding a recently identified small nucleolar RNA, v-snoRNA1 (742). 
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5. Investigating the function of the BHRF1 miRNAs in the context of BL 
5.1 Introduction 
In the previous chapters we correlated viral miRNA expression with levels of BHRF1 and 
BART transcripts in a variety of cell lines with different forms of EBV infection. Our study 
demonstrated for the first time that the three BHRF1 miRNAs are abundantly expressed in 
Wp-restricted BL (Wp BL) but not Latency I BL (Lat I BL) cell lines.  
Earlier studies have demonstrated that the broader viral antigen expression found in Wp BL 
lines grants these cells more resistance to induced cell death than their Lat I counterparts 
(681). Previous reports have investigated the contributions of gene products expressed in Wp 
BL but not Lat I BL (BHRF1, EBNA-LP and EBNA3) towards the increased pro-survival 
signal (320, 511, 512). The observation that the BHRF1 miRNAs support B cell growth and 
survival (750, 751) prompted us to ask whether the BHRF1 miRNAs also contribute to the 
pro-survival phenotype of Wp- restricted Burkitt lymphoma (681).  
Thus we wanted to establish which genes, either cellular or viral, are targeted by the BHRF1 
miRNAs and test if such targets may contribute to the underlying mechanism of apoptosis 
resistance in Wp BL. In order to achieve this we undertook two complementary approaches. 
Firstly we attempted to knock down the BHRF1 miRNAs in Wp BL lines using antisense 
oligonucleotide inhibitors. Secondly we attempted to express the BHRF1 miRNAs in either 
an EBV negative or Lat I BL line. In the first part of this chapter, we will focus on the design 
and validation of the methodologies used to investigate BHRF1 miRNA function. In the 
second part of this chapter we will investigate the effects of the BHRF1 miRNAs on the 
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transcriptome of a BL cell line as well as their contribution towards cell growth and cell 
survival.  
 
5.2 Establishing a reporter system to assess functional changes in BHRF1 
miRNA expression 
Before developing methodologies for knockdown or expression of the BHRF1 miRNAs, we 
needed to have a system to detect functional changes in BHRF1 miRNA levels. For this we 
exploited the pMIR-REPORT
TM
 miRNA expression reporter vector system by Ambion®.  
 
5.2.1 Cloning of the BHRF1 miRNA reporter constructs 
The firefly luciferase construct (pMIR-REPORT
TM
 Luciferase) contains a multiple cloning 
site (MCS) in the luciferase gene 3′ UTR for cloning of known or artificial miRNA targets. 
This allows the miRNA of interest to negatively regulate firefly luciferase activity. We 
therefore cloned DNA oligonucleotide sequences representing individual BHRF1 miRNA 
binding sites (Fig. 5.1B) between the HindIII and SacI cloning sites of pMIR-REPORT
TM
 
Luciferase (Fig. 5.1A). The resulting miR-BHRF1-1, 1-2 and 1-3 reporter constructs each had 
a single perfectly complementary miR-BHRF1-1, 1-2 and 1-3 binding site, respectively, in the 
luciferase gene 3′ UTR.  
 
5.2.2 Validation of the BHRF1 miRNA reporter constructs 
To test that the luciferase activities of the BHRF1 miRNA reporter constructs were 
specifically reduced in the presence BHRF1 miRNAs, we transfected each construct into the 
5’-AGCTTTAACCTGATCAGCCCCGGAGTTGAGCT-3’ 
3’- AATTGGACTAGTCGGGGCCTCAAC-5’ 
5’-AGCTTTATCTTTTGCGGCAGAAATTGAGAGCT-3’ 
3’-AATAGAAAACGCCGTCTTTAACTC-5’ 
5’-AGCTTTAACGGGAAGTGTGTAAGCACAGAGCT-3’ 
3’-AATTGCCCTTCACACATTCGTGTC-5’ 
(Hind III) (Sac I) 
miR-BHRF1-1 
Binding Site 
miR-BHRF1-2 
Binding Site 
miR-BHRF1-3 
Binding Site 
Fig. 5.1. Schematic describing the generation of the BHRF1 miRNA luciferase 
reporter constructs. (A) The miRNA firefly reporter vector pMIR-REPORTTM 
Luciferase, commercially available from Ambion®, served as a starting point 
for the generation of the BHRF1 miRNA reporter constructs. Sequences 
corresponding to miRNA target sites are introduced into the multiple cloning 
site of the luciferase 3′ UTR such that luciferase expression will be inhibited if 
the target miRNA is expressed in the transfected host cell. (B) DNA 
oligonucleotide sequences corresponding to individual BHRF1 miRNA 
binding sites were inserted between the HindIII and SacI cloning sites of 
pMIR-REPORTTM Luciferase to yield the miRBHRF1-1, 1-2 and 1-3 reporter 
constructs. 
A 
B 
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EBV negative BL line DG75 and the EBV positive Wp-restricted BL line Oku-BL (Fig. 5.2). 
The results show that in the presence of the BHRF1 miRNAs (Oku BL), all three miRNA 
reporter constructs were significantly down-regulated (P < 0.05); luciferase activities of the 
BHRF1-1 and BHRF1-3 miRNA reporters were reduced between 3-4 fold relative to the 
unmodified pMIR-REPORT
TM
 construct while that of the BHRF1-2 miRNA reporter was 
reduced nearly 10 fold. In the absence of the BHRF1 miRNAs (DG75 BL) however, all three 
BHRF1 miRNA reporters showed similar activities to the unmodified pMIR-REPORT
TM
 
construct with differences rarely exceeding 15%. Thus expression of all three miRNA 
reporters was specifically inhibited in the presence of BHRF1 miRNAs. 
 
5.3 Investigating antisense technology as a means to knockdown the BHRF1 
miRNAs 
Having established a system to monitor the suppressive effects of the BHRF1 miRNAs, next 
we wanted to determine whether we could functionally knock down the BHRF1 miRNAs 
using anti-miRNA oligonucleotides (AMOs). 
 
5.3.1 An introduction to anti-miRNA oligonucleotides (AMOs) 
The current knowledge of AMOs has been reviewed by Lennox and Behlke (792). While 
antisense technology itself has been around for over 30 years, more recently it has been 
successfully adapted to the study of small non-coding RNAs such as miRNAs. In order to 
functionally inhibit a miRNA, an AMO needs to contain a sequence that is the reverse 
complement of the target miRNA seed. Possible mechanisms by which AMOs inhibit miRNA 
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Fig. 5.2. The BHRF1 miRNAs are capable of specifically down regulating an 
artificial reporter construct. EBV positive Oku (Wp BL) cells were transfected 
with either the empty control pMIR-REPORTTM firefly reporter construct or 
derivatives containing a single binding site for miR-BHRF1-1, 1-2 or 1-3. The 
same cells were co-transfected with the pRL SV40 Renilla reporter construct, 
commercially available from Promega. Firefly luciferase activity was 
measured in cell lysates prepared 24h post-transfection and normalized to 
Renilla luciferase activity measured in the same samples. Normalized 
luciferase data was expressed relative to the empty control pMIR-REPORTTM 
firefly reporter (set at 100%). These values are listed above each column. 
DG75 (EBV negative) cells were used as a control. Error bars indicate 
standard deviation of three separate experiments. Normalized luciferase 
activity for each BHRF1 miRNA reporter was compared to that of the control 
reporter in each cell line, using a paired t test with a P value cut off set to 0.05. 
P values are listed below each column using green and red text to denote 
statistical significance and insignificance respectively.  
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function are to cause its degradation or sequester it in an inactive duplex; precisely which 
occurs may be dependent on the chemical nature of the AMO in question (793). It is also 
possible to design an AMO that interferes with miRNA processing (794). 
The potency of an antisense miRNA inhibitor depends amongst other things on its ability to 
resist nuclease degradation, to specifically and strongly interact with its target, and to be 
efficiently taken up by the cell (792). Straightforward DNA based AMOs are rapidly 
degraded when exposed to serum nucleases (795). Their stability and overall efficacy may be 
boosted by any number of previously tried and tested chemical modifications used in mRNA 
knockdown studies (792, 796).  For instance several earlier studies have achieved miRNA 
knockdown using 2′-O-alkyl RNA such as 2′-O-methyl RNA (2′OMe) and 2′-O-methoxy-
ethyl RNA (MOE) (797-800). The presence of a 2′-O-alkyl group in place of a 2′-OH group 
on the ribose ring of this class of AMO confers greater nuclease resistance and target affinity 
as compared to DNA. Similarly other groups have incorporated phosphorothioate (PS) 
linkages into their miRNA inhibitors, which interfere with the ability of nucleases to degrade 
the phosphate bond between nucleotides (801, 802).  
Nowadays there are a large number of effective chemical modifications and combinations 
thereof available (792). In the following sections we will investigate two relatively novel 
types of AMOs, which incorporate Locked nucleic acids (LNA
TM
) and Morpholino oligos 
respectively. 
 
5.3.2 Locked nucleic acid (LNA
TM
) miRNA inhibitors 
Locked nucleic acid (LNA
TM
) differs from DNA in that it is conformationally restricted via a 
methylene bridge on the ribose ring linking the 2′ O atom and 4′ C atom (803-805). This 
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results in remarkable nuclease resistance and high target binding affinity. LNA
TM
 inhibitors 
have been successfully applied to the study of cellular and viral (EBV and KSHV) miRNAs 
(764, 792, 806). They presumably function by retaining the mature miRNA in an inactive 
duplex without inducing target degradation (793).  
The specific inhibitors used in our knockdown experiments are the miRCURY LNA
TM
 
miRNA Power Inhibitors (Exiqon) (http://www.exiqon.com/mirna-inhibitors). They differ 
from conventional LNA
TM
 miRNA inhibitors in that they incorporate PS linkages in the 
phosphate backbone, resulting in increased stability. They are designed to achieve optimum 
potency at low doses (1-100nM) in order to avoid cellular toxicity. 
Using our BHRF1 miRNA reporter constructs, we investigated whether and to what extent we 
could achieve BHRF1 miRNA knockdown in Oku BL cells using LNA
TM
 miRNA inhibitors. 
Briefly we transfected Oku BL cells with inhibitors designed against either the miR-BHRF1-3 
or miR-BHRF1-1 miRNA in combination with the relevant BHRF1 miRNA reporter 
construct and assessed knockdown at 24h post-transfection (Fig. 5.3). In the representative 
experiment shown in Fig. 5.3A, the 500nM concentration of the miR-BHRF1-3 inhibitor de-
repressed luciferase activity of the miR-BHRF1-3 reporter by 2.3 fold, compared to a much 
smaller 1.3 fold change for the control reporter. This indicates a partial functional knockdown 
of miR-BHRF1-3. Barely any knockdown was observed when using a 100nM concentration 
of the miR-BHRF1-3 inhibitor.  
Repeating the experiment using the miR-BHRF1-1 inhibitor, our results show that the control 
firefly reporter displayed a greater fold increase in luciferase activity than did the miR-
BHRF1-1 reporter at both the 100nM and 500nM inhibitor concentration (Fig. 5.3B). 
A 
B 
LNA (miR-BHRF1-3) 
LNA (miR-BHRF1-1) 
Fig. 5.3. Knockdown of the BHRF1 miRNAs using locked nucleic acid 
(LNATM) miRNA inhibitors. EBV positive Oku (Wp BL) cells were co-
transfected with increasing doses of a LNA against (A) miR-BHRF1-3 or (B) 
miR-BHRF1-1 and either the empty control pMIR-REPORTTM firefly reporter 
construct or a derivative containing a single binding site for miR-BHRF1-1 or 
miR-BHRF1-3. Cells were co-transfected with a β-Gal control vector, 
commercially available from Ambion®. Firefly luciferase activity was 
measured in cell lysates prepared 24h post-transfection and normalized to β-
Gal activity measured in the same samples. Normalized luciferase data was 
expressed relative to the uninhibited empty control pMIR-REPORTTM firefly 
reporter (set at 100%). Data for the miR-BHRF1-3 inhibitor correspond to one 
of two replicate experiments, while the miR-BHRF1-1 inhibitor data are from 
a single experiment. The numbers above the columns indicate  fold increases 
in relative luciferase signal attributed to the LNA inhibitor. 
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Consequently it is not possible to distinguish between genuine miR-BHRF1-1 knockdown 
and off target effects.   
 
5.3.3 Morpholino miRNA inhibitors   
In parallel work, we also tested the effects of Morpholino inhibitors against the BHRF1 
miRNAs. Morpholino nucleotides differ from DNA in that their backbone contains 
morpholine rings in place of deoxyribose rings and incorporate uncharged 
phosphorodiamidate (PN) linkages in place of phosphodiester (PO) linkages (796). 
Morpholino AMOs have been used in a number of miRNA knockdown experiments; a 
complete list of publications can be viewed on the Gene Tools, LLC website 
(http://www.gene-tools.com/node/31#miRNAcitations). Our Morpholino BHRF1 miRNA 
inhibitors were synthesized by Gene Tools, LLC and designed to not only be highly stable 
and target specific, but simultaneously interfere with both mature miRNA function and 
miRNA processing. Note that it was not possible to design a Morpholino inhibitor against 
miR-BHRF1-1 (see Discussion) 
Oku BL cells were transfected with inhibitors designed to functionally inhibit either miR-
BHRF1-2 or miR-BHRF1-3 in combination with the relevant BHRF1 miRNA reporter 
construct; knockdown was assessed at 24h post-transfection (Fig. 5.4). In the representative 
experiment shown in Fig. 5.4A, the 10μM and 20μM concentrations of the miR-BHRF1-3 
inhibitor de-repressed luciferase activity of the miR-BHRF1-3 firefly reporter by 1.8 and 1.9 
fold, respectively, without de-repressing the control reporter. This indicates a partial 
functional knockdown of miR-BHRF1-3.  
A 
B 
Morpholino (miR-BHRF1-3) 
Morpholino (miR-BHRF1-2) 
Fig. 5.4. Knockdown of the BHRF1 miRNAs using Morpholino miRNA 
inhibitors. EBV positive Oku (Wp BL) cells were co-transfected with 
increasing doses of a Morpholino against (A) miR-BHRF1-3 or (B) miR-
BHRF1-2 and either the empty control pMIR-REPORTTM firefly reporter 
construct or a derivative containing a single binding site for miR-BHRF1-2 or 
miR-BHRF1-3. Cells were co-transfected with a β-Gal control vector. Firefly 
luciferase activity was measured in cell lysates prepared 24h post-transfection 
and normalized to β-Gal activity measured in the same samples. Normalized 
luciferase data was expressed relative to the uninhibited empty control pMIR-
REPORTTM firefly reporter (set at 100%). Data for the miR-BHRF1-3 inhibitor 
correspond to one of two replicate experiments, while the miR-BHRF1-2 data 
are from a single experiment. The numbers above the columns indicate  fold 
increases in relative luciferase signal attributed to the Morpholino inhibitor. 
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Neither dose of the miR-BHRF1-2 inhibitor caused a noticeable de-repression of the miR-
BHRF1-2 firefly reporter when compared to the control reporter (Fig. 5.4B). We noted that 
the 10μM dose of the miR-BHRF1-2 inhibitor caused a 2 fold change in normalized luciferase 
activity of the control reporter. However closer inspection of the data revealed that this was 
caused by a technical issue with β-gal detection in this sample, rather than reflecting a real 
change in normalized luciferase activity  (see Discussion). In conclusion we were only able to 
achieve knockdown of one BHRF1 miRNA when using LNA
TM
 or Morpholino AMOs. 
Consequently we chose to abandon the use of antisense oligonucleotides as a means to study 
the BHRF1 miRNAs.  
 
5.4 Establishing a lentivirus system for the stable, inducible expression of 
the BHRF1 miRNAs 
Previous studies have demonstrated the expression of functional miRNAs using a lentivirus 
delivery system (807, 808). The appeal of a lentivirus lies in its ability to stably integrate into 
the host genome to allow continuous expression of the miRNA cassette. Earlier we observed 
that all three BHRF1 miRNAs were expressed during Lat III infection whilst during lytic 
cycle miR-BHRF1-2 and miR-BHRF1-3 were expressed in the absence of miR-BHRF1-1 
(809). Therefore we designed two separate BHRF1 miRNA constructs to mimic these two 
scenarios.  
Our cloning strategy was designed to include a number of useful features necessary in the 
final constructs. First miRNA expression should be under the control of a pol II promoter, 
since RNA pol II transcribes the viral miRNAs in the context of the virus genome (789). 
Second our miRNA expression cassettes should be inducible so that we can completely 
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control their expression. Thirdly our final constructs should constitutively express GFP to 
facilitate sorting of lentivirus transduced cells.  
Our cloning strategy used two lentivirus vectors termed FTGW and FH1t(INSR)UTG which 
were kindly supplied by Marco Herold (Fig 5.5) (810). FTGW was used as the intermediate 
cloning vector in our strategy (Fig 5.5A). It expresses eGFP under the control of the pol II 
CMV immediate-early promoter TREX-p; TREX-p contains two tetracycline operator (TetO) 
sites and is therefore repressed by binding of the tetracycline repressor (TetR). Note that in 
this vector, TREX-p is constitutively active because FTGW lacks a TetR gene. 
FH1t(INSR)UTG served as the final lentivirus vector in our strategy (Fig 5.5B). It expresses 
eGFP and TetR under the control of the constitutively active ubiquitin promoter (hUbc-p). 
Note that in the parental FH1t(INSR)UTG vector, there is an expression cassette encoding a 
shRNA (IR5) against the insulin receptor (INSR) expressed from the H1tetO promoter (811, 
812); this cassette is replaced in the final construct with the TREX-p-miRNA cassette, as 
described below. 
 
5.4.1 Generation of the intermediate lentiviral BHRF1 miRNA expression 
constructs 
The first step of our cloning strategy is illustrated in Fig. 5.6. Briefly we used PCR to amplify 
a fragment spanning a 553 bp region of the Oku-BL BHRF1 3′ UTR encompassing miR-
BHRF1-2 and miR-BHRF1-3; primers were designed to include an internal PacI site as well 
as terminal EcoRI and BamHI sites. This fragment was then inserted immediately downstream 
of TREX-p using EcoRI and BamHI sites, replacing eGFP in the process (Fig. 5.6A). The 
resulting vector was dubbed FTGW (BHRF1-2/1-3). In parallel we generated a second 
Fig. 5.5. Schematic describing the starting vectors used to generate lentiviral 
constructs for the tetracycline inducible expression of the BHRF1 miRNAs. 
(A) FTGW expresses eGFP under the control of the pol II tetracycline 
inducible promoter TREX-p. (B) FH1t(INSR)UTG expresses a small hairpin 
RNA (shRNA) against the insulin receptor (INSR) under the control of the pol 
III tetracycline inducible promoter H1tetO-p. It also expresses the tetracycline 
repressor protein (TetR) and eGFP under the control of the constitutively 
active ubiquitin promoter (hUbc-p). Both vectors transcribe the viral RNA 
genome from a pol II CMV promoter. Rev-dependent nuclear export of the 
nascent genome is mediated by the HIV Rev response element (HIV-RRE). 
The long terminal repeats (LTR) mediate integration of lentiviral DNA. The 
wood chuck hepatitis virus post-transcriptional regulatory element (WPRE) 
increases transgene expression. Both vectors were designed and kindly 
supplied by Marco Herold (810). 
A 
B 
BHRF1-2 BHRF1-3
BHRF1 3′ UTR Fragment
BamH1 EcoR1Pac1
A 
B 
(553 bp) 
BHRF1-1
BHRF1 5′ UTR Fragment
BamH1 Bgl2
(274 bp) 
Fig. 5.6. Schematic describing the first step in the generation of the lentiviral 
BHRF1 miRNA expression constructs. (A) PCR was used to amplify a 
fragment of the BHRF1 3′ UTR containing miR-BHRF1-2 and miR-BHRF1-3; 
primers were designed to include EcoRI, BamHI and PacI sites. The fragment 
was then inserted downstream of the FTGW TREX promoter using EcoRI and 
BamHI sites to generate the FTGW(BHRF1-2/1-3) vector. (B) Similarly a 
fragment of the BHRF1 5′ UTR containing miR-BHRF1-1 was inserted into 
the BamHI site downstream of the FTGW(BHRF1-2/1-3) TREX promoter to 
generate the FTWG(BHRF1-1/1-2/1-3) vector. Note that BglII and BamHI 
sticky ends are compatible with one another.  
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intermediate vector containing all 3 BHRF1 miRNAs, by using PCR to amplify a fragment 
spanning a 274 bp region of the Oku BL BHRF1 5′ UTR encompassing miR-BHRF1-1; 
primers were designed to include terminal BglII and BamHI sites. This fragment was then 
inserted into the BamHI site between TREX-p and BHRF1-2/1-3 (Fig 5.6B) to form FTWG 
(BHRF1-1/1-2/1-3). 
 
5.4.2 Confirming expression of the BHRF1 miRNAs from intermediate 
lentiviral vectors FTGW (BHRF1-2/1-3) and FTGW (BHRF1-1/1-2/1-3) 
In preliminary experiments, we wanted to test whether the intermediate FTGW-derived 
lentiviral vectors could generate detectable levels of the BHRF1 miRNAs. Therefore we 
transfected EBV negative DG75 BL cells with either FTGW BHRF1-2/1-3 or FTGW 
BHRF1-1/1-2/1-3, and assessed cells for BHRF1 miRNA expression 72h later (Fig. 5.7). Our 
results clearly show that both FTGW vectors express miR-BHRF1-2 and miR-BHRF1-3 at 
much higher levels than seen in control DG75 cells. FTGW BHRF1-1/1-2/1-3 additionally 
expresses miR-BHRF1-1 as expected. Given this positive result we then proceeded with the 
final step of the lentiviruses cloning. 
 
5.4.3 Generation of the final lentiviral BHRF1 miRNA expression 
constructs 
The final step in our cloning strategy is illustrated in Fig. 5.8 and is identical for both the 
FTGW (BHRF1-2/1-3) and FTGW (BHRF1-1/1-2/1-3). The complete TREX-p – BHRF1 
miRNA expression cassette was excised via two PacI sites and cloned into FH1t(INSR)UTG 
miR-BHRF1-1 
BHRF1-1/1-2/1-3 
miR-BHRF1-2 
miR-BHRF1-3 
     BHRF1-2/1-3 
            BHRF1-1/1-2/1-3 
     BHRF1-2/1-3 
Neg. Control 
     BHRF1-1/1-2/1-3 
BHRF1-2/1-3 
Fig. 5.7. Expression of the BHRF1 miRNAs from the intermediate FTGW 
lentiviral vectors. EBV negative DG75 BL cells were transfected with 
lentiviral BHRF1 miRNA expression vectors (FTGW BHRF1-2/1-3 or FTGW 
BHRF1-1/1-2/1-3) and assessed for BHRF1 miRNA expression. Shown are 
PCR amplification plots for each BHRF1 miRNA, with untransfected DG75 
BL cells used as a negative control. Note that BHRF1-2/1-3 does not express 
miR-BHRF1-1. 
 
 
 
Neg. Control 
Neg. Control 
BHRF1-2 BHRF1-3
Tet Inducible Promoter
Pac1 Pac1
BHRF1-2 BHRF1-3
Tet Inducible Promoter
Pac1 Pac1
BHRF1-1
Fig. 5.8. Schematic describing the final step in the generation of lentiviral 
constructs for the tetracycline inducible expression of the BHRF1 miRNAs. 
The TREX-p – BHRF1 miRNA expression cassette was excised from from 
both the FTGW(BHRF1-2/1-3) and FTGW(BHRF1-1/1-2/1-3) intermediate 
vectors by PacI digest. Each cassette was then cloned individually into 
FH1t(INSR)UTG using PacI sites to generate the TREX(BHRF1-2/1-3)UTG 
and TREX(BHRF1-1/1-2/1-3)UTG vectors respectively. Note that each 
expression cassette was inserted into FH1t(INSR)UTG  in the reverse 
orientation relative to the direction in which the viral genome is transcribed. 
The final constructs express either miR-BHRF1-2 and miR-BHRF1-3 or all 
three BHRF1 miRNAs from a pol II tetracycline inducible promoter; 
additionally the constitutively express TetR and eGFP from promoter hUbc.  
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thus replacing the H1tetO promoter and IR5 shRNA; note the fragment was inserted in the 
reverse orientation relative to the direction in which the viral genome is transcribed (see 
discussion). The final BHRF1 miRNA expression vectors were dubbed TREX(BHRF1-2/1-
3)UTG and TREX(BHRF1-1/1-2/1-3)UTG respectively. Both vectors expressed the relevant 
combinations of BHRF1 miRNAs from a tetracycline inducible pol II promoter and 
constitutively expressed eGFP and TetR.  
To generate an appropriate control vector we excised the H1tetO-p – shRNA expression 
cassette from FH1t(INSR)UTG to create an empty vector dubbed CON(empty)UTG. We 
sequenced across two overlapping regions of the TREX-p – BHRF1 miRNA expression 
cassette in TREX(BHRF1-2/1-3)UTG and TREX(BHRF1-1/1-2/1-3)UTG and checked the 
size of each vector backbone using a range of suitable digests (data not shown). Neither 
construct displayed any unexpected sequence changes and/or digest patterns.  
 
5.4.4 Sorting of TREX(BHRF1-2/1-3)UTG and TREX(BHRF1-1/1-2/1-3) 
transduced BL lines 
After generating suitable lentivirus stocks, two EBV negative BL lines (BL41 and BL30) and 
two Lat I BL lines (Akata and Mutu59) were then individually transduced with 
TREX(BHRF1-2/1-3)UTG, TREX(BHRF1-1/1-2/1-3)UTG) and CON(empty)UTG. Roughly 
two weeks post-transduction each lentivirus transduced BL line was assessed for GFP 
expression by FACS; representative measurements for the BL41 and Akata BL lines are 
shown in Fig. 5.9. Transduction efficiencies varied widely both with different constructs and 
different BL lines. Generally the BL41 and Akata BL cells were easier to transduce (always 
>40% GFP positive) than were BL30 and Mutu59 BL cells (always <40% GFP positive) (Fig. 
A 
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GFP + cells → GFP + cells → GFP + cells → 
BL41 (EBV -ve) 
Akata (Lat I BL) 
Fig. 5.9. Sorting of lentivirus transduced BL lines. EBV negative BL41 and 
BL30 BL cells and EBV positive Lat I Akata and Mutu59 BL cells were 
transduced with a lentiviral BHRF1 miRNA expression vector (empty vector, 
BHRF1-2/1-3 or BHRF1-1/1-2/1-3). Shown are representative FACS 
measurements for the BL41 BL (A) and Akata BL (B) lines. The first set of 
measurements were taken a day before sorting, approximately two weeks post-
transduction (pre-sort). The second set of measurements were taken four weeks 
after sorting (post-sort).  
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5.9 and data not shown); similarly the CON(empty)UTG) virus transduced cells much more 
efficiently than did either the TREX(BHRF1-2/1-3)UTG or TREX(BHRF1-1/1-2/1-3)UTG 
virus.  
GFP positive cells were subsequently sorted from each lentivirus transduced BL line; where 
possible we sorted each BL line in triplicate, i.e. BL41(empty vector), BL41(BHRF1-2/1-3) 
and BL41(BHRF1-1/1-2/1-3), to similar mean GFP intensities. Sorted BL lines were returned 
to culture and assessed for GFP expression on a bimonthly basis to ensure that they were still 
100% GFP positive; the data in Fig. 5.9 are representative measurements taken one month 
post-sort.  
 
5.4.5 Quantifying BHRF1 miRNA expression from TREX lentiviral vectors 
Having established lentivirus transduced BL lines, we next investigated if they could express 
the BHRF1 miRNAs. To this end cells were treated with a tetracycline derivative 
(doxycycline) for 72h, and BHRF1 miRNA expression was subsequently measured by QPCR 
(Fig. 5.10). Our data show that all four BL lines transduced with TREX(BHRF1-2/1-3)UTG 
expressed miR-BHRF1-2 and miR-BHRF1-3 in the absence of miR-BHRF1-1. In turn all BL 
lines transduced with TREX(BHRF1-1/1-2/1-3)UTG expressed all three BHRF1 miRNAs. 
We noted that while both vectors produced comparable levels of miR-BHRF1-2 in the same 
BL line, miR-BHRF1-3 expression from TREX(BHRF1-1/1-2/1-3)UTG was markedly 
reduced. Overall the copy numbers of miR-BHRF1-1 and BHRF1-2 ranged between 50-100 
copies per pg RNA and 25-100 copies per pg RNA respectively; this is the same range seen in 
Wp BL (Fig. 3.8B). Overall the copy numbers of miR-BHRF1-3 were reduced as compared 
those detected in Wp BL, but still generally similar to copy numbers seen in Lat III BL. As 
BL41 (EBV -ve) 
Akata (Lat I BL) 
A 
B 
Fig. 5.10. Expression of the BHRF1 miRNAs from the final lentiviral vectors. 
(A) EBV negative BL41 and BL30 BL cells and (B) EBV positive Lat I Akata 
and Mutu 59 BL cells transduced with a lentiviral BHRF1 miRNA expression 
vector (empty vector, BHRF1-2/1-3 or BHRF1-1/1-2/1-3) were assessed for 
BHRF1 miRNA expression. Different BHRF1 miRNAs are colour coded using 
red (miR-BHRF1-1), blue (miR-BHRF1-2) and green (miR-BHRF1-3). Data 
were quantified by QPCR and expressed as absolute copy numbers per pg total 
RNA. Each data point corresponds to the average of two replicate assay 
measurements. Note that BHRF1-2/1-3 does not express miR-BHRF1-1. 
 
 
 
BL30 (EBV -ve) 
Mutu 59 (Lat I BL) 
Lentiviral Vector Lentiviral Vector 
Lentiviral Vector Lentiviral Vector 
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expected the BHRF1 miRNAs were only detectable at low background levels in 
CON(empty)UTG transduced BL lines. The only exception was Mutu 59 BL for which trace 
levels of all BHRF1 miRNAs could be detected; this is likely due to some cells having drifted 
toward Lat III (781). Consequently Mutu 59 BL was removed from future studies. 
 
5.4.6 BHRF1 miRNAs expressed from lentivectors are capable of 
specifically down regulating an artificial target 
Next we asked whether the lentiviral expressed BHRF1 miRNAs could functionally knock 
down a reporter target. BL41 and Akata BL cells stably transduced with TREX(BHRF1-2/1-
3)UTG, TREX(BHRF1-1/1-2/1-3)UTG or CON(empty)UTG were treated with doxycycline 
for 72h as before and transfected individually with each BHRF1 miRNA reporter construct 
(Fig. 5.11). 
As expected the BHRF1-2 and BHRF1-3 reporters, but not the BHRF1-1 reporter, were 
significantly down regulated in TREX(BHRF1-2/1-3)UTG transduced BL41 and Akata BL 
cells (P < 0.05). In turn the BHRF1-1 and BHRF1-2 reporters, but not the BHRF1-3 reporter, 
were significantly down regulated in cells transduced with TREX(BHRF1-1/1-2/1-3)UTG. 
This is consistent with the pattern of miRNA expression shown in Fig. 5.10 and confirms that 
miR-BHRF1-3 is expressed at lower levels from TREX(BHRF1-1/1-2/1-3)UTG than from 
TREX(BHRF1-2/1-3)UTG. Luciferase knockdown, when it occurred, was similar for all three 
BHRF1 miRNA reporters and ranged from 40% to 50% in the BL41 BL background and 
from 50% to 60% in the Akata BL background. This is also consistent with our QPCR data 
showing that overall levels of the BHRF1 miRNAs are higher in Akata cells (Fig 5.10). 
 
050
100
150
200
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 S
ig
n
a
l 
(%
)
0
50
100
150
200
0
50
100
150
200
empty vector BHRF1-2/1-3 BHRF1-1/1-2/1-3 
0
50
100
150
200
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 S
ig
n
a
l 
(%
)
0
50
100
150
200
0
50
100
150
200
0
50
100
150
200
250 BHRF1-1 Reporter
BHRF1-2 Reporter
BHRF1-3 Reporter
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 S
ig
n
a
l 
(%
)
BL41 (EBV -ve) 
A 
B 
empty vector BHRF1-2/1-3 BHRF1-1/1-2/1-3 
0
50
100
150
200
250 BHRF1-1 Reporter
BHRF1-2 Reporter
BHRF1-3 Reporter
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 S
ig
n
a
l 
(%
)
Akata (Lat I BL) 
Fig. 5.11. The BHRF1 miRNAs expressed from lentivectors are capable of 
specifically down regulating an artificial target. Lentiviral vector (empty 
vector, BHRF1-2/1-3 or BHRF1-1/1-2/1-3) transduced EBV negative BL41 
(A) cells or EBV positive Akata (B) cells were transfected with either the 
control pMIR-REPORTTM firefly reporter construct or derivatives containing a 
single binding site for miR-BHRF1-1, 1-2 or 1-3. The same cells were co-
transfected with the pRL SV40 Renilla reporter construct. Firefly luciferase 
activity was measured in cell lysates prepared 24h post-transfection and 
normalized to Renilla luciferase activity measured in the same samples. 
Normalized luciferase data was expressed relative to the empty control pMIR-
REPORTTM firefly reporter (set at 100%). Error bars indicate standard 
deviation of three separate experiments. Normalized luciferase activity in 
BHRF1-2/1-3 and BHRF1-1/1-2/1-3 transduced cells was compared to that of 
empty vector transduced cells for each BHRF1 miRNA reporter, using an 
unpaired t test with a P value cut off set to 0.05. P values are listed above each 
column using green and red text to denote statistical significance and 
insignificance respectively 
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5.4.7 Assessing the inducibility of BHRF1 miRNA expression from TREX 
lentiviral vectors 
In a final validation experiment we tested the inducibility of our TREX lentiviral vectors. 
BL41 and Akata BL cells stably transduced with TREX(BHRF1-2/1-3)UTG, TREX(BHRF1-
1/1-2/1-3)UTG or CON(empty)UTG were cultured either in the presence or absence of 
doxycycline for 72h. Subsequently cells were assessed both for BHRF1 miRNAs expression 
and BHRF1 miRNA reporter construct knockdown as before. 
Shown in Fig. 5.12 are representative data for the TREX(BHRF1-1/1-2/1-3)UTG transduced 
BL41 and Akata BL lines. Both lentivirus transduced BL lines were characterized by similar 
levels of leaky BHRF1 miRNAs expression in the absence of doxycycline (Fig. 5.12A). Upon 
doxycycline treatment, levels of miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 in the 
lentivirus transduced BL41 BL line increased by 4.1, 3.5 and 1.9 fold, respectively. By 
comparison miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 in Akata BL increased by 9.3, 
7.5 and 3.4, respectively.  
Doxycycline induced BHRF1 miRNAs repressed the BHRF1-1 and 1-2 reporters, but not the 
BHRF1-3 reporter construct, in both BL lines tested (Fig. 5.12B). This is consistent with the 
reporter knockdown data shown in Fig. 5.11. Interestingly, leaky BHRF1 miRNA expression 
in doxycycline untreated BL41 cells caused a similar degree of BHRF1 miRNA reporter 
knockdown as induced BHRF1 miRNA expression in doxycycline treated BL41 cells. By 
contrast, leaky BHRF1 miRNA expression in doxycycline untreated Akata cells had no effect 
on BHRF1 miRNA reporter activity. 
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Fig. 5.12. Inducibility of the BHRF1 miRNAs from the final lentiviral vectors. 
(A) EBV negative BL41 BL cells and EBV positive Lat I Akata BL cells 
transduced with TREX(BHRF1-1/1-2/1-3)UTG lentiviral expression vector 
were cultured in parallel either in the presence (+) or absence (-) of 
doxycycline and assessed for BHRF1 miRNA expression. Different BHRF1 
miRNAs are colour coded using red (miR-BHRF1-1), blue (miR-BHRF1-2) 
and green (miR-BHRF1-3). The numbers above the columns indicate fold 
increases in miRNA levels attributed to doxycycline treatment. Shown are the 
averages of two replicate assay measurements obtained from a single 
preparation of RNA. (B) The same cells were transfected with either the 
control pMIR-REPORTTM firefly reporter construct or derivatives containing a 
single binding site for miR-BHRF1-1, 1-2 or 1-3. Luciferase data were 
expressed relative to the empty control pMIR-REPORTTM firefly reporter (set 
at 100%). Each data point corresponds to the average of two replicate assay 
measurements obtained from the same preparation of cell lysate. 
4.1 3.5 
1.9 
9.3 
7.5 
3.4 
0
50
100
150
200
250
BHRF1-1/1-2/1-3 ( + ) BHRF1-1/1-2/1-3 ( - )
C
o
p
y
 N
u
m
b
e
r 
/
 p
g
 R
N
A
BL41 (EBV -ve)
BHRF1-1
BHRF1-2
BHRF1-3
0
50
100
150
200
250
BHRF1-1/1-2/1-3 ( + ) BHRF1-1/1-2/1-3 ( - )
C
o
p
y
 N
u
m
b
e
r 
/
 p
g
 R
N
A
Akata (Lat I BL)
BHRF1-1
BHRF1-2
BHRF1-3
0
50
100
150
200
250
BHRF1-1/1-2/1-3 ( + ) BHRF1-1/1-2/1-3 ( - )
C
o
p
y
 N
u
m
b
e
r 
/
 p
g
 R
N
A
BL41 (EBV -ve)
BHRF1-1
BHRF1-2
BHRF1-3
Chapter 5 
 
116 
 
5.5 Investigating the effects of the BHRF1 miRNAs on cellular transcripts 
In chapter 1.4 we discussed the variety of transcriptional and post-transcriptional mechanisms 
by which miRNAs silence their targets. One possibility is that they interfere with translation 
initiation or elongation, thereby decreasing the levels of target protein but not target mRNA. 
Conversely they can decrease levels of target mRNA either by deadenylation and degradation 
or, in rare cases, by endonucleolytic cleavage. It has been estimated that up to 85% of cellular 
miRNA induced protein changes result from decreases in mRNA levels (151). Interestingly a 
number of validated EBV miRNA targets are also repressed at the transcript level; these 
include cellular CXCL11 (miR-BHRF1-3), Dicer (miR-BART6-5p), PUMA (miR-BART5) 
as well as viral BALF5 (miR-BART2) and LMP1 (miR-BART9) (753, 756, 757, 759, 762). 
Furthermore we note that any EBV miRNA associated changes to the cellular proteome may 
well exert secondary downstream effects on cellular transcription. 
 
5.5.1 Array analysis of Akata BL cells stably expressing BHRF1 miRNAs 
In the next series of experiments, we used gene expression profiling to ask whether the 
BHRF1 miRNAs were capable of altering the levels of cellular transcripts in BL cells. To this 
end we screened total RNA preparations using the whole transcript (WT) GeneChip® Human 
Gene 1.0 ST Array system (Affymetrix). Unlike standard 3′ arrays, the HG 1.0 ST array 
contains probes which are spread evenly throughout the length of the gene; consequently they 
can detect differentially spliced transcripts, truncated transcripts and transcripts with 
alternative polyadenylation sites. Importantly microarrays have reliably been used to detect 
target genes for both KSHV (MAF) and EBV (PUMA) miRNAs (754, 806), providing further 
rationale for our approach. 
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In preparation for the array analysis, Akata BL cells stably transduced with the 
TREX(BHRF1-2/1-3)UTG, TREX(BHRF1-1/1-2/1-3)UTG or CON(empty)UTG constructs 
were treated with doxycycline for 72 h.  Subsequently each cell line was split into three 
separate cultures; one was used to generate RNA for the array while the others were used to 
assess miRNA expression by QPCR (Fig. 5.10) and the effects of the BHRF1 miRNAs on a 
reporter target (Fig. 5.11). This routine was performed a total of three times in order to gain 
three experimental RNA replicates for our array. Using the 2100 Bioanalyzer (Agilent 
Technologies), the overall quality of the RNA was deemed to be excellent. Samples were then 
submitted to the Affymetrix Microarray Facility within the School of Cancer Sciences 
(University of Birmingham) for analysis. 
The raw array data were initially processed using the AltAnalyze software package 
(http://www.altanalyze.org/) (780). Differentially expressed genes were then identified using 
Limma analysis (813). A p-value cut off of 0.01 and a fold change cut off to 1.5 were applied; 
note that smaller fold changes would be difficult to reliably validate by other RNA detection 
methods. These data have been summarized as a Venn diagram in Fig. 5.13. Using these 
criteria, 77 genes were differentially regulated between Akata BL cells expressing miR-
BHRF1-2 and miR-BHRF1-3 vs. the empty control. The same number of genes was 
differentially regulated between Akata BL cells expressing all BHRF1 miRNAs vs. the empty 
vector. Finally 88 genes were differentially regulated between Akata BL cells expressing all 
BHRF1 miRNAs vs. miR-BHRF1-2 and miR-BHRF1-3 alone. Note that at this point we are 
not distinguishing between up or down regulated genes. Names, fold changes and P values of 
differentially regulated genes found across the three biological comparisons have been listed 
in Table 5.1.  
 
Fig. 5.13. Investigating the effects of the BHRF1 miRNAs on cellular 
transcription. Lentiviral vector (empty vector, BHRF1-2/1-3 or BHRF1-1/1-
2/1-3) transduced EBV positive Akata BL cells were subjected to total cellular 
transcript analysis using the GeneChip®  Human Gene 1.0 ST Array system 
(Affymetrix). Data were initially processed using the AltAnalyse software. 
Differentially expressed genes were identified using limma. The p-value cut 
off was set to 0.01 and the fold change cut off to 1.5. The total number of 
genes differentially expressed between the three TREX lentivirus transduced 
Akata BL lines are summarized in the Venn Diagram. 
BHRF1-1/1-2/1-3  
vs. empty vector 
BHRF1-2/1-3  
vs. empty vector 
BHRF1-1/1-2/1-3  
vs. BHRF1-2/1-3 

Table 5.1. Investigating the effects of the BHRF1 miRNAs on cellular 
transcription. Lentiviral vector (empty vector, BHRF1-2/1-3 or BHRF1-1/1-
2/1-3) transduced EBV positive Akata BL cells were subjected to total cellular 
transcript analysis using the GeneChip®  Human Gene 1.0 ST Array system 
(Affymetrix). Data were initially processed using the AltAnalyse software. 
Differentially expressed genes were identified using limma. The p-value cut 
off was set to 0.01 and the fold change cut off to 1.5.  
Chapter 5 
 
118 
 
5.5.2 QPCR validation of genes found differentially regulated on the array  
Next we investigated if these gene changes could be validated by another method of RNA 
detection. Therefore we randomly selected 15 differentially expressed genes for further 
validation by QPCR. In preliminary experiments we tested each QPCR assay using a small 
panel of lymphoid and epithelial cell lines in order to find suitable positive reference lines 
(data not shown). These lines included the EBV positive Akata BL and EH LCL2 B cell lines 
described in section 3.3, the EBV positive epithelial line C666.1 and the EBV negative NK 
line NKL. Five genes were found to be undetectable in Akata BL (ADAM18, DSCR8, ASZ1, 
HSPA4L and GRM5) and thus excluded from further analysis.  
Expression of the remaining genes (MIPEP, TDRD7, CRYBG3, FCRL2, IQSEC2, CELF2, 
MAN1B1, MMP14, OCA2 and ITGA5) was assessed by QPCR in the same RNA samples 
used in the microarray analysis. Relative expression levels of each gene are shown in Fig. 5. 
14, alongside the paired array data. According to the array analysis, transcript levels of all ten 
genes varied by 1.5-3 fold between Akata cultures transduced with different lentiviral vectors 
(Fig. 5.14A). For instance TDRD7 was up-regulated by 1.51 fold in BHRF1-2/1-3 transduced 
Akata cells relative to the BHRF1-1/1-2/1-3 vector. OCA2 in turn was down-regulated by 
2.99 fold in BHRF1-1/1-2/1-3 transduced Akata cells relative to the empty vector. 
Remarkably none of these changes could be reproduced when detection was carried out using 
QPCR (Fig. 5.14B); levels of all genes, including TDRD7 and OCA2, were near identical 
between for all three lentiviral vector transduced Akata cultures. 
In order to better understand the lack of correlation between the array and QPCR data sets, we 
re-analyzed our raw array data with R/Bioconductor using the XPS software package 
(http://www.bioconductor.org). From this new normalized dataset we then examined 
CELF2 CELF2 
CRYBG3 CRYBG3 
FCRL2 FCRL2 
IQSEC2 IQSEC2 
ITGA5 ITGA5 
MAN1B1 MAN1B1 
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Array (AltAnalyze) QPCR 
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MMP14 MMP14 
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TDRD7 TDRD7 
A B 
Fig. 5.14. Investigating the effects of the BHRF1 miRNAs on cellular 
transcription. (A) Lentiviral vector (empty vector, BHRF1-2/1-3 or BHRF1-
1/1-2/1-3) transduced EBV positive Akata cells were subjected to total cellular 
transcription analysis using the GeneChip®  Human Gene 1.0 ST Array system 
(Affymetrix). Data were processed using the AltAnalyse software. (B) 
Transcriptional changes seen in array were validated by QPCR for a random 
selection of genes. Data are expressed relative to the empty vector control (set 
at one). Error bars indicate standard deviation of three separate experiments.  
Array (AltAnalyze) QPCR 
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expression levels of nine genes shown earlier in Fig. 5.14. These new XPS-generated values 
are shown in Fig. 5.15, also alongside the paired QPCR data. In contrast to the AltAnalyze 
data, the XPS data indicates that all nine genes (MIPEP, TDRD7, FCRL2, IQSEC2, CELF2 
MAN1B1, MMP14, OCA2 and ITGA5) are expressed to similar levels in all three lentiviral 
vector transduced Akata cultures (Fig. 5.15A). These data clearly agree more with QPCR data 
(Fig. 5.15B) than the AltAnalyze data (Fig. 5.14A). Overall these findings suggest that all 15 
genes originally identified as differentially expressed from the AltAnalyze data set were false 
positives. Unfortunately due to lack of time, it was not possible to perform a Limma analysis 
to identify potential differentially regulated genes from the new XPS data set. 
 
5.5.3 Analysis of CXCL11 expression  
In a final attempt to validate our array data, we asked whether our array data was consistent 
with previous studies which had identified BHRF1 miRNA targets. At the time of this study 
only two groups had investigated the effects of the BHRF1 miRNAs at both protein and 
mRNA levels. Li et al. found that miR-BHRF1-1 reduced levels of p53 protein but not p53 
mRNA (752), while Xia et al. reported that miR-BHRF1-3 reduced both levels of CXCL11 
protein and mRNA (753). Out of our two BHRF1 miRNA expression vectors, the BHRF1-
2/1-3 construct generated higher levels of miR-BHRF1-3 sufficient to knock down a target 
reporter (Fig. 5.16A). Consequently we interrogated our array data for CXCL11 transcript 
levels in empty vector vs. BHRF1-2/1-3 transduced Akata BL cells but our data did not reveal 
any reduction in CXCL11 mRNA levels in the presence of miR-BHRF1-3 (Fig. 5.16B). 
However we can not draw any concrete conclusions on the overall validity of our array data 
until we have fully analyzed the data using the alternative XPS analysis. 
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Fig. 5.15. Investigating the effects of the BHRF1 miRNAs on cellular 
transcription. (A) Lentiviral vector (empty vector, BHRF1-2/1-3 or BHRF1-
1/1-2/1-3) transduced EBV positive Akata cells were subjected to total cellular 
transcription analysis using the GeneChip®  Human Gene 1.0 ST Array system 
(Affymetrix). Data were processed using the XPS software (B) Transcriptional 
changes seen in array were validated by QPCR for a random selection of 
genes. Data are expressed relative to the empty vector control (set at one). 
Error bars indicate standard deviation of three separate experiments.  
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Fig. 5.16. Validation of a published BHRF1 miRNA target. (A) Data presented 
in Fig. 5.11 revealed that the BHRF1-2 and BHRF1-3 firefly reporter 
constructs are specifically repressed in EBV positive Akata cells transduced 
with the BHRF1-2/1-3 but not the empty lentiviral expression vector. (B) 
Affymetrix array data for the same cells, processed either using the AltAnalyse 
or XPS software, reveals no corresponding change in the levels of CXCL11 
mRNA. 
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5.6 Investigating the effects of the BHRF1 miRNAs on cell growth 
In chapter 1.5 we described how cellular miRNAs regulate proliferation. Most cellular 
miRNAs exert anti-proliferative effects through the targeting of cyclins and CDK family 
members (199). A number of KSHV and EBV miRNAs exert pro-proliferative effects by 
targeting inhibitors of proliferation. Thus KSHV miRNAs target CDK inhibitors such as 
WEE1 (miR-K12-1 and miR-K12-12), p21 (miR-K12-1), p27 (miR-K12-11) and PP2A (miR-
K12-1) (814-817). EBV miRNAs can also target inhibitors of proliferation such as p53 (miR-
BHRF1-1) (752). Furthermore the EBV BART miRNAs are predicted to target numerous cell 
cycle proteins while the BHRF1 miRNAs are known to assist in cell cycle progression during 
early EBV infection (750, 751, 764). 
Therefore we asked whether the BHRF1 miRNAs might confer a proliferative advantage to 
BL cells. To this end EBV negative BL41 cells and EBV positive Lat I Akata BL cells, both 
stably transduced with lentivirus (empty vector, BHRF1-2/1-3 or BHRF1-1/1-2/1-3), were 
treated with doxycycline for 72 h as before. Cells were seeded at 10
5
 cells/ml, and viable 
GFP-positive cells were subsequently enumerated at 24 h, 48 h and 72 h using flow 
cytometry. The representative experiments illustrated in Fig. 5.17 show that the growth rates 
of BL41 cells in the presence or absence of the BHRF1 miRNAs are remarkably similar; 
similar results can be observed for Akata BL cells. Thus the BHRF1 miRNAs do not appear 
to alter the growth rates of the BL tumour lines, at least under in vitro conditions. 
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Fig. 5.17. Investigating the effects of the BHRF1 miRNAs on cell growth. 
Lentiviral vector (empty vector, BHRF1-2/1-3 or BHRF1-1/1-2/1-3) 
transduced EBV negative BL41 BL cells and EBV positive Lat I Akata BL 
cells were seeded at low density (105 cells/ml). Live GFP-positive cells were 
enumerated daily over a 3 day period using flow cytometry. One of two 
representative experiments are shown for each BL line tested. Error bars 
indicate standard deviation of three replicate measurements. Fold changes in 
live cell counts for BHRF1 miRNA expressing cultures were compared to 
those of empty vector transduced cells on day 3 using an unpaired t test with a 
P value cut off set to 0.05. P values are listed to the right of each graph using 
green and red text to denote statistical significance and insignificance 
respectively.  
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5.7 Investigating the effects of the BHRF1 miRNAs on apoptosis 
In chapter 1.5 we also described how many cellular miRNAs regulate apoptosis (programmed 
cell death). Apoptosis can occur through the intrinsic pathway, which is regulated by Bcl-2 
family members, and the extrinsic pathway, which is regulated by cell-cell signalling (188). In 
the intrinsic pathway, pro- and anti-apoptotic members of the Bcl-2 family interact to 
carefully control mitochondrial cytochrome c release which consequently triggers cell death. 
EBV BART miRNAs are already known to enhance cell survival by repressing pro-apoptotic 
Bcl-2 family members such PUMA (miR-BART5) and Bim (miR-BART 1, 3, 9, 11 and 12) 
(754, 756). Likewise the BHRF1 miRNAs are reported to confer cell survival during early 
EBV infection, though their precise targets remain unclear (751).  
 
5.7.1 Expression of Bcl-2 family proteins in BL41 BL cells stably expressing 
BHRF1 miRNAs 
To address the possibility that the BHRF1 miRNAs also target Bcl-2 family members, we 
initially screened our array data for changes in transcript levels of Bcl-2 family genes using 
the AltAnalyze array data set.  There were no changes which were both greater than 1.5 fold 
and statistically significant (p<0.01) (data not shown). Consequently any potential regulation 
of Bcl-2 family members by the BHRF1 miRNAs would most likely be post-transcriptional. 
To investigate this further, EBV negative BL41 cells stably transduced with lentivirus (empty 
vector, BHRF1-2/1-3 or BHRF1-1/1-2/1-3) were cultured for 72 h either in the presence or 
absence of doxycycline. Subsequently cells were assessed by western blot for the expression 
of pro-apoptotic (Bak, Bax, PUMA, Bim, Noxa and Bid) and anti-apoptotic (Bcl-2, Bcl-XL 
and Mcl-1) Bcl-2 family members (Fig. 5.18); note that Bcl-6 is not a Bcl-2 family member 
B-ACTIN 
Bak 
Calregulin 
Bax 
Calregulin 
Bim 
B-ACTIN 
PUMA 
Calregulin 
Bcl-2 
Calregulin 
Noxa 
Calregulin 
Mcl-1 
Calregulin 
Bcl-XL 
Bid Bcl-6 
Calregulin Calregulin 
C
o
n
tr
o
l 
B
H
R
F
1
-1
/1
-2
/1
-3
 (
-)
 
Fig. 5.18. Expression of Bcl-2 family member proteins in a lentivirus 
transduced BL line. Pro-apoptotic (Bak, Bax, PUMA, Bim, Noxa and Bid) and 
anti-apoptotic (Bcl-2, Bcl-XL and Mcl-1) members of the Bcl-2 family were 
detected by western blot in EBV negative BL41 BL cells transduced with a 
lentiviral BHRF1 miRNA expression vector (empty vector, BHRF1-2/1-3 or 
BHRF1-1/1-2/1-3). Where indicated, BL41 BL cells were cultured in parallel 
either in the presence (+) or absence (-) of doxycycline. Parental BL41 BL and 
Oku BL lines were included as BHRF1 miRNA negative and positive controls 
respectively. DG75 (Bak and Bax), 293 ft (PUMA), BL2 (Bim) and Kem I 
(Bcl-XL and Bcl-6) were included as negative controls. EH LCL2 (Bcl-2) was 
included as a positive control. No suitable controls were known/available for 
Mcl-2, Noxa and Bid. Detection of either B-Actin or Calregulin was 
performed as a loading control.  
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but was added to the list because it is a predicted target of the miR-BHRF1-2 seed 
(AUCUUUU) according to Targetscan (102, 107).  
In general, levels of all Bcl-2 family members tested were similar in BL41 cells transduced 
with the BHRF1-2/1-3, BHRF1-1/1-2/1-3 or empty lentiviral expression construct; this was 
true for both the doxycycline treated and untreated samples. In some cases, minor differences 
between protein band intensities were observed but these were almost always mirrored by 
similar changes in the loading control e.g. Bid and calregulin levels in untreated BHRF1-1/1-
2/1-3 transduced cells. One exception was Bcl-XL which appeared to be reduced in BL41 
cells transduced with the BHRF1-1/1-2/1-3 construct; however this result was not 
reproducible in every experiment (data not shown). We were unable to confirm if miR-
BHRF1-2 regulates Bcl-6 as it was undetectable in the BL41 cell line. 
 
5.7.2 Survival of BL cells stably expressing the BHRF1 miRNAs cultured in 
the presence of ionomycin 
In a final experiment we asked if the BHRF1 miRNAs conferred any resistance to cell death 
in the BL cell line model. Therefore we treated lentiviral vector (empty vector, BHRF1-2/1-3, 
BHRF1-1/1-2/1-3 or BHRF1 protein) transduced EBV negative BL41 and BL30 cells and 
EBV positive Lat I Akata BL cells for 48 h with doxycycline. Thereafter cells were cultured 
in the presence or absence of ionomycin for an additional 48 h; note that ionomycin induces 
apoptosis via the intrinsic apoptosis pathway by increasing intracellular Ca
2+
 levels (818-820). 
Total cell death was then assessed by flow cytometry, using syto17 and PI to stain for live and 
dead cells, respectively (Fig. 5.19).  
Fig. 5.19. Investigating the effects of the BHRF1 miRNAs on cell survival. 
Lentiviral vector (empty vector, BHRF1-2/1-3, BHRF1-1/1-2/1-3 or BHRF1 
protein) transduced EBV negative BL41 and BL30 BL cells and EBV positive 
Lat I Akata BL cells were treated for 48h with the apoptosis-inducing drug 
ionomycin. (A) Total cell death was enumerated using flow cytometry. Live 
cells were stained using syto17; this is a membrane permeable dye which 
brightly stains live, but not apoptotic and dead cells. Dead cells were stained 
using PI; this is a membrane impermeable dye and thus only stains cells with 
degenerate membranes. (B) Two replicate experiments are shown for each BL 
line tested. Error bars indicate standard deviation of three replicate 
measurements. Total cell death in BHRF1 miRNA and protein expressing 
cultures was compared to that in empty vector transduced cells using an 
unpaired t test with a P value cut off set to 0.05. P values are listed above each 
column using green and red text to denote statistical significance and 
insignificance respectively.  
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Broadly speaking BL41 cells transduced with the BHRF1 miRNAs expression constructs 
(BHRF1-2/1-3 or BHRF1-1/1-2/1-3) appeared slightly more resistant to cell death than cells 
transduced with the empty vector. By contrast BL30 cells transduced with the BHRF1 
miRNAs expression constructs appeared slightly more sensitive to cell death than cells 
transduced with the empty vector. Finally the sensitivities to cell death were broadly similar 
for all three TREX lentivirus transduced Akata BL lines.  
As a control we included BL41, BL30 and Akata BL cells stably transduced with a BHRF1 
protein expression construct (kindly provided by Leah Fitzsimmons). BHRF1 is the main 
viral Bcl-2 homolog and is considered an important contributor to the survival advantage of 
Wp-BL over Lat I BL (320, 681). All three BL lines tested were significantly (P < 0.05) and 
reproducibly protected from cell death in the presence of the BHRF1 protein. The level of 
protection ranged from ~2 fold (BL30) to nearly absolute protection (BL41 BL and Akata 
BL). By comparison the effects of the BHRF1 miRNAs on cell death were remarkably small 
in all BL lines tested and lacked reproducibility. 
 
5.8 Discussion 
5.8.1 Detecting functional changes in BHRF1 miRNA expression 
A wide range of methodologies have been used to investigate the function of EBV miRNAs. 
These include genetic deletion, down regulation by AMOs, down regulation by sponge 
constructs or artificial expression of the miRNA of interest (750-752, 755, 764). We 
investigated a number of these methodologies as possible means by which to study the 
function of the BHRF1 miRNAs in the context of Wp BL.  
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As a first step we designed luciferase reporter constructs with individual BHRF1 miRNA 
binding sites to detect functional changes in miRNA levels (Fig. 5.1). These constructs were 
successful in that inhibition was only observed in a cell line expressing relevant BHRF1 
miRNAs (Fig. 5.2). Interestingly, we observed a greater repression of the BHRF1-2 miRNA 
construct as compared to the other reporters. This is unlikely due to an excess of the BHRF1-
2 miRNA, as copy numbers of all three BHRF1 miRNAs in Oku BL are within a 2-fold range 
(Fig. 3.8B) (743). This result could represent a higher affinity of the BHRF1-2 miRNA for its 
binding site in the luciferase mRNA 3′ UTR. 
Our reporter system used perfectly complementary binding sites for each of the BHRF1 
miRNAs. Use of physiological binding sites for miR-BHRF1-1 or miR-BHRF1-2 was not 
possible as there were no validated targets for these miRNAs at the time we developed our 
reporter system. Although miR-BHRF1-3 was shown to target CXCL11, it was presumed to 
do so via a 100% complementary sequence (250, 753). Consequently the miR-BHRF1-3 
binding site in our reporter system could be seen as physiological. The use of perfectly 
complementary binding sites is advantageous when designing a sensitive reporter system as 
perfect miRNA-target associations result in stronger repression than do imperfect miRNA-
target matches (821). 
 
5.8.2 Using anti-miRNA oligonucleotides to study BHRF1 miRNA function  
The successfully application of LNA
TM
 inhibitors to the study of cellular miRNAs has been 
extensively documented (792). More recently LNA
TM
 inhibitors have also been to study the 
function of viral miRNAs; miRNA knockdown studies have implicated KSHV miRNAs 
(miR-K12-6 and miR-K12-11) in targeting the cellular transcription factor MAF (806) and an 
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EBV miRNA (miR-BART10-3p) in targeting BHRF1 (764). The use of Morpholino 
inhibitors to study cellular miRNAs has also has been extensively documented 
(http://www.gene-tools.com/node/31#miRNAcitations). Success stories include 
demonstrating that miR-24a regulates apoptosis during retinal development (822) while miR-
125b regulates p53 expression in humans and zebrafish (823). Thus we had ample evidence to 
suggest that LNA
TM
 and Morpholinos inhibitors could be used to successfully knockdown the 
BHRF1 miRNAs. 
Thus having designed our BHRF1 miRNA reporter constructs, we investigated whether we 
could achieve BHRF1 miRNA knockdown in Oku BL using inhibitors, and which inhibitor 
(LNA
TM
 and Morpholinos) would give us the best results (Fig. 5.3 and 5.4). We concluded 
that miR-BHRF1-3 knockdown was achievable using both inhibitors. While higher doses of 
Morpholinos were required to achieve an effect, as compared to LNA
TM
, the overall price per 
quantity was much cheaper, making the former a more cost effective approach. Following our 
success with both of the miR-BHRF1-3 inhibitors we then proceeded to test an LNA
TM
 
inhibitor against miR-BHRF1-1 and a Morpholino inhibitor against miR-BHRF1-2. The 
LNA
TM
 inhibitor against miR-BHRF1-1 increased reporter activity in a non-specific manner 
i.e. both the BHRF1-1 and the control reporters were affected. We speculate our inhibitor 
could be in part acting as carrier DNA by improving plasmid uptake; the effects of carrier 
DNA on transfection have been documented elsewhere (824). Thus we could not distinguish 
genuine miR-BHRF1-1 knockdown from off target effects. Because of this result we chose 
not to order an LNA
TM
 inhibitor against miR-BHRF1-2. 
Results with the Morpholino inhibitor against miR-BHRF1-2 were difficult to interpret due to 
technical issues with our β-gal assay. Briefly the duplicate β-gal readings taken for each 
sample often deviated from each other by more than two fold. Consequently when we 
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normalized our firefly luciferase data to β-gal we occasionally obtained nonsensical results, 
such as the apparent 2-fold increase in control reporter activity at the 10μM inhibitor 
concentration. We eventually resolved this issue by using the pRL SV40 Renilla reporter 
construct for data normalization. Nonetheless it was clear that the miR-BHRF1-2 inhibitor 
could not achieve satisfactory miR-BHRF1-2 knockdown; doubling the inhibitor dose made 
no difference to our results. Note that Gene Tool, LLC were unable to design a Morpholino 
inhibitor against miR-BHRF1-1; a tetra-G sequence in the inhibitor would render it water 
insoluble (http://www.gene-tools.com/node/18). Consequently it would not have been possible 
to knockdown all three BHRF1 miRNAs using LNA
TM
 inhibitors, Morpholino inhibitors, or 
combinations thereof.  
Oku BL expresses broadly similar levels of all three BHRF1 miRNAs (Fig. 3.8B). Therefore 
if we assume that neither the LNA
TM
 inhibitor against miR-BHRF1-1 nor the Morpholino 
inhibitor against miR-BHRF1-2 was defective, then the only way to explain our lack of 
success with both is that they are less efficient in mediating target knockdown than either 
miR-BHRF1-3 inhibitor. Therefore it follows that the amount of miR-BHRF1-1 and miR-
BHRF1-2 inhibitor taken up by the cell was likely insufficient to mediate target knockdown. 
On that note Wp BL lines are very difficult to transfect; this could explain our overall lack of 
success with anti-miRNA oligonucleotides (AMOs). 
Issues with transfection efficiencies may well have complicated future attempts to deliver a 
pool of inhibitors capable of simultaneously knocking down multiple BHRF1 miRNAs. 
Likewise it impacts on the cost of our experiments as higher doses of inhibitor per 
transfection are required to achieve knockdown. Adding to the issue of cost are the scrambled 
miRNA inhibitors required to control for non-specific effects for each type of inhibitor used 
in our experiments; the process of introducing foreign DNA to the cell may itself affect cell 
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cycle progression and apoptosis (825), two cellular process previously associated with the 
BHRF1 miRNAs (750, 751).  
A recent study by Obad et al. documented the use of small LNA
TM
 inhibitors against the 
miRNA seed (826). These inhibitors were found to target closely related miRNAs without 
causing off-target effects; specifically, binding of small LNA
TM
 inhibitors to sites in the ORF 
and UTR regions of mRNA did not influence protein output. Small LNA
TM
 inhibitors, by 
virtue of their size, may also have allowed for more efficient cellular delivery than those 
inhibitors used in the present study. Unfortunately we were unaware of the existence of these 
inhibitors at the time we conducted our AMO experiments. Thus the overall unsatisfactory 
results and high cost of this line of work led us to seek alternative methodologies to study 
BHRF1 miRNA function.  
 
5.8.3 Using lentivirus expression vectors to study BHRF1 miRNA function 
One alternative approach to study the function of the BHRF1 miRNAs is to use lentiviral 
constructs to express the BHRF1 miRNAs in a panel of EBV negative and Lat I lines (Fig 5.5 
– Fig 5.8). As reviewed by Liu and Berkhout, the use of lentiviruses to express miRNAs has a 
number of advantages as well as potential drawbacks (827). The main advantage is that 
lentivirus vectors stably integrate into the host genome thereby allowing continuous 
expression of the miRNA expression cassette. A major disadvantage is the theoretical ability 
of the miRNA expression cassette to interfere with virus production in producer cells. If the 
cassette is inserted in the sense orientation, then the viral RNA genome will contain Drosha 
cleavage sites; if the cassette is inserted in the antisense orientation then the viral RNA 
genome will contain miRNA target sites. 
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Our BHRF1 miRNA expression cassettes were inserted in the reverse orientation thus 
avoiding the presence of Drosha cleavage sites in the viral RNA genome (Fig 5.8). The 
accumulation of the tetracycline repressor protein (TetR) in producer cells should in theory 
minimize BHRF1 miRNA expression and potential targeting of the viral RNA genome. A 
possible issue with inserting the BHRF1 miRNA expression cassette in the reverse orientation 
is that the viral RNA genome would contain the BHRF1 poly-A signal. This could lead to 
reduced viral titre by inducing early transcriptional termination of the viral RNA genome 
(828). On the other hand removal of the BHRF1 poly-A signal might have destabilized the 
miRNA precursor transcript (828). However we speculated that a reduction in virus titre could 
be compensated for by sorting cells with high GFP expression.  
We generated two BHRF1 miRNA expression constructs; one to express the combination of 
miR-BHRF1-2 and miR-BHRF1-3, and the other to express all three BHRF1 miRNAs, thus 
mimicking BHRF1 miRNA expression in lytic cycle and Lat III, respectively. Overall we 
found that the same construct produced similar BHRF1 miRNA copy numbers across all four 
BL backgrounds (BL41, BL30, Akata BL, Mutu 59 BL); the small variations in BHRF1 
miRNA expression between BL lines likely reflects differences in transduction efficiency (Fig 
5.10). Importantly the observed levels of BHRF1 miRNA expression were physiologically 
comparable to Wp BL and Lat III BL (809). Specifically the copy numbers measured for 
miR-BHRF1-1 and BHRF1-2 were comparable to those seen in Wp BL while those of miR-
BHRF1-3 were comparable to Lat III BL.  
At this point we noted a few technical issues with our BHRF1 miRNA expression system. In 
all BL lines tested we found a degree of leaky BHRF1 miRNA expression in the absence of 
doxycycline (Fig. 5.12 and data not shown). We assessed the effects of leaky BHRF1 miRNA 
expression on relevant target reporters in the BL41 and Akata BL lines. Interestingly 
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knockdown was only seen in BL41 cells, despite both lines expressing similar background 
levels of the BHRF1 miRNAs. It is tempting to speculate that BHRF1 miRNAs might 
function more effectively in some backgrounds over others, perhaps because they are able to 
associate with miRISC more easily. On that note, Riley et al. observed that a small group of 
just 12 BART miRNAs appeared to compete for 22% of all Ago sites in the Jijoye BL line. 
The BHRF1 miRNAs would have to compete with the BART miRNAs for Ago sites in Akata 
BL, but not BL41, possibly explaining the discrepancies in BHRF1 miRNA function between 
these lines. More importantly, the leaky BHRF1 miRNA expression posed a problem in that 
we could not necessarily rely on using doxycycline untreated cells as a negative control in our 
experiments. For this reason we generated the empty control vector CON(empty)UTG.  
We also found that miR-BHRF1-3 copy numbers were notably reduced in the construct 
expressing all three BHRF1 miRNAs as compared to the construct expressing just miR-
BHRF1-2 and miR-BHRF1-3. Due to the artificial nature of our construct, we can only 
speculate as to why joining parts of the BHRF1 5′ UTR (miR-BHRF1-1) and 3′ UTR (miR-
BHRF1-2 and miR-BHRF1-3) would result in diminished miR-BHRF1-3 expression. 
Changes in the miR-BHRF1-2 sequence can impair processing of the miR-BHRF1-3, which 
means that sequences outside the pre-miRNA can also affect miRNA processing (829). 
Nonetheless we find it strange that the presence of the miR-BHRF1-1 sequence would impair 
miR-BHRF1-3 processing but not that of the adjacent miR-BHRF1-2. The ability of the pri-
miRNA tertiary structure to trigger the differential accumulation of individual miRNAs 
within the same cluster has been documented (830). Thus it is possible that the presence of the 
miR-BHRF1-1 sequence triggers a conformational change in the pri-miRNA structure that 
makes miR-BHRF1-3 less accessible to miRNA processing machinery.  
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With these caveats in mind, we proceeded to assess the functional impact of all three BHRF1 
miRNAs on our firefly reporter system (Fig 5.11). The results were highly satisfactory. Firstly 
there was a very good correlation between BHRF1 miRNA expression and luciferase 
knockdown. Secondly knockdown was satisfactory, usually ranging between 40% and 60%. 
Thirdly the same degree of knockdown was highly reproducible across three separate 
experiments. Consequently we chose to use our BHRF1 miRNA expression system to 
investigate the function of the BHRF1 miRNAs in the context of Wp BL. 
 
5.8.4 Investigating potential phenotypes conferred by the BHRF1 miRNAs  
The majority of cellular miRNAs are believed to fine-tune gene expression rather than 
completely shut off expression of their target (106). Nonetheless some miRNAs are able to 
mediate dramatic phenotypic changes e.g. transgenic expression of miR-155 causes B cell 
malignancies in mice (218). Thus there is a rationale for investigating potential miRNA 
associated phenotypes as opposed to merely elucidating their 3′ UTR binding sites. So far 
only two phenotypic studies have been conducted on the EBV miRNAs, both of which 
demonstrated a contributing role for the BHRF1 miRNAs in B cell growth transformation 
(750, 751).   
Seto et al. were first to note that, when compared to the wild type 2089 strain, a BHRF1 
miRNA deleted variant (Δ123 EBV) was 4-5 fold reduced in its ability to mediate B cell 
outgrowth over the first 5-12 days post infection; note that later time points were not 
investigated (751). Consistent with the impaired transforming phenotype, fewer B cells 
infected with Δ123 EBV survived over the same time frame and only half as many were 
found to be undergoing DNA synthesis (S phase), compared to cells infected with the wild 
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type virus. Feederle performed a similar study at later time points using a Δ123 EBV variant 
of the B95-8 strain (750). Compared to the wild type B95-8 strain, they observed that 
outgrowth of Δ123 EBV infected B cells was reduced by ~2.5 fold at 29 days cells post-
infection under conditions of bulk infection . This effect was found to be amplified at 8 weeks 
post-infection under stringent culture conditions i.e. low cell density. In agreement with Seto 
et al., fewer Δ123 EBV infected B cells were noted to have entered into S phase. Interestingly 
Feederle et al. noted higher relative levels of both Cp and Wp transcription in Δ123 EBV 
infected B cells between 11 and 73 days post-infection which was generally mirrored by 
higher levels of latent protein production.  
Thus we chose to investigate whether the BHRF1 miRNAs could confer a survival or growth 
advantage in the context of malignant BL cells (Figs. 5.17 through 5.19). However we found 
little evidence to suggest that the growth rates of either BL line tested were altered in the 
presence of the BHRF1 miRNAs. Similarly the BHRF1 miRNAs did not appear to alter the 
Bcl-2 family profile or protect from ionomycin induced cell death.   
The lack of a detectable phenotype under in vitro conditions could be due to a number of 
technical differences between the past and present studies. For instance our BHRF1-1/1-2/1-3 
lentiviral construct generated high levels of miR-BHRF1-1 and miR-BHRF1-2, but lower 
amounts of miR-BHRF1-3 (Fig. 5.10); it is possible that abundant levels of all three BHRF1 
miRNAs are necessary to cooperate to alter the growth and survival characteristics of BL 
cells. Interestingly Seto et al observed 8000-12000 copies of BHRF1 miRNAs in the majority 
of established LCL lines tested (751), levels which are much higher than previously reported 
in LCL lines (743, 809). By comparison our BL lines stably only expressed between 500-
1000 copies of miR-BHRF1-1 and miR-BHRF1-2 per cell and 250-1000 copies of miR-
BHRF1-3 per cell; perhaps these levels were insufficient to cause an overt phenotypic change.  
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Another difference between the past and present studies is that Seto et al. and Feederle et al. 
did not exclude the possibility that alterations in the levels of the BHRF1 protein are 
contributing to the observed phenotype. BHRF1 protein is known to contribute towards 
growth transformation by protecting de novo infected B cells from apoptosis (513). While 
both groups noted similar levels of BHRF1 transcript in the wild type and Δ123 EBV strains, 
scrambling parts of the BHRF1 5′ and 3′ UTR regions may have affected the efficiency of 
BHRF1 translation.  
Another possible reason we did not see a change in the growth or survival phenotype of BL 
lines stably expressing the BHRF1 miRNAs is because the roles of the BHRF1 miRNAs in 
resting B cells and established tumour lines are fundamentally different. In the context of 
primary infection, the BHRF1 miRNAs likely contribute towards early LCL formation. Such 
contributions may become redundant as the developing LCL acquires a number of additional 
changes during the immortalization process; as discussed in section 1.10 these changes 
include telomerase activation, (355-358), chromosomal aberrations (361), p53 mutations 
(362), enhanced tumour-like growth properties  (362) and an altered resistance to cytotoxic 
drugs (363). On this point, Seto et al. observed no apparent contribution of the BHRF1 
miRNAs towards survival in established LCL lines whilst the cell cycle distribution was only 
marginally altered in these cells (751). Similarly Feederle et al. found that the relatively high 
levels Cp and Wp activity observed in  Δ123 EBV infected B cells began to tail off between 
36 days and 73 days post-infection (750). These findings support the idea that the phenotypic 
contributions of the BHRF1 miRNAs gradually become dispensable as immortalization 
progresses. 
Similarly one could argue that the BHRF1 miRNAs confer growth and survival advantages 
during the formation of BL but not once the tumours have been established. The near 100% 
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association of EBV with endemic BL and the monoclonal origin of the tumour imply an 
essential role for the virus in tumour formation (254, 473, 474, 492). Nonetheless, at least in 
some BL lines, EBV is dispensable for tumour growth in vitro as demonstrated by the 
formation of spontaneous EBV loss clones (500). Thus in the context of BL, the c-myc 
translocation and p53 mutations could gradually diminish the requirement for EBV growth 
promoting and survival properties (477, 480, 481, 502, 503). For instance, the ability of 
EBNA1 to destabilize p53 via HAUSP may be important during early BL tumour formation, 
but not in established BL carrying p53 aberrations. Similarly the BHRF1 miRNAs may 
simply not confer overt growth or survival advantages in established BL tumours. 
 
5.8.5 Microarray analysis of BL lines stably expressing the BHRF1 miRNAs  
In order to pin point possible genes and pathways regulated by the BHRF1 miRNAs, we 
performed a whole transcript array analysis and then used the AltAnalyze software (780) for 
data pre-processing, such as elimination of background noise, filtering of probe sets, data 
summarization and normalization. This revealed a total of 203 differentially regulated genes 
between all three biological comparisons (empty vector vs. BHRF1-2/1-3, empty vector vs. 
BHRF1-1/1-2/1-3 and BHRF1-2/1-3 vs. BHRF1-1/1-2/1-3). Subsequently 15 differentially 
regulated genes were selected at random for validation by QPCR but unfortunately not one of 
these gene changes could be confirmed. These findings imply a false positivity rate of at least 
7.4%, although this number is likely to be much larger considering we randomly selected 
gene changes for validation. Notably many of the identified genes were expressed at very low 
levels in the test lines, consistent with the finding that five genes (ADAM18, DSCR8, ASZ1, 
HSPA4L and GRM5) were not even detectable by QPCR. 
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It is important to note that the probe sets screened by AltAnalyze and primer/probe 
combinations used in the QPCR assays were targetted against constitutive exons i.e. those 
present in all splice variants of a given mRNA species. Thus the discordant results cannot be 
accounted for by the detection of different splice variants by the two methods. It remains 
possible that the high rate of false positives predicted in the array analysis simply reflects the 
fact that the BHRF1 miRNAs regulate their targets at a post-transcriptional level. However 
this is difficult to reconcile with the general observation that ~84% of miRNA induced protein 
changes are associated with reductions in mRNA levels (151). Furthermore any significant 
changes to the cellular proteome would be expected to have some degree of downstream 
transcriptional effect. 
Towards the end of our study, we chose to reanalyze the raw array data using the XPS 
software. Using this approach, the array results for the same set of 15 validation genes agreed 
more closely with the QPCR data. This highlights a number of important issues about the 
interpretation of microarray analysis. First using different software algorithms to calculate 
changes in gene expression can yield a very different gene list (831). There is still no “best” 
way to analyze microarray data and consequently the development of analysis algorithms is a 
very busy area of research (832). Unfortunately due to time constraints we were unable to 
generate a list of differentially regulated genes based on the XPS data. It would be interesting 
to determine the degree of overlap between the AltAnalyze and XPS data sets, as such a 
comparison might help us chose more reliable targets for validation by QPCR. 
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6. Conclusions and future work 
In the first part of this thesis, we described an in depth investigation into the expression of 
EBV miRNAs in a variety of cell lines with different forms of EBV infection. Our study 
provided a number of novel findings. First, we demonstrated that all three BHRF1 miRNAs 
are abundantly expressed in Wp-restricted BL (Wp BL), but not in Latency I BL (Lat I BL) 
cell lines in which the Cp and Wp promoters are silent; this is the first example of BHRF1 
miRNA expression in the context of a BL tumour background. Second, in contrast to some 
earlier studies, we show that the BART miRNAs are abundantly expressed in cells of B 
lymphoid origin. While these findings help resolve controversies in the literature regarding 
the expression of the BART miRNAs in different cell lineages (738, 748), they also 
highlighted the widely different levels of individual BART miRNAs within a cell line. Finally 
we demonstrated that changes in BHRF1 and BART transcription are not necessarily reflected 
in altered miRNA levels, suggesting that miRNA maturation is a key step in regulating 
steady-state levels of EBV miRNAs. 
Studies on EBV miRNA expression have provided us with a number of vital clues as to their 
possible roles in different stages of the viral life cycle and tumour pathogenesis. For instance, 
the presence of the BHRF1 miRNAs in B cells early after EBV infection provided a rationale 
for investigating their potential contribution to B cell transformation (750, 751), while the 
finding that the BHRF1 miRNAs are present in a subset of BL tumours raises the possibility 
that they can also contribute to BL pathogenesis. However, in light of recent studies, it may 
be informative to determine not just the total levels of EBV miRNAs but also the amount of 
miRNAs specifically associated with Ago proteins. On this note, Riley et al. recently used 
high throughput sequencing (HITS-CLIP) to quantify only those miRNAs bound to Ago 
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proteins in the Jijoye BL cell line (764). This study not only revealed that 25% of all Ago-
bound miRNAs were EBV-derived but that the 12 highest expressed BART miRNAs (which 
included miR-BART10, miR-BART13, miR-BART4, miR-BART7 and miR-BART22) 
comprised 90% of all EBV miRNA sequence reads. By contrast the BHRF1 miRNAs were 
barely detected in this study, a result which is in stark contrast to previous northern blot 
analyses of Jijoye cells (738, 741, 748, 764). These findings raise two interesting possibilities. 
Firstly, EBV miRNAs might be preferentially loaded into miRISC complexes compared to 
cellular miRNAs. Secondly, the frequency with which individual EBV miRNAs bind Ago, 
and thus can exert their biological effects, may not necessarily correlate with absolute miRNA 
copy numbers.  
One striking finding of our study was the observation that individual BART miRNAs are 
present at widely different levels within a given cell line. Factors involved in regulating the 
maturation of cellular miRNAs were discussed earlier in section 1.3. For instance, SMAD, 
KSRP, p53 and ADAR are all capable of regulating pri-miRNA processing by the micro-
processor complex in the nucleus, while TUT4 has been shown to regulate pre-miRNA 
processing by Dicer in the cytoplasm. There is also evidence that pre-miRNA export from the 
nucleus is regulated by an, as yet, unidentified mechanism. At present the contribution of 
these factors to the differential accumulation of EBV miRNAs remains mostly unexplored. It 
has recently been suggested that four EBV pri-miRNAs sequences (miR-BHRF1-1, miR-
BART8, miR-BART16 and miR-BART6) are subject to editing by ADAR deaminases, which 
converts adenosine to inosine (757); this would lead to impaired Drosha processing and 
eventual degradation by the ribonuclease Tudor-SN, which specifically recognizes inosine 
containing dsRNA (76). Interestingly, A – I editing of the mature miRNA seed sequence may 
also direct a given miRNA to target an entirely different set of genes (833). Further studies are 
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therefore clearly required to understand how EBV miRNA levels are regulated by the 
complex miRNA maturation pathway.  
In the second part of our work we sought to explore the functions of the BHRF1 miRNAs in 
the context of a BL cell line model. Our phenotypic studies revealed that the growth rates and 
survival properties of BL cells were unaffected by BHRF1 miRNAs. However attempts to 
identify potential BHRF1 miRNA targets using a whole transcriptome approach are at this 
point inconclusive, possibly due to technical issues involving the data processing (section 
5.8.5). Further analysis of the raw array data may yet provide us with meaningful insight into 
BHRF1 miRNA function.  
At present we speculate that the BHRF1 miRNAs contribute to the pro-survival phenotype 
Wp BL but may be functionally redundant in the context of EBV negative and Lat I BL lines. 
Vereide and Sugden recently assessed the contributions of EBV to a number of virus-
associated malignancies by using dominant negative EBNA1 inhibitors to force genome loss 
(834, 835). Overall they observed a strong correlation between the number of different latent 
gene products expressed in a given tumour cell and its dependence on the growth and survival 
properties of EBV. Thus PTLD tumour lines (Lat III) and Oku BL cells (Wp BL) which had 
lost the EBV genome were more susceptible to spontaneous cell death than EBV loss 
derivatives of Lat I BL cells. Similarly PTLD cells and Oku-BL cells were more dependent on 
the presence of the EBV genome for proliferation when compared to Lat I BL cells. It has 
been hypothesized that the reduced dependence of Lat I BL cells on EBV is due to a greater 
accumulation of cellular mutations (834). In agreement with this prediction, Wp BL lines 
appear to carry wild type p53 whilst Lat I BL cells are usually characterized by p53 mutations 
(503, 511). Interestingly a recent study by Schmitz et al. observed that 38% of sporadic BL 
tumours and 2% of endemic BL tumours produced a highly stable mutant of cyclin-D3 (836). 
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Similarly 70% of sporadic BL and 40% of endemic BL tumours contained mutations in 
transcription factor 3 (TCF3) or its inhibitor, ID3. Collectively these mutations would favour 
cell cycle progression, cell survival and an increased expression of genes important in 
germinal centre development. Since the present study largely focused on an EBV positive Lat 
I BL line (Akata) and two EBV negative sporadic BL lines (BL30 and BL41) (276, 344), it is 
possible that the function of the BHRF1 miRNAs in these cells may be redundant due to 
additional cellular genetic changes. 
It is also likely that BHRF1 miRNA function may depend on the presence of other Lat III 
associated EBV gene products e.g. EBNA-LP, EBNA3 and BHRF1 which are expressed in 
Lat III infection and in Wp BLs, but not in Lat I BLs or EBV negative lines. This also raises 
the possibility that the BHRF1 miRNAs may regulate EBV gene products themselves, a view 
supported by the observation that Lat III gene expression is apparently deregulated in LCLs 
infected with a recombinant EBV lacking all three BHRF1 miRNAs (750). However Skalsky 
and co-workers concluded that there are no predicted BHRF1 miRNA binding sites in the 
latent EBV transcripts (763). Alternatively the BHRF1 miRNAs could function to counteract 
the effects of EBV latent gene products on cellular gene expression. For instance the BHRF1 
miRNAs could regulate any of the hundreds of cellular genes predicted to be targeted by one 
or more of the EBNA3 proteins (612). Another possibility is that the BHRF1 miRNAs 
mediate some or all of their effects by cooperating with cellular miRNAs; in this context Lat 
III associated gene products may first be required to alter the cellular miRNA profile (745). 
Originally we had aimed to answer these specific questions in the context of Wp BL by 
setting up a methodology for the efficient knockdown of the BHRF1 miRNAs (section 5.3); 
however such attempts using anti miRNA inhibitors had only limited success. As an 
alternative strategy, preliminary work was initiated to construct a miRNA “sponge” ie. a 
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transcribed RNA species with multiple binding sites complementary to the miRNA of interest 
(837). Such miRNA sponges can be highly effective in mediating miRNA knockdown and 
have been successfully applied to the study of EBV and KSHV miRNAs (755, 815). Unlike 
anti-miRNA oligonucleotides, lentivirus mediated sponge expression would allow transduced 
cells to be sorted using a GFP marker, thus eliminating the problem of the inherently low 
transfection efficiency associated with Wp BL lines.  
To this end, we had already begun construction of a sponge carrying nine binding sites against 
miR-BHRF1-2, with a view to knocking down expression of miR-BHRF1-2 in Wp BL cell 
lines. This work could be continued, in the first instance, by validating knockdown of miR-
BHRF1-2 using our newly developed luciferase reporters. If this proved successful, we would 
then try to incorporate binding sites for different combinations of all three BHRF1 miRNAs 
into the sponge. Ultimately we would envision performing Ago precipitation (e.g. HITS-
CLIP) on sponge-transduced cells followed by deep sequencing or microarray analysis. To 
counter the argument that such approaches may not detect post transcriptional changes, we 
could also exploit techniques such as SILAC to perform a quantitative analysis of protein 
levels in cells expressing different combinations of sponge sequences. In this way, we would 
hope to study the function of the BHRF1 miRNAs in the more physiologically relevant setting 
of endemic Wp BL lines, rather than in EBV negative sporadic BL or Lat I BL cells used in 
the current work. 
We note that, even today, very little is known about the specific roles of the BHRF1 miRNAs 
in virus mediated oncogenesis, with the possible exception of B cell transformation (750, 
751), and, despite extensive studies, very few EBV miRNA targets have been fully validated 
(754, 755, 759, 760, 763, 764). Indeed we still have a poor understanding of what makes a 
good or bad miRNA target. In some cases, EBV miRNAs can regulate transcripts lacking a 
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predicted binding site (miR-BART3 and BACH1), while in others they fail to regulate a target 
with a predicted binding site (miR-BART2 and CLIC4) (763). It is therefore important to 
understand the different methods which are used to identify potential miRNA targets. 
Much of what we know about miRNA-mRNA interactions has come from target prediction 
software. Indeed almost every published study on EBV miRNAs has attempted to use a 
computational approach to predict target genes for a given miRNA of interest. Some 
commonly used target prediction software and algorithms were discussed briefly in section 
1.4. We therefore decided to investigate target predictions for miR-BHRF1-1, miR-BHRF1-2, 
miR-BHRF1-2* and miR-BHRF1-3 from three commonly used software packages 
(TargetScan v5.2, RepTar and Diana-microT v3.0) (1, 114, 838, 839). Surprisingly there was 
very little overlap in the target predictions generated from the three data sets (Fig. 6.1); only 
25 target genes were common all three programs, and only nine of those were predicted to be 
targeted by the exact same BHRF1 miRNA. As a postive control, we confirmed that the 
Diana-microT algorithm could predict Dicer as a target of miR-BART6-5p (757). These 
findings clearly highlight the shortcomings of relying solely on computational approaches to 
identify miRNA targets, and identify a need for comprehensive, robust biochemical analysis 
(114).  
One such biochemical approach involves deep sequencing of miRNA-containing Ago 
complexes. However despite the huge amounts of data generated by this method, there still 
appears to be little overlap between EBV miRNA targetomes predicted by different studies. 
Recent reports by Skalsky et al. and Dolken et al. both obtained data sets for potential BHRF1 
miRNA target genes (758, 763), either in the context of an LCL, or in the case of Dolken et 
al. using the Jijoye BL line. An overlap of the putative BHRF1 miRNA targets revealed in 
these two studies, together with the 203 differentially regulated genes from our array, is 
Fig 6.1. A comparison of three different miRNA prediction software programs. 
Predicted targets of miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 were 
determined with TargetScan version 5.2 (1), RepTar (838) and Diana-microT version 
3.0 (839) using standard parameters. The total number of genes predicted to be 
targeted by one or more of the BHRF1 miRNAs has been summarized for each 
program in the Venn Diagram 
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illustrated in Fig. 6.2. Note that Dolken et al. did not assign specific miRNAs to the majority 
of their predicted 44 EBV miRNA targeted transcripts. Therefore we included only those 
genes in our comparison which were predicted to be targeted by one or more BHRF1 miRNA 
in at least one of the target prediction packages. Using these criteria, we found zero overlap 
between the predicted genes in any of the three studies (Fig. 6.2). 
Very recently, a third study by Riley et al. identified more than 1500 EBV miRNA targets 
using HITS-CLIP of Ago bound RNA species (764). Collectively these three studies used 
similar methods to investigate either the LCL (Skalsky and Dolken) or the Jijoye BL (Dolken 
and Riley) miRNA targetome. We therefore compared all three published studies, but 
restricted our analysis to a single miRNA, miR-BART4 (Fig. 6.3). In this case, there was a 
small degree of overlap based on pairwise comparisons but no individual gene was identified 
by all three studies. Whether these discrepancies arise from different methodologies or the use 
of different cell types warrants further investigation.  
Putting aside this lack of agreement between published studies, EBV miRNAs are predicted 
to target genes involved in cell cycle, apoptosis, transcription and Wnt signalling. These 
comprehensive profiling studies have clearly demonstrated their merits by identifying new 
targets and validating some of those discovered in earlier studies e.g. PUMA, MICB and 
IPO7 (755, 756, 758, 763, 764). Interestingly a number of studies have confirmed the same 
targets in different cellular contexts, but find them to be regulated by a different set of EBV 
miRNAs. For instance four groups have confirmed that LMP1 is an EBV miRNA target (760, 
762-764); Lo et al. showed miR-BART1-5p, 16-5p and 17-5p regulate LMP1, Skalsky et al. 
confirmed the interaction with miR-BART1-5p, Riley et al suggested that miR-BART5-5p 
and miR-BART19-5p were involved whilst Ramakrishnan et al. validated miR-BART9. 
Fig 6.2. A comparison of candidate BHRF1 miRNA targets from three studies. The 
total number of genes differentially expressed between the three TREX lentivirus 
transduced Akata BL lines (AltAnalyze) was compared to the total number of genes 
predicted to be targeted by one or more BHRF1 miRNAs in the studies conducted 
by Dolken et al. (758) and Skalsky et al. (763). Data have been summarized in the 
Venn Diagram. 
 
Fig 6.3. A comparison of miR-BART4 targets predicted by three similar studies. The 
total number of genes predicted to be targeted miRBART4 in the studies conducted 
by Dolken et al. (758), Riley et al. (764) and Skalsky et al. (763) have been 
summarized for each study in the Venn Diagram. 
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In summary, our knowledge of EBV miRNAs and their roles in EBV infection and 
lymphomagenesis is steadily increasing, but several fundamental questions still remain 
unanswered. In terms of EBV miRNA expression, we need to better understand the cellular 
mechanisms which control the biogenesis and maturation of EBV miRNAs from the BHRF1 
and BART transcripts. Further studies are also required to investigate if EBV miRNAs can 
selectively gain access into miRISC silencing complexes. On the question of EBV miRNA 
function, the current literature is both confusing and contradictory. Therefore future studies 
will need to combine complementary genetic and biochemical approaches in order to fully 
characterise the relationship between the EBV miRNA targetome and cell phenotype. Finally 
our increased understanding of the role of EBV miRNAs in lymphomagenesis may lead to the 
identification of novel therapeutic targets for the treatment of EBV associated lymphomas.  
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